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Abstract
The murine cytomegalovirus (MCMV) immediate early 1 (IE1) protein has been
described as a trans-activator of viral and host gene expression. However, the
precise role that IE1 plays in the viral life cycle, and in particular its effect on
the host immune response is not known. This thesis investigates the functional
relationship of the IE1 protein and the immune response induced after infec-
tion. By using an ie1-deletion mutant MCMV (MCMVdie1) it was demonstrated
that, early after infection, tumor necrosis factor (tnf ) gene activation and protein
production was significantly induced in infected-primary macrophages (Mθ) to
a much greater extent than its wild type counterpart. In addition, preliminary
studies on the signalling pathways activated upon infection were carried out in
order to gain information about the pathways that might be involved in MCMV-
induced modulation of tnf activation. Initial observations on the MAPK family
members Erk1/2, p38 and JNK did not revealed any differential activation in the
absence of IE1. However, due to a number of limitations, it was not possible to
draw any firm conclusions from this study.
Investigation of the role of IE1 in the in vivo production of TNF were also
performed in both susceptible (BALB/c) and resistant (C57Bl/6) mice. These ex-
periments confirmed the attenuated phenotype of MCMVdie1 in vivo, whereby
the mutant strain grew to much lower titers than wild type. When cytokine pro-
duction was assessed in relation to PFU levels a significant production of TNF
after infection is observed in different organs of both mice strains. This raises
the question whether IE1 contributes to MCMV modulation of TNF production
in the natural host. Although, because it is still unclear whether the phenotype
of MCMVdie1 in vivo is due to a defect in the virus or the result of a immune
ii
iii
response, it was not possible to conclude unequivocally that IE1 is responsible
for dampening this cytokine response.
This thesis also tested whether the attenuated replication of MCMVdie1 in
vivo was due to the increased TNF production induced after infection. An initial
investigation in tnf depleted mice revealed that the MCMVdie1 growth pheno-
type is not due to TNF response.
Overall, this study has provided insight into a potential immune modulatory
function by MCMV associated with IE1 protein and the regulation of TNF in vivo
and in vitro.
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1.1 Herpesviruses: General overview
Herpesviridae are a large family of viruses highly disseminated in nature which
can cause disease in humans. All Herpesviruses share a common structure, they
all are DNA viruses and replicate in the nucleus of infected cells. Another com-
mon feature of this family is the capacity to establish latency after the initial
infection. The cells where the viruses establish latent infection varies from one
virus to another as well as the reactivation mechanism of the virus from latency.
The exact mechanisms by which this process takes place is still under study.
1.1.1 Structure and Classification of Herpesviruses
Initially, inclusion within the Herpesvirus family was based on the virion struc-
ture (see Figure 1.1). The Herpesvirus virion consists of a torus-shape core asso-
ciated with the viral double-stranded DNA of about 120 to 230 kilobase pairs, de-
pending on the Herpesvirus. The viral DNA is housed in an icosahedral capsid
composed by approximately 162 capsomers, or morphological units. Surround-
ing the capsid is the tegument which also contains virally expressed proteins.
These proteins are introduced in the host cell with the aim of modifying the cel-
lular environment for the successful initiation of the infection. Examples of this
include the shut down of the cellular protein synthesis, enhancement of viral
gene transcription or immune evasion strategies. Finally, the outer layer is called
envelope and is composed by altered host membranes and viral glycoproteins.
The envelope can also contain external glycoproteins spikes which play a key
role during the initial stages of viral infection.
1
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Figure 1.1: Typical Herpesvirus virion
In addition to the virion architecture, there are also four main characteristics
shared by all Herpesviruses [Pellett P. E., 2006]:
1. All viruses encode a number of enzymes involved in nucleotide metabolism,
DNA replication and protein synthesis.
2. Viral DNA replication and assembly of new virions occur in the nuclear
compartment of the cell.
3. Production of new progeny virions during lytic replication generally re-
sults in the destruction of the infected cell.
4. All Herpesviruses are able to remain in the host cell in a latent state. After
correct stimuli latent virus can be reactivated and cause disease.
Approximately 100 Herpesviruses have been isolated and to date 8 Herpesviruses
in this family infect and cause disease in humans. They are subdivided into three
subfamilies based on their biological properties (Table 1.1).
Inspite of the common characteristics of the members of the Herpesvirus fam-
ily, there are also specific features for each virus. For instance, the host cell range
is very wide for the alpha Herpesviruses whereas it is more restricted for beta
and gamma Herpesvirus. This restriction is related to the distribution of cellular
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Table 1.1: Classification of Herpesviruses
Type Name Subfamily
HHV-1 Herpes simplex virus-1 (HSV-1) Alphaherpesvirinae
HHV-2 Herpes simplex virus-2 (HSV-2) Alphaherpesvirinae
HHV-3 Varicella zoster virus (VZV) Alphaherpesvirinae
HHV-4 Epstein-Barr virus (EBV) Gammaherpesvirinae
HHV-5 Cytomegalovirus (CMV) Betaherpesvirinae
HHV-6 - Betaherpesvirinae
HHV-7 - Betaherpesvirinae
HHV-8 Kaposi’s sarcoma-associated herpesvirus (KSHV) Gammaherpesvirinae
receptors for the viral particle, making the cells more or less permissive for infec-
tion. There is also variation in the length of the replication cycle, HSV has a short
replicative cycle of approximately 18 hours while CMV requires up to 48 hours
to complete it.
1.1.2 Herpesvirus Replication Overview
The replication cycle of the Herpesviruses can be divided into several stages (see
Figures 1.2 and 1.3): (1) attachment of the virus to the host cell and penetration,
(2) transcription and (3) viral replication, both events happening in the nuclear
compartment of the host cell, (4) assembly of the new progeny of virions and
(5) egress from the cell to the exterior. A general introduction of these phases is
described below.
Attachment and entry
The initial step in the Herpesvirus life cycle is the attachment of the viral par-
ticle to cellular receptors, followed by the fusion of the viral envelope with the
cell plasma membrane. Once the virion has been attached both viral envelope
and cell plasma membrane fuse. Glycoproteins found in the virion envelope are
key players in the initiation of the cycle. Upon entry the viral nucleocapsid with
associated tegument proteins is transported by the cellular cytoskeleton to the
nuclear pores. It is believed that the presence of these tegument proteins dur-
ing these early stages of infection is essential to create the correct environment
for efficient replication of the virus. For example, along with HSV capsid the
tegumentary proteins VP16 and vhs are also introduced in the host cell. VP16
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Figure 1.2: Life cycle of Herpesviruses
is transported to the nucleus where acts as an inducer of immediate early gene
transcription [Campbell et al., 1984] whereas vhs remains in the cytoplasm where
it induces degradation of both cellular and viral mRNAs [Fenwick and Clark,
1982, Fenwick and McMenamin, 1984].
Transcription
Transcription of all Herpesviruses takes place in the nucleus and viral proteins
are synthesized in the cellular cytoplasm. In infected cells the cellular RNA poly-
merase II is responsible for the transcription of viral genes. In addition, this pro-
cess occurs in a regulated temporal cascade starting with the expression of the α
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or immediate early genes, followed by the β or early genes and γ or late genes.
The expression of immediate early genes does not require prior viral protein syn-
thesis, however sometimes the virus particle has some proteins which enhance
this initial process. Expression of the early genes requires the presence of some
immediate early proteins but not the onset of viral DNA replication. The early
genes encode for proteins required for viral replication, nucleotide metabolism
and expression of the last set of viral genes. The late gene expression is nor-
mally increased after viral DNA replication and they encode for virion structure
proteins.
Replication
Herpesviruses encode their own DNA-dependent DNA polymerase responsi-
ble for viral DNA replication. The replicated DNA is present as concatameric
molecules, that is a long DNA molecule containing multiple repeats of the vi-
ral genome, which is generate by the rolling-circle method of replication. The
concatemers are then cleaved to correct size of DNA to be packaged into new
progeny of virions.
Assembly
Assembly of new capsids takes place in the nucleus, therefore new capsid pro-
teins are transported from the cellular cytoplasm to the nucleus. Along with viral
scaffolding proteins the assembly of capsids occurs. These scaffolding proteins
will be later degraded by a viral protease. Finally, the viral DNA which is in the
form of concatemers is cleaved and packaged into the capsid.
Viral envelopment and egress.
Once the capsid has been formed the virion needs to obtain the tegument and
envelope. This complex procedure is not completely understood but it is known
to start by fusion of the capsid with the nuclear membrane obtaining an initial
envelop. There are two different pathway of envelopment: (1) the dual envel-
opment pathway and (2) the single nuclear envelopment pathway. In the dual
envelopment pathway the virus acquires the envelope from the nuclear inner
membrane and follows a progressive de-envelopment and re-envelopment as the
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virion moves from different cellular compartments [Jeffrey I. Cohen, 2001, Pellett
P. E., 2001]. On the other hand, in the single envelopment pathway the virus ac-
quires the envelop from the inner nuclear membrane after which enters a vesicle
at the outer nuclear membrane in which the virus is transported to the plasma
membrane. Finally, by fusion with the plasma membrane the virus is released
from the cell.
Figure 1.3: Possible egress pathways
The egress of the new virion from the infected cell can follow two pathways. One involves
the de-envelopment of the virion when it passes through the outer nuclear membrane and
re-envelopment from the trans-Golgi network, being released in secretory vesicles. The second
pathway does not involve the re-envelopment sequence and is transported in vesicles to the
plasma membrane. Adapted from [Roizman and Knipe, 2001]
1.2 Alpha Herpesviruses
The Alpha Herpesviruses exhibit a wide range of host cells, and are also charac-
terized by a short replicative cycle and rapid cell-to-cell spread in culture. Infec-
tion with Alpha Herpesviruses results in the effective destruction of the cells and
also the establishment of a latent infection in sensory ganglia. This subfamily
includes Herpes Simplex Virus 1 and 2 (HSV1 and HSV2) and Varicella Zoster
virus (VZV).
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Infection with HSV1 and HSV2 is distributed worldwide. Initial infection
with HSV1 appears to be very frequent at early age during childhood. However
geographic location and socioeconomic status seem to be factors affecting acqui-
sition of HSV. In fact, several studies have revealed the high seroprevalence of
HSV in the population [Roizman B., 2006]. In the case of pregnant women this
also increase the risk of reactivation of the virus and transmission of the virus
to the newborn. When infection is initiated viral replication takes place at the
site of infection. A key step in viral pathogenesis is the ability of the virus to
replicate and subsequently be transported to dorsal root ganglia where it can es-
tablishment of latency. The recurrence of HSV infection is also normal, resulting
in vesicular lesions of the skin in the lips or genitalia.
The capacity of HSV to infect the nervous system is an important viral prop-
erty for human pathogenesis. Animal models have been very useful to study
viral pathogenesis of HSV infection.
VZV infection is initiated by inoculation of the respiratory mucosa or close
contact with an infected individual. VZV causes varicella, also known as chicken
pox, a highly contagious infection, causing annual outbreaks. Unlike other mem-
bers of the alpha Herpesvirus subfamily, VZV has a tropism for T lymphocytes.
VZV can also establish latency after primary infection in cells of the dorsal root
ganglia. Reactivation of VZV from latency results in herpes zoster, commonly
known as shingles. VZV reactivation can also cause post-herpetic neuralgia.
1.3 Beta Herpesviruses
Beta Herpesviruses are characterized by a strict species specificity, relatively slow
replication cycle and the induction of the enlargement of infected cells, also
known as cytomegalia. Beta Herpesviruses can also establish latency in the host
as do other Hespesviruses. This subfamily contains Cytomegalovirus and Hu-
man Herpesvirus 6 and 7. Although HHV6 and 7 are relatively recently discov-
ered viruses, the murine virus (MCMV) has been extensively used as a model for
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studying human virus (HCMV)-induced pathogenesis, thanks to the biological
similarities between viruses and to the ease of handling the virus.
Like HCMV, infection with MCMV results normally in an asymptomatic in-
fection and establishment of latency. However, in immunocompromised hosts
the outcome of the infection could be fatal. The immune system controls the level
of reactivation from latency leading to a life-threatening disease in immunosup-
pressed patients. AIDs patients and transplant recipients are commonly vul-
nerable to reactivated viral infection. Congenital infection also occurs and is
associated with serious damage of the central nervous system, including malde-
velopment and deafness.
HHV6 and HHV7 compose the Roseolovirus within the beta Herpesvirus sub-
family, sharing some features with CMV. As seen for CMV infection HHV6 and 7
are ubiquitous with more than 90% of the population infected. Two HHV6 vari-
ants have been identified, HHV6A and HHV6B. With HHV7, infection of these
viruses cause the infant disease exanthem subitum (ES), also referred to as rose-
ola infantum. Infection with the variant B of HHV6 is more common than the A
variant, and so far no clear disease has been associated with HHV6A.
1.4 Gamma Herpesviruses
Gamma Herpesviruses have a more restricted host and host cell range. They are
lymphotropic viruses, specific to either T or B cells, where latency is also estab-
lished. This subfamily contains two genera: (γ-1) Lymphocryptovirus, which in-
cludes EBV, and (γ-2) Rhadinovirus, which includes KSHV, Herpesvirus Saimiri
(HVS), Rhesus monkey rhadinovirus (RRV), Equine Herpesvirus 2 and murine
gammaherpesvirus 68 (MHV68). An important feature of the gamma Herpesviruses
is the association with cancer.
The study of gamma Herpesviruses has not been easy due to the difficulty of
these viruses to replicate in vitro, as well as the tendency of establishing latency
instead of a lytic infection. On the other hand, ethical restrictions to study hu-
man gamma Herpesviruses in the natural host have also impeded to have a better
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information about the biology of these viruses. However of the interest in vet-
erinary medicine gamma Herpesviruses are now very valuable animal models,
providing important information regarding the infection in the natural host.
EBV was the first Herpesvirus to be sequenced and cloned [Baer et al., 1984]
and it has been extensively studied in contrast to the rest of gamma Herpesviruses.
There are two variants of EBV, subtype 1 or A and subtype 2 or B and they both
present antigenically differences. There are studies suggesting that EBV subtype
1 is more prevalent that subtype 2 but this last one is found prominently in Africa
[Gratama and Ernberg, 1995]. EBV is capable of infecting several cell types, T-
and B-cells, as well as epithelial cells. Transmission of EBV infection is mainly
through the saliva of infected individuals, however EBV has also been detected
in genital secretions. EBV is the agent of infectious mononucleosis and Burkitt’s
lymphoma and it has also been associated with Hodgkin’s lymphoma, nasopha-
rangeal carcinoma and some forms of gastric cancer [Rickinson A. B., 2006]. An
important characteristic of EBV infection is the different latency programs. In
addition, these programs are also characteristic of various EBV-associated malig-
nancies [Rowe et al., 1992]. Interestingly, the viral latent gene expression varies
according to the program.
The other member of the gamma Herpesvirus subfamily to infect humans is
the very recently discovered KSHV or HHV-8. It resembles EBV in its tropimsm
for B cells, in the establishment of latent state and difficulty of using the virus
in vitro. KSHV infection has been associated with Kaposi’s sarcoma, a tumour
of endothelial cells origin, Primary Effusion Lymphoma and Multicentric Castle-
man’s Disease, both of which are rare B-cell lymphoproliferative diseases.
1.5 Focus on Murine CMV
The ability to study a natural infection in the natural host makes MCMV a virus
worth studying. Due to the strict species specificity of CMV, studies on HCMV
have been restricted to in vitro systems. However the biological similarities to
MCMV (virion structure, life cycle, general biology) makes the murine virus an
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excellent model to study HCMV biology and pathogenesis. There are also a num-
ber of similarities in the immune response to control viral infection. For instance,
in both human and murine MCMV infection CD8+ T cells play an important
role for viral control [E. S. Mocarski, 1996]. In fact, the most important target
for both HCMV and MCMV-specific CD8+ T cells is the immediate early 1 (IE1)
protein [Kern et al., 1999, Reddehase et al., 1985]. Nevertheless, information ob-
tained from the MCMV model should be not extrapolated to the HCMV since
there are also a number of differences between these viruses [Rawlinson et al.,
1996], for instance both viruses have developed immune evasion strategies to
overcome host response against infection, however the molecular mechanisms
of such strategies are not identical.
1.5.1 Virion structure and Genetics of MCMV
CMVs are the principal members of the beta Herpesvirus subfamily. They also
share common characteristics with other Herpesviruses like virion structure and
establishment of latency. CMV virion structure consists on an icosahedral cap-
sid where the linear double-stranded DNA of 235 kb is housed. CMV has also
an envelope and between the capsid and envelope there is the tegument. Both
HCMV and MCMV genomes have been sequenced and it has been established
that approximately 80 of the 170 ORFs share homology with HCMV [Rawlinson
et al., 1996]. In contrast to HCMV genome organization, MCMV presents a single
unique sequence flanked by terminal repeats [Rawlinson et al., 1996].
As other Herpesviruses, MCMV gene expression is regulated as a 3-phase
temporal cascade: (1) the immediate early phase, independent on any previous
viral gene expression, (2) the early phase which relies on the IE proteins and (3)
the late phase dependent on viral DNA replication. During the late phase struc-
tural proteins are encoded. The genetic regions encoding for these 3 different
classes of genes were described by Keil and coworkers [Keil et al., 1984].
The IE genes of the MCMV are organized in a genomic region known as the
major immediate early (MIE) locus from where the IE proteins are expressed
under the strict control of the MIE enhancer/promoter. This enhancer region
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Figure 1.4: Genetic organization of the major immediate early (MIE) region of
the Murine Cytomegalovirus
The MIE consists in two transcriptional units: the ie1/ie3 and the ie2, both under the control
of specific promoters, at both sides of the enhancer region. The differential splicing from the
ie1/ie3 unit drive to the production of two proteins, the IE1 and IE3. The exon 3 from the ie2
transcriptional unit is responsible for encoding the IE2 protein. Adapted from [Reddehase, 2002]
is a large sequence containing a number of binding sites for different transcrip-
tion factors, including NFκB, retinoic acid receptor (RAR), AP1 and CREB. These
factors are shared within the different CMVs enhancers [Stinski and Isomura,
2008]. The enhancer region is necessary for viral replication, since it has been
shown that a mutant lacking the enhancer is deficient for replication in tissue
culture [Angulo et al., 1998]. Moreover, this study also showed that the enhancer
is not responsible for the species specificity of the virus since it was possible to
restore viral growth when the human virus enhancer region was introduced to
the enhancerless virus. In addition, the enhancer region of MCMV is absolutely
essential for viral pathogenesis in the natural host [Ghazal et al., 2003].
Two different transcription units can be differentiated at both sides of the en-
hancer region, the ie1/ie3 and ie2, each one driven by specific promoters (Figure
1.4). Differential splicing of the ie1/ie3 region results in the production of two
proteins: the IE1, encoded by exons 1-4, and IE3, encoded by exons 1-3 and 5.
The IE2 protein is encoded by the exon 3 of the ie2 gene. The structure of this
last protein was studied by [Messerle et al., 1991] and different investigations
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revealed no actual function for the MCMV IE2 protein, as well as complete unaf-
fected viral growth in the absence of this protein [Manning and Mocarski, 1988].
Therefore, the following sections will be focused on IE1 and IE3 proteins.
Immediate early 1 protein
Sequence and structural organization of the immediate early 1 gene was de-
scribed by Keil and coworkers [Keil et al., 1987b]. Years later, and thanks to
the bacterial artificial chromosome (BAC) technology, which allowed for cloning
of the viral genome, studies were designed in order to dissect the role that viral
genes might play in the context of a viral infection. Therefore, by using BAC
strategy, a MCMV genome carrying a mutation within the ie1 gene was con-
structed [Messerle et al., 1997]. The initial observation when studying the func-
tion of this gene was that, in the absence of ie1, the virus presented slightly lower
replication in tissue culture. Ghazal and coworkers generated a second mutant
virus where the ie1 exon 4 was deleted from the viral genome and showed that
the IE1 protein was not required for efficient replication in vitro [Ghazal et al.,
2005]. However, in the natural host the ie1-deletion mutant MCMV had an at-
tenuated phenotype, demonstrating a critical role of the viral protein for viral
replication in vivo. Moreover, the construction of a revertant virus, where the
exon 4 was reintroduced, further confirmed that these results were due to IE1,
since no differences were found between parental and revertant MCMV.
It has been shown that MCMV IE1 contributes to the transcriptional activa-
tion of the early genes, but in combination with the IE3 protein [Messerle et al.,
1992]. The IE1-induced activation of gene expression is not completely under-
stood, although the ability of IE1 to interact with chromatin through histones
[Munch et al., 1988, Munch et al., 1992] might be responsible for this regula-
tory function. The ability of the MCMV IE1 protein to activate gene expression
has also been demonstrated [Koszinowski et al., 1986], and it was later con-
firmed by showing that this viral protein induces the transcription of specific
genes such as NFκB [Gribaudo et al., 1996] and c-fos, both involved in the cellu-
lar cycle [Schickedanz et al., 1988], as well as genes involved in thymidylic acid
metabolism [Gribaudo et al., 2000], and ribonucleotide reductase [Lembo et al.,
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2000], which are required for viral DNA replication and cell cycle regulation.
This ability of IE1 to activate gene transcription is also shared with the HCMV
homolog IE1 protein [Wade et al., 1992, Hayhurst et al., 1995], although very lit-
tle homology exist between the nucleic acid and amino acidic sequence of both
proteins [Keil et al., 1987b].
Another functional characteristic of the IE1 protein is its interaction with Nu-
clear domain 10 (ND10), also known as promyelocytic leukemia (PML) onco-
genic domains (PODs). ND10s are nuclear structures comprising protein aggre-
gates including PML, Sp100 and Daxx. These aggregates have been shown to
be nuclear sites of viral initiation of replication, including herpesvirus and aden-
ovirus [Maul, 1998]. Components of ND10 are known transcriptional repressors,
such as PML and Daxx. In addition, they have been associated with antiviral ac-
tivities since their expression is induced by IFN [Grotzinger et al., 1996, Gongora
et al., 2001]. However, the role that these structures play in CMV infection is
not completely understood. Infection with HCMV results in the disruption of
ND10 nuclear bodies which seems to relieve the transcriptional repression in-
duced by proteins like Daxx. HCMV has been shown to induce degradation of
this protein by the tegument protein pp71 [Saffert and Kalejta, 2006], which will
subsequently allow expression of IE genes. This would be consistent with the en-
hancement of viral replication seen in the absence of PML or Daxx [Tavalai et al.,
2008]. HCMV IE1 protein has also been involved in ND10 disruption by the
modification of PML [Lee et al., 2004]. Like HCMV, MCMV IE1 disperses ND10
bodies soon after infection [Tang and Maul, 2003, Ghazal et al., 2005], an abil-
ity which is also shared by other herpesviruses [Everett, 2001], including HSV-1.
The HSV-1 ICP0 protein has been shown to disrupt ND10 nuclear bodies by in-
ducing the proteosomal degradation of PML [Everett et al., 1998]. In contrast,
MCMV IE1 does not induce the degradation of either PML or Daxx. Instead, it
has been suggested that it might induce changes in the phosphorylation status
of Daxx, which affects its repression abilities [Maul and Negorev, 2008].
Interestingly, HCMV and HSV-1 mutant viruses, failing to express IE1 and
ICP-0, respectively, exhibit a dose-dependent phenotype in cultured cells [Greaves
14
and Mocarski, 1998, Everett et al., 2004]. This phenotype has been associated
with the failure of ND10 disruption, accompanied by the transcriptional repres-
sion induced by ND10 components [Gawn and Greaves, 2002, Everett et al., 2008]
which limit the expression of IE genes. However, in contrast to these mutants,
the MCMV ie1-deletion mutant showed comparable replication to wild type in
a number of permissive cells [Ghazal et al., 2005]. As expected, disruption of
ND10 at early times did not take place in ie1 mutant-infected cells, indicating
that ND10 bodies are not required for MCMV initiation of replication. How-
ever, later in MCMV ie1-deletion mutant infection, ND10 disruption was seen
in an IE1-independent manner, perhaps by other viral products which take over
this function for future replication cycles. It is also noteworthy that the ratio
particle to PFU in HCMV and HSV-1 IE1 mutants are high [Greaves and Mo-
carski, 1998, Everett, 1989]. This ratio measures the number of viral particles to
infectious particles of virus. However, Ghazal and coworkers showed an indis-
tinguishable growth kinetics of MCMV ie1-deletion mutant in a series of permis-
sive cell types and therefore so far it has been assumed that the absence of ie1
does not result in a defective new virion progeny. In any case, it would be very
informative to investigate what the particle to PFU ratio is in this mutant virus.
Immediate early 3 protein
MCMV IE3 is similar to its human homolog IE2, in both structural and functional
characteristics [Keil et al., 1987a]. This protein is encoded by exons 1, 2, 3 and 5
from the ie1/ie3 transcriptional unit. Characterization of the protein resulted in a
88 kDa protein, with similar kinetics as the IE1 protein [Messerle et al., 1992]. The
same study demonstrated that the switch from the immediate early phase to the
early phase requires IE3 protein which, at the same time, acts as a transcriptional
repressor of the ie1/ie3 promoter.
The role of the ie3 gene product has been studied by the construction of an ie3-
deletion MCMV mutant [Angulo et al., 2000]. In order to disrupt the ie3 gene and
prevent the production of the IE3 protein, the exon 5 of the ie1/ie3 transcriptional
unit was deleted. At the same time, and in order to study whether the resulting
phenotype was due to solely the ie3 gene, a revertant virus was also constructed.
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In this study, Angulo and coworkers demonstrated the absolute requirement of
ie3 for viral growth. The fact that only ie1 transcripts were found in infected
fibroblasts and neither early nor late proteins were expressed also confirmed the
role of the IE3 protein in the activation of viral gene expression. Indeed, IE3 has
been shown to negatively regulate the ie1/ie3 promoter, indicating the regulatory
role of this protein in the viral gene expression [Messerle et al., 1992].
Early and Late genes
IE gene products are required for expression of the early genes, which play a role
in viral DNA replication. Upon viral replication late genes are then expressed,
encoding for structural proteins which make up the viral capsid as well as pro-
teins involved in virion maturation and egress from the cell.
1.5.2 Pathogenesis
CMV is transmitted by bodily secretions (saliva, semen, blood). During preg-
nancy, transplacental transmission might occur, as well as during breastfeeding,
which is considered the most common source of transmission from mother to
child. Primary infection of immunocompetent hosts with HCMV is very com-
mon and frequently results in asymptomatic disease. However, the virus is never
completely cleared by the immune response and the virus establishes latency.
Furthermore, when the immune system of the host is undeveloped as in the case
of congenital infections, or compromised as in the case of transplant recipients or
patients with AIDS, the outcome of the infection could be fatal. Along with the
immune status of the host, there are several other factors affecting viral patho-
genesis, such as viral replication, evasion of the immune system and dissemina-
tion.
Congenital HCMV infection is characterized by damage to the central ner-
vous system (CNS). Maldevelopment of the CNS, deafness and impaired vi-
sion are very common in congenitally-infected newborns [Stagno et al., 1986].
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HCMV-related disease is very important for transplant recipients, where pneu-
monitis and gastrointestinal inflammation are very common. The source of vi-
ral infection in these patients could be as a result of reactivation of latent virus
or transmission from the organ donor. HCMV has also been associated with
atherogenesis. The mechanisms by which the disease is initiated are not known,
although injury to endothelial cells has been implicated as an important factor.
HCMV has tropism for endothelial cells and viral replication induces an inflam-
matory response. The activation of Mθs, a central player in inflammation, re-
sults in the production of cytokines and chemokines which also contribute to
the maintainance of inflammation and the evolution of atherogenesis. In fact,
there is evidence showing that MCMV infection of Mθs favor the differentiation
of these cells into an active pro-inflammatory Mθs, which will contribute to the
aggravation of atherosclerosis [Vliegen et al., 2004]. It is also known that HCMV
infects monocytes and disseminates throughout the host by using these cells as
vehicles. This dissemination process is also important for pathogenesis, as well
as cytokine production which has been implicated in reactivation of virus from
latency, as seen for TNF [Simon et al., 2005, Hummel et al., 2001]. HCMV infec-
tion of intestinal cells has been associated with inflammatory bowel disease by
induction of cytokine production [Rahbar et al., 2003].
Viral induction of adhesion molecules in the cell surface could also affect cel-
lular migration and subsequent tumor invasiveness [Soderberg-Naucler, 2006].
HCMV has also been suggested to play a role in immune evasion of tumor cells,
since it could help to avoid the immune response.
Because clinical abnormalities of HCMV infection are similar to that observed
in corresponding animal models, the use of these systems have helped to un-
derstand the pathologies associated with CMV infections. The murine model
have been extensively used in this regard. When studying MCMV pathogene-
sis several factors have to be taken into consideration regarding the outcome of
infection. For instance, the route of infection or the origin of the viral inoculum
and immune status of the host are key factors which could affect the infection
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[Krmpotic et al., 2003]. Infection of immunocompetent mice with salivary gland-
derived virus (SGV) results in high viral replication in several organs, including
the liver. In this tissue, viral replication induces an inflammatory response, char-
acterized by high levels of TNF [Trgovcich et al., 2000], which have been asso-
ciated with hepatitis. Cytokine-induced activation of bystander cells could also
aggravate damage to the tissue. As in HCMV, infection of immunocompromised
hosts could lead to life-threating disease.
1.5.3 Innate immunity against MCMV
Study of the control of MCMV infection has been the focus of many groups in
the last decade. This effort has made it possible to understand the specific mech-
anisms involved with controling virus infection. The studies have identified the
key immune cells that play an important role against MCMV infection, as well as
their molecular mediators. The establishment of the animal model for studying
the human virus has been crucial to determine what immune cells are important
in the control of viral infection. Several studies have identified the following cel-
lular populations as the main contributors for the immunity against MCMV as
well as targets for the immune evasion strategies developed by the virus.
Natural Killer Cells (NK)
The use of NK cell-depleted mice using either genetically strategies or specific
antibodies against this cellular population have demonstrated the key role of
NK cells in the innate immune response to MCMV [Orange et al., 1995, Krm-
potic et al., 2002]. The response has also been shown to be organ-specific [Tay
and Welsh, 1997]. An important feature of these cells is that they allowed the
identification of genetic MCMV susceptibility based on the ability of these cells
be activated after viral infection. This difference in susceptibility relies on the
level of NK cell activation, which is under control of the Cmv1 locus [Scalzo et al.,
1990] which lies within the NK gene complex [Scalzo et al., 1992]. Cmv1 encodes
the activated NK cell receptor Ly49H. NK cells from BALB/c mice lack this locus
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and consequently they do not induce the correct signals for NK cell activation
after MCMV infection. However, 50% of the NK cells of C57Bl/6 mice bear the
Cmv1 locus and express Ly49H. Therefore, the BALB/c mouse strain is consid-
ered as MCMV-susceptible while the C57Bl/6 are MCMV-resistant.
MCMV-infected cells express the viral protein M157, which has been shown
to be a strong ligand for Ly49H [Arase et al., 2002]. It is interesting that the
virus expresses a protein which will induce activation of NK cells and therefore
the innate immune response. However, despite this viral protein, MCMV has
also evolved immunevasive mechanisms to escape from NK cells. For instance,
Arase and coworkers also showed that M157 binds the inhibitory receptor Ly49I,
which association will block NK activation. A second receptor essential for NK
cell activation is NKG2D. This receptor is a potent activator of NK cells which
has also been shown to be targeted by both HCMV and MCMV (reviewed in
[Lenac et al., 2008].
Monocytes/Macrophages (Mθs)
Monocytes are produced in the bone marrow from haematopoietic precursors.
They circulate in the blood until they move to the tissues, where they mature
into Mθs. Monocytes and Mθs have been shown to be a replication site for
MCMV. Moreover, upon infection, MCMV disseminates to other organs aided
by blood monocytes, which act as vehicles. It has been reported that the dif-
ferentiation process defining the maturation of monocytes into Mθs favors viral
infection [Hanson et al., 1999]. Mθs also play a role during latency, since it has
been found that these cells are a major site of persistence of MCMV DNA in the
latent state. Moreover, the bone marrow has been defined as a ’source’ of latent
MCMV [Pollock et al., 1997, Mitchell et al., 1996].
Besides, Mθs represent the first line of defense along with NK and dendritic
cells. Upon activation, Mθs produce a number of mediators which will activate
and recruit other immune cells to the site of infection. Mθs also coordinate innate
and adaptive immunity. Therefore, it is not surprising that different viruses have
developed strategies to avoid Mθs activation or Mθ-induced immune responses.
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Indeed, MCMV has been demonstrated to reduce the expression of MHC-class
II on the surface of infected macrophages, by inducing the production of IL10
[Redpath et al., 1999].
Because Mθs also play a role in CMV-induced pathogenesis, there are several
studies trying to identify the viral genes responsible for Mθs tropism, and find
homologues for HCMV.
Dendritic Cells (DC)
DCs are professional antigen presenting cells (APC). Upon activation, DCs mi-
grate to lymphoid tissues where they present antigens to T cells. Several sub-
types of DCs have been described. They differ in Toll like receptors (TLRs), cos-
timulatory proteins and cytokines produced. Therefore, the type of immune re-
sponse induced by DCs depends on the subtype infected or activated. MCMV
can infect DCs. Moreover, there is evidence showing that MCMV induces changes
in the cytokine profile of the cells as well as their capacity to activate T cells [An-
drews et al., 2001].
Direct contact between DCs and NK cells is required for T lymphocyte ef-
fector cell expansion. Therefore, interfering with the expression of costimularoty
proteins on the surface of DCs might block this expansion and interfere with both
innate and adaptive cellular immune response. MCMV has been reported to in-
terfere with the expression of costimulatory proteins in APC. In fact, the m138
gene product has been reported to downmodulate B7.1 in DCs [Mintern et al.,
2006] and modB7-2 has been identified to downmodulate B7.2 in Mθs [Loewen-
dorf et al., 2004]. These proteins are important T cell stimulators and therefore
by modulating their expression the virus also interferes with T cell activation.
Activated DCs produce IL12 which is important for NK activation and sub-
sequent IFNγ production. DCs have been described as major producer of type I
IFN after MCMV infection [Dalod et al., 2002].
HCMV has been also reported to target DC function. Chang and coworkers
showed that HCMV induces an alteration in DC migration and IL12 production
which will then have an effect on NK and T cell activation. Interestingly, these
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effects were seen to be mediated by a IL10 viral homolog, known as cmvIL10
[Chang et al., 2004]. In addition to this strategy there are other studies showing
the ability of HCMV to manipulate the expression of several chemokines respon-
sible for DC migration to lymphoid organs [Varani et al., 2005].
A recent report has shown that HCMV infection of plasmacytoid DC results
in a differential regulation of B and T cells. Activation of pDC by HCMV resulted
in the release of several cytokines which favor B cell activation. However, in
contrast to this response, the ability of pDC to activate T cells were decreased
[Varani et al., 2007]. These studies highlight the importance of cross-talk amongst
cells of the immune response against viral infection.
Cytokines and chemokines
An important part of the immune response against MCMV is played by cy-
tokines and chemokines. These chemical mediators are crucial for recruiting
more immune cells to the site of infection and alerting non-infected bystander
cells to the presence of the pathogen. In the following section, several cytokines
known to mediate a key role during MCMV infection are briefly described, as
well as the immune evasion mechanisms known to be used by the virus, to coun-
teract these mediators.
Interferon (IFN) Type I IFN comprising members of the IFNαβ family induce an-
tiviral responses following binding to the receptors IFNAR1 and IFNAR2. Upon
ligand binding, Jak1 and Tyk2 are phosphorylated, leading to the phosphoryla-
tion of STAT1 and STAT2. Activation of these proteins drives to the formation of
a transcriptional complex known as IFN-stimulated gene factor 3 (ISGF3), which
is a trimolecular complex composed of STAT1, STAT2 and the transcription fac-
tor IRF9. This transcriptional complex will then bind to IFN-stimulated response
elements (ISRE) and induce gene expression.
Studies on IFNβ production have shown that full induction of the IFNβ gene
required the contribution of three transcription factors, c-Jun/ATF-2, NF-κB and
interferon regulatory factor 3 (IRF3). This first wave of IFN induces a positive
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feedback loop dependent on IRF7 which will contribute to a robust IFNαβ re-
sponse.
After MCMV infection, IFNαβ levels can be early detected in spleen and
liver of infected mice. Plasmacytoid (pDC) and non-plasmacytoid dentritic cells
(DC) are responsible for this first induction of IFNαβ [Orange and Biron, 1996,
Hokeness-Antonelli et al., 2007, Zucchini et al., 2007]. In addition, a very recent
report has demonstrated that stromal cells in the spleen of infected mice play a
key role in the production of IFNαβ [Schneider et al., 2008]. B cells-produced
lymphotoxin β (LTβ) which activate the splenic stromal cells through the LTβ-
LTβR signalling pathway, leading to the production of IFNαβ. In contrast, pDC-
induced IFNαβ which is dependent on the activation of the TLR9/MyD88 sig-
nalling pathway in the spleen, but it is TLR9-independent and MyD88-dependent
in the liver [Delale et al., 2005, Hokeness-Antonelli et al., 2007]. A second wave
of IFNαβ production has been observed in an IRF8-dependent fashion [Tailor
et al., 2007], which ensures the optimal cytokine antiviral response.
The role of IFNαβ in the control of MCMV infection in the natural host has
also been studied. It is now well established that IFNαβ activates natural killer
(NK) and CD8+ T cells which in turn are induced to produce IFNγ. Furthermore,
this cascade of events has to be under strict control since high levels of IFNαβ
could lead to autoimmune damage [Hahm et al., 2005]. A recent study has shown
that NK cells balance the pDC-induced IFNαβ by controlling viral replication
and avoiding overwhelming activation signals to CD8+ T cells [Robbins et al.,
2007].
CMV has evolved with the host by developing evasive strategies: the human
CMV IE1 protein prevents binding of the ISGF3 complex to IFN-induced promot-
ers by physically interacting with STAT1 and STAT2 [Paulus et al., 2006]. Unlike
HCMV, MCMV IE1 has not been shown to share the same function. Instead, a re-
cent investigation suggests that MCMV IE1 is required for an efficient induction
of IFN-induced genes [Busche et al., 2008]. Another recent report has revealed
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that MCMV inhibits IFNβ transcription by interfering with the transcription fac-
tor involved in the formation of the enhanceosome [Le et al., 2008]. Although
this report showed that MCMV gene expression is required for this immune eva-
sive strategy, the exact mechanisms of this process remain undetermined. Tyk2
has been shown to be crucial for the antiviral response against MCMV infection
both in vitro and in vivo [Strobl et al., 2005], however since the IFNαβ-induced re-
sponse was not impaired in the absence of Tyk2, the mechanisms by which this
kinase exerts its antiviral effects still remains unidentified.
Type II IFN refers to IFNγ. Following activation of NK and CD8+ T cells,
IFNγ is produced and binds to the IFNγ receptor (IFNGR), which is composed of
two subunits: IFNGR1 and IFNGR2, both of which are ubiquitously expressed.
IFNγ helps to activate bystander cells and is known by the induction of the an-
tiviral state by which the cells prepare to control viral infection. However, the
mechanism of IFNγ-induced inhibition of viral replication is not entirely under-
stood. Ligand binding to the receptor induces the phosphorylation of Jak1 and
Jak2. Activated Jak1 then phosphorylates STAT1 which associates with other
phosphorylated STAT1 to form homodimers. These complexes translocate to
the nucleus and bind to IFNγ-activation site elements (GAS) which will induce
the activation of IFNγ-induced gene expression. Although IFNγ-induced sig-
nalling pathways are STAT1-dependent, there are several studies showing that
also STAT1-independent pathways also exist which are important for antiviral
activity [Ramana et al., 2002].
The role of this cytokine in the control of MCMV infection has been exten-
sively studied both in vivo [Pomeroy et al., 1998, Heise and Virgin, 1995] and
in vitro [Lucin et al., 1994]. Considering the role that IFNγ plays in antiviral
immunity it is not surprising that MCMV has evolved strategies to evade IFNγ-
induced antiviral activity. Indeed, it has been demonstrated that MCMV inhibits
IFNγ-induced MHC class II expression on the cell surface by affecting expres-
sion of the MHC II components [Heise et al., 1998] and by inducing cellular IL10,
which is a known anti-inflammatory cytokine [Redpath et al., 1999]. It has been
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also reported strategies by which the virus affects both type I and II IFN path-
ways by targeting STAT2. In fact, the MCMV viral protein pM27 specifically
binds to STAT2 and leads to its degradation [Zimmermann et al., 2005]. This
mechanism would affect the crosstalk between both pathways during the an-
tiviral activity. This mechanism allows MCMV to escape from the activation of
CD4+ T cells. However, and despite the antiviral effect of IFNγ, its production
is maintained in spleen cells even after the resolution of the acute infection, sug-
gesting a role in the activation of latent virus [Shanley et al., 2001]. IFNγ is also
important for viral clearance from the salivary glands [Lucin et al., 1992].
Interleukins Different interleukins have been shown to play a role in the control
of MCMV infection. In this section some of them will be described in more detail
according to the relevance of their function in the context of MCMV infection.
IL10 is produced by a variety of immune cells including Mθs, DCs, and T
cells. The anti-inflammatory function of this cytokine is well established, its role
in limiting the production of proinflammatory cytokines, such as tumor necro-
sis factor (TNF), IL6 and IL12 has been throughly characterized. IL10 has also
been reported to have a role in MCMV infection in primary Mθs. Redpath and
coworkers demonstrated that MCMV-induced down-regulation of MHC class II
in infected cells was driven by the induction of IL10 in these cells [Redpath et al.,
1999]. Very recently IL10 has been described as an important regulator of the
immune response against infection, since it can control both pathogen invasion
and pathology [Couper et al., 2008]. This would be consistent with a recent study
showing that the depletion of IL10 resulted in more severe symptoms of MCMV
infection in the natural host, due to the uncontrolled production of inflammatory
cytokines such as IFNγ, IL6 and TNF [Oakley et al., 2008]. IL10 is also crucial
for the control of MCMV infection in salivary glands, where the virus can still
replicate even after clearance of the acute infection. Humphreys and cowork-
ers suggest that MCMV persists in this gland by manipulation of IL10-induced
blockade of IFNγ production [Humphreys et al., 2007]. Human CMV, but not the
murine virus, encodes a viral homolog of IL10 known as cmvIL10 [Kotenko et al.,
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2000]. This viral cytokine is also capable of engaging the IL10 receptor as well
as activating signalling molecules such as STAT3 [Spencer, 2007]. Other viruses,
such as Epstein Barr (EBV) and Orf virus, have also been reported to encode viral
homologues of IL10 (reviewed in [Alcami, 2003]).
The IL6 receptor is a heterotrimeric complex consisting of an α chain and a
signal transducing chain, also known as gp130. After ligand binding the conse-
quent association between the α chain and gp130 drives the activation of Jak1,
Jak2 and Tyk2 which leads to phosphorylation of STAT1 and STAT3. IL6 is pro-
duced by Mθs, T and B cells, endothelial cells and fibroblasts. It is induced by
a variety of stimuli, including TNF, IL1 and LPS. It was initially identified as a
factor required for B cell differentiation into plasma cells. In addition, IL6 has
been shown to be involved in T cell activation. IL6 also has a role in the inflam-
matory response by inducing the production of MCP1, which recruits other im-
mune cells [Rahbar et al., 2003]. However, there is evidence demonstrating that
IL6 might also act as an anti-inflammatory cytokine. For instance, IL6 induces
the release of glucocorticoids, which negatively regulate immune functions [Bar-
ton, 1997]. MCMV infection results in the production of IL6 [Ruzek et al., 1997].
In addition, IL6 production has been associated with MCMV-induced atheroge-
nesis [Rott et al., 2003]. In HCMV-infected patients IL6-induced inflammatory
response might have consequences in patients with inflammatory bowel disease
[Rahbar et al., 2003]. The human virus induces a transcriptional regulation of IL6
mRNA in Mθs by a mechanism involving the IE1 protein [Geist and Dai, 1996],
maybe through the activation of NFκB. NFκB has also been shown to be essential
for il6 expression [Libermann and Baltimore, 1990].
IL12 is also produced very early after infection and is required for the optimal
activation of NK cells and subsequent production of IFNγ in spleen and liver
after acute infection. The strength of IL12 signalling is related to the activation of
NK cells [Orange et al., 1995]. In addition, IL12 production is also under control
since it has been reported that IFNαβ inhibits IL12 production, which in turn
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affects the consequent NK-induced IFNγ. It has also been shown that MCMV
infection of DCs results in a significant reduction in IL12 production after 4 days
post infection [Andrews et al., 2001], resulting in a decrease in the activation of
NK and T cells. However, the mechanisms by which this reduction is regulated
have not been elucidated.
IL1 has also been shown to play a role in the control of CMV infection. This
pro-inflammatory cytokine is mainly produced by monocytes and Mθs, and it
has been reported that it induces the blockade of viral spread in different cell
types [Randolph-Habecker et al., 2002]. It is suggested in this study that IL1
might limit viral spread by induction of IFNβ production.
Tumor necrosis factor (TNF) and Lymphotoxin (LT) TNF, also known as tumor
necrosis factor-α, is mainly produced by Mθs, and also by NK, DC and activated
T cells. TNF exerts its biological activities via signalling through two receptors:
TNR receptor 1 (TNFR1, CD120a or p55) and TNR receptor 2 (TNFR2, CD120b
or p75), both of which belong to the TNF receptor superfamily. Members of
this family can be subdivided into different groups depending on their cytosolic
signalling domains: death domain (DD)-containing, also known as death recep-
tors, and TNFR-associated factor (TRAF) binding receptors [Benedict et al., 2003].
TNFR1 is a DD-containing receptor along with others such as Fas, TNF-related
apoptosis inducing ligand receptor 1 (TRAIL-R1) and TRAIL-R2. Engagement of
these receptors leads to the activation of apoptosis, via recruitment of signalling
molecules which induce caspase activation. The second group of receptors sig-
nal through the recruitment of TRAF molecules which results in the activation of
gene expression by activation of NF-κB as well as members of the mitogen acti-
vated protein kinases (MAPK). Despite these two opposite responses, cell death
or survival, these signalling cascades are also characterized by crosstalks which
ultimately will decide the final outcome of the TNF-induced response. There-
fore, it is understandable that TNF has been considered to be a ’double-edged
sword’ in the immune response, since it can induce processes both positive and
negative for the cell [Aggarwal, 2003].
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Although both receptors can be found in a wide range of cell types, TNFR2
appears to be restricted to immune cells. It has been proposed that TNFR1 me-
diates the majority of TNF-induced responses. TNF is important for lymphoid
tissue and hematopoietic proliferation and protection against pathogen invasion
but uncontrolled TNF production also leads to tissue destruction, as in rheuma-
toid arthritis and other diseases.
One of the main activities of TNF is to provide protection against pathogen
invasion. Therefore, and considering the role of this cytokine in the fate of cells,
TNF might be considered as the perfect target for pathogens, since both cell
death and gene expression could be modulated by controlling TNF-induced sig-
nalling pathways. Indeed, there are a number of pathogens which have devel-
oped several mechanisms to inhibit or modulate different stages of the TNF re-
sponse, from the blockage of TNF binding to the receptor to inhibition of specific
TNF-induced responses, such as gene expression or caspase activation [Herbein
and O’Brien, 2000, Benedict and Ware, 2001, Rahman and McFadden, 2006]. To
date both human and murine CMV have been reported to block TNF-induced
gene expression by interfering with TNF receptor expression [Popkin and Vir-
gin, 2003, Baillie et al., 2003, Montag et al., 2006]. Others have shown that HCMV
inhibits TNF-induced caspase-dependent apoptosis by encoding viral inhibitors
[Skaletskaya et al., 2001]. Very recently murine MCMV has been shown to block
caspase-independent apoptosis by direct binding and degradation of receptor-
interacting protein RIP1 by the viral protein M45 [Mack et al., 2008]. RIP1 degra-
dation occurs upstream of activation of NF-κB and MAPK during the TNF-induced
signalling pathway.
Despite the large amount of information detailing viral strategies to modu-
late TNF-induced responses, there are only a few examples in the literature of
viral proteins which interfere with tnf gene expression or protein production.
One of these examples is the African Swine fever virus (ASFV). It has been re-
ported that ASFV infection of Mθs results in the inhibition of TNF expression
by interfering with the activity of CBP/p300 [Granja et al., 2006]. Epstein Barr
(EBV) has also been shown to inhibit TNF production in cell culture [Gosselin
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et al., 1992], however the molecular mechanism of this regulation is not clearly
understood. By contrast, another study has shown that EBV gp350 induces TNF
[D’Addario et al., 2000]. In contrast to the TNF evasion measures that CMV has
evolved, work done by Geist and coworkers have indicated that the IE1 protein
of HCMV is involved in the induction of tnf gene expression in Mθs, probably
by interfering with the transcription factors involved in the activation of the pro-
moter [Geist et al., 1994, Geist et al., 1997]. However, the exact mechanism of this
regulation is not completely understood. So far there is no evidence showing the
same regulation by the murine virus.
In MCMV infection, there have been several studies trying to elucidate the
role of this cytokine in the control of viral infection in the natural host. How-
ever, results provide contradictory evidence. Shanley and colleagues showed
that after both lethal and sublethal infection of BALB/c mice TNF levels were
undetectable in serum. However, levels of this cytokine in serum were found
in MCMV-infected BALB/c [Trgovcich et al., 2000] and C57BL/6 [Lenzo et al.,
2001] and in all organs examined. It also appears that TNF was produced in
a viral dose-dependent manner. In addition, studies by Trgovcich showed that
the tnf gene was expressed during sublethal infection in spleen, liver and lung.
Tang-Feldman reported on the levels of expression of different cytokines after
MCMV infection in BALB/c mice, showing an induction in TNF expression at
day 5 p.i in spleen, liver, lungs and salivary glands [Tang-Feldman et al., 2006].
Thus, the production of TNF early after infection suggests a role in the control of
in vivo infection of different strains of mice in serum, spleen, liver and heart.
Although the use of specific antibodies to neutralize TNF activity in vivo did
not result in a significant increase of viral titers [Shanley et al., 1994, Heise and
Virgin, 1995], Lucin and coworkers demonstrated that TNF in combination with
IFNγ has a more effective anti-MCMV effect [Lucin et al., 1994]. Also TNF has
an autocrine/paracrine action. By its paracrine action it can help to activate by-
stander cells to respond to viral infection. In fact, TNF blockade has been shown
to affect Mθs activation and infiltration during MCMV and HSV infection [Heise
and Virgin, 1995].
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Within the TNF superfamily, another ligand has to be taken into considera-
tion in the context of MCMV infection, namely Lymphotoxin (LT). As with TNF,
LT also has a role in the development of lymphoid tissues and immune cells. LTα
binds to the same receptors as TNF (TNFR1 and TNFR2). LTα can also form with
LTβ the heterotrimer LTαβ which binds to the LTβ receptor (LTβR). This receptor
also binds a second ligand known as LIGHT, which also binds to the herpesvirus
entry mediator or HVEM [Aggarwal, 2003]. The role of the LTαβ-LTβR system in
the control of MCMV infection has been studied. Different investigations have
demonstrated that the LTβ signalling pathway plays an important role in hu-
man CMV infection by inducing IFNβ production. However, this response relies
on the presence of HCMV [Benedict et al., 2001]. They have also reported that
LTαβ-LTβR is pivotal for MCMV infection in vivo, since genetic depletion of LTα
resulted in a high susceptibility to MCMV infection. LTβ is also produced af-
ter infection and LTβ-LTβR signalling is crucial for the production of IFNαβ by
splenic stromal cells. Thus, it is not surprising that blocking LTβ- induced sig-
nalling results in high viral burden. The crosstalk between LTβ-LTβR signalling
and IFNβ was demonstrated when the antiviral activity was restored by admin-
istrating IFNβ [Banks et al., 2005].
Chemokines Chemokines are a small family of chemoattractant cytokines whose
main function is to induce trafficking and recruitment of other cells. Chemokines
are divided into different groups depending on the molecular structure. There
are four main groups: CC chemokines (or β-chemokines), CXC chemokines (or
α-chemokines), C chemokines (or γ-chemokines) and CX3C chemokine (or δ-
chemokines). Amongst the functions of these cytokines are: trafficking of leuko-
cytes and regulation and differentiation of cells of hematopoietic lineage and
inflammation [Schall and Bacon, 1994]. There are also several studies show-
ing the production of chemokines and their effect on viral infection (reviewed
in [Melchjorsen et al., 2003]). Moreover, the fact that an important number of
viruses encode their own chemokines and chemokine receptors reveals the key
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role that these mediators play during the immune response against viral infec-
tion. Both human and murine CMV encode viral chemokines. For instance,
HCMV UL146 product vCXC-1 has been reported to function as an agonist of
human IL18. It induces neutrophil chemotaxis to the site of infection favoring
viral dissemination [Penfold et al., 1999]. MCMV chemokines MCK-1 and MCK-
2 also control viral dissemination in the natural host by recruiting leukocytes to
the site of infection [Saederup et al., 1999]. HCMV encodes 4 chemokine recep-
tors, UL33, UL78, US27 and US28 [Chee et al., 1990]. US28 has been reported to
bind and sequester chemokines from the extracellular environment, which will
inhibit lymphocyte recruitment and activation [Bodaghi et al., 1998]. In addi-
tion, the ability of HCMV US28 to induce migration of smooth muscle cells has
implicated this viral chemokine receptor in the development of atherosclerosis
[Streblow et al., 1999]. The murine homolog of HCMV UL33, known as M33,
has been reported to be important for viral replication in vivo, particularly in the
salivary glands [Davis-Poynter et al., 1997].
In addition to several other herpesviruses which have been reported to en-
code viral chemokines, there are other viruses too which have evolved this eva-
sion strategy (reviewed in [Alcami, 2003], demonstrating the key role that these
proteins play in the regulation of the immune response.
1.5.4 Adaptive immunity
The adaptive immune response follows the initial innate response, and is char-
acterized by the activation of T and B cells. The protective role of T cell subsets
has been studied. CD8+ T cells become activated by the recognition of antigens
presented by MHC class I molecules, as well as the presence of several coestim-
ulatory proteins. Even though it is known that CD8+ T cells play an important
role in MCMV protection, different studies revealed that MCMV was also cleared
when this subset was absent [Jonjic et al., 1990]. Surprisingly, viral clearance ap-
peared to rely on CD4+ T cells. These results are also important since they re-
vealed the flexibility of the immune response to adapt to specific conditions and
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induce compensatory mechanisms keeping the organism protected. In fact, this
central role of CD4+ T cells is only apparent in the absence of CD8+ T cells.
Naive CD4+ T cells are activated following interaction between the T-cell
receptor (TCR) and antigens bound to MHC class II molecules, expressed on
the surface of APC. Activation of CD4+ T cells results in the expression of a
wide range of cytokines which will orchestrate the immune response. Jonjic and
coworkers also studied the role of CD4+ T cells during MCMV infection. In vivo
studies showed that these cells are key players in control of MCMV infection in
the salivary glands [Jonjic et al., 1989], where they mediate immunity through
the production of TNF and IFNγ. In the absence of CD4+ T cells, CD8+ T cells
are still central in MCMV clearance, although with slower kinetics.
In addition to viral evasion strategies for escaping the innate immune re-
sponse, there are also studies showing viral immunomodulatory strategies to
counteract adaptive immunity. These are generally based on the disruption of
antigen presenting pathways. These evasion strategies are also shared by other
viruses, including HSV, EBV and HIV, revealing the importance of this path-
way in the immune response (reviewed in [Alcami et al., 2005]). Both human
and murine CMV encode proteins which reduce the expression of MHC class I
molecules, either by inducing their degradation, like HCMV US2 and US11 pro-
teins, or MCMV gp34, gp48 and gp40 (reviewed in [Hengel et al., 1998]). Disrup-
tion of CD4+ T cell activation due to HCMV and MCMV has also been reported
by interference with expression of MHC class II molecules. HCMV infection re-
duces the expression of IFNγ-induced MHC class II by either interfering with
the IFNγ signalling pathway or by inducing the production of HCMV cmvIL10,
an inhibitor of MHC class II expression [Spencer et al., 2002]. MCMV however
induces cellular IL10 in order to inhibit IFNγ-induced MHC II expression in peri-
toneal Mθs [Redpath et al., 1999]. Also in Mθs it was seen that type I IFN might
also be involved in the inhibition of the expression of MHC class II [Heise et al.,
1998].
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Unlike T cells, the role of B cells in MCMV infection is not well defined. On
the one hand, it is very difficult to completely delete B cells, since antibody de-
pletion strategies do not inhibit plasma cells. On the other hand, the interaction
between B and T cells has to be taken into consideration when drawing any con-
clusions, since B cells are important for T cell expansion. However, it has been
shown that B cell-induced immunity is not required for viral clearance during
primary infection [Jonjic et al., 1994]. Later, by using an immunocompromised
mouse model, protection against MCMV after adoptive transfer of memory B
cells was demonstrated [Klenovsek et al., 2007]. This study also showed that the
antiviral protection was antibody-dependent. Understanding the role of these
cells in the immune response is crucial for bone marrow transplantation.
1.5.5 Latency
One of the hallmarks of herpesviruses is the ability to establish a long term in-
fection within the host, which might last for life, known as a latent infection.
The study of HCMV latency has been problematic due to the fact that, unlike
other viruses in which the establishment of latency is restricted to specific tis-
sues, HCMV can be found in a latent state in several tissues, including lungs,
kidney, liver and bone marrow [Koffron et al., 1997, Minton et al., 1994] and the
same situation has been described for MCMV as well [Koffron et al., 1998]. Al-
though the molecular mechanisms controlling establishment and maintenance of
CMV latency are not known, the role of the immune system has been extensively
studied. For instance, after primary infection cell-mediated immunity does not
completely clear the virus, even though viral replication is inhibited primarily
by NK and CD8 T cells. Instead, the virus persists for longer periods by the es-
tablishment of latency. The initiation of this process has also been suggested to
be part of the viral immune evasion strategy. Therefore, by shutting down viral
gene expression the virus limits the number of antigens which might be recog-
nized by CTLs.
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The role of Mθs in CMV latency has been extensively reported. Thus, it is
now known that DNA for human and murine CMV can be found in Mθs dur-
ing latent infection [Jarvis and Nelson, 2002, Mitchell et al., 1996, Pollock et al.,
1997]. Moreover, bone marrow cells have also been shown to harbor latent DNA,
suggesting that it might act as a source of latent virus. Mθs have also been im-
plicated as vehicles for dissemination not only during acute infection [Stoddart
et al., 1994] but also during latency [Pollock et al., 1997].
Although in some of the aforementioned studies no viral transcripts were
found, it is generally accepted that latency might involve a low basal transcrip-
tional activation in latently-infected cells. For instance, Kurz and coworkers
showed that during latency, the MCMV ie1/ie3 transcriptional unit remains ac-
tive in lungs [Kurz et al., 1999]. This transcriptional activity is restricted to ie1
but is not sufficient to induce reactivation of the virus. Since IE3 is responsible
for activation of the early phase of the viral cycle, the lack of IE3 explains why,
even though IE1 transcripts are detected, no reactivation can be seen. In fact,
CD8 memory T cells specific for IE1 are key players in this stage of latency, since
there is a continuous control for viral antigens and inhibit any attempt of reacti-
vation [Simon et al., 2006]. This study suggest an important role of the MIE locus
in dictating MCMV reactivation in this tissue.
Viral reactivation from latency has been suggested to occur though several
mechanisms, including inflammatory signals, cellular differentiation and allo-
geneic stimulation. Notably, the role of the immune system is common to all
mechanisms proposed. Under immunosuppressive conditions the monitoring of
viral antigens performed by memory T cells might be absent. Therefore, the basal
transcriptional activity which has been described in latent CMV infection might
continue towards the expression of viral genes leading to a replicative cycle and
complete reactivation. On the other hand, during transplantation and cellular
differentiation, cytokine production might occur. Within the cytokine pool, TNF
has been shown to play a role in viral reactivation. This proinflammatory cy-
tokine is known to induce activation of several transcription factors which bind
to the MCMV MIEP enhancer region, including NF-κB and AP1 [Hummel et al.,
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2001]. However, it has also been shown that this TNF-dependent viral gene ex-
pression reactivation might be organ-specific [Hummel et al., 2001, Hummel and
Abecassis, 2002] and would not explain the reactivation process in other organs.
In any case, it seems that the immune system is crucial during the whole la-
tency period, as described by Redpath and coworkers in their model for viral
latency [Redpath et al., 2001]. Latency might be described as a state of balance
between the virus and the immune system. This model suggests that the main-
tenance of latency depends on the activation threshold of immune cells, which
changes with the immune status of the host. In this model the associated risk to
both virus and host due to reactivation is also considered; injury to the host due
to virus-associated disease and inhibition of the virus due to immune control.
Importantly, this model is not only restricted to CMV but also to other viruses
which are capable of establishing latency.
1.5.6 Human Herpesvirus 6 and Human Herpesvirus 7
HHV6 and HHV7 also belongs to the beta Herpesvirus subfamily, and they com-
pose the Roseolovirus genus. They all share characteristics with the more exten-
sively studied CMV. These viruses are T lymphotropic but they also infect other
types of cells. HHV6 infects T and B cells, macrophages and NK cells. In contrast,
HHV7 has a more restricted cell tropism based on the finding that it utilises CD4
as a receptor [Lusso et al., 1994], infecting T cells. In vivo epithelial cells from
the salivary gland have also been identified as targets for HHV7. Because Rose-
oloviruses have been recently discovered the kinetics of gene expression have
not been studied in extent, however it seems to follow the typical temporal cas-
cade characteristic of other Herpesviruses. During the latent infection viral gene
expression is limited to those genes involved in maintenance of latency. HHV6
latent infection can be detected in monocytes-macrophages as well as in salivary
glands. A site for HHV7 latency is CD4 T cells, epithelial cells from the sali-
vary glands among others. Roseoloviruses share with VZV the re-envelopment
pathway for virion egress as previously explain in Section 1.1.2.
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After HHV6 and HHV7 infection cellular immunity seems to have a key role
in the control of viral infection, particularly T cells response [Yakushijin et al.,
1991, Yakushijin et al., 1992, Yasukawa et al., 1993]. Clinical data also indicate
the role for IFNα and NK cells [Takahashi et al., 1992]. Other cytokines like
TNF, IFNγ and IL1β have also been shown to be produced after HHV6 infection
[Flamand et al., 1991].
HHV6 and HHV7 infection occurs during infancy. Although the transmis-
sion mechanism is not clear yet it seems that saliva is the most common route
of infection. HHV6 has also been detected in the cervix of pregnant women,
suggesting a possible transmission to newborns. Breast-feeding has also been
suggested to help the transmission of HHV7. Other routes of infections have
also been suggested such as bone marrow or solid organ transplantation in the
case of HHV6.
As introduced before, HHV6 and HHV7 infection causes ES in infants char-
acterized by transient rash after following by sudden fever. In rare cases febrile
convulsion could happen as a result of the sudden high fever. In most cases ES
does not have any clinical complication. In adults infection could cause mononucleosis-
like disease. HHV6 can persist in the central nervous system and it might be as-
sociated with cases of HHV6-induce encephalitis. Like CMV infection, infection
of immunocompromised hosts could be fatal, as for those transplant recipients
or AIDS patients. Reactivation of HHV6 has been reported after bone marrow or
solid organ transplantation, as well as potential association with HCMV.
1.6 This Thesis: Rationale and Central Hypothesis
As has been discussed, the IE1 protein of MCMV plays a role in the regulation
of viral and host gene expression. In the virus, it trans-activates the expression
of early genes, in coordination with the IE3 protein, and in the host it seems that
the IE1-induced gene expression prepares the cellular environment to favor viral
replication. By using BAC technology an ie1-deletion mutant of MCMV, (referred
to as MCMVdie1 hereafter), was constructed in order to determine the exact role
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that this viral protein plays in the MCMV infection. In addition, the revertant
of this mutant, named MCMVrev, was also constructed in order to rule out any
second site mutations. So far, it has been demonstrated that, unlike the IE3 pro-
tein, IE1 is not required for efficient replication in different cell types. However,
in immunecompetent mice the mutant virus presents an attenuated phenotype.
Moreover, in SCID mice lacking B and T cells and relying on innate immunity to
control the infection, the mutant virus also showed a growth defect. These ob-
servations have led to the hypothesis that IE1 is involved in the regulation of the
host immune response. This would be consistent with the growth defect seen for
MCMVdie1 in vivo, most likely because the host immune response is not under
the control of the viral protein, leading to a stronger response which control viral
infection sooner. In other words, IE1 might act as a immunomodulator. To in-
vestigate this hypothesis the following questions were prompted and define the
different Chapters of this thesis:
1. How does the absence of IE1 affect viral replication in BMMθs?
BMMθs were used as a experimental system in this project, since they play
a crucial role not only for viral infection but also in the immune response
against MCMV. Moreover, MCMVdie1 replication has not been studied in
this cellular population. Therefore it was of interest to study MCMVdie1
infection in a cell type involved in the control of viral infection. In addition,
IE1 protein has been described as a trans-activator of cell and viral gene
expression. Therefore it was also of interest to study the effect that the
absence of this viral protein might have in the host gene expression. In
order to have an initial observation of the effect of MCMVdie1 infection in
BMMθs a pilot study was carried out between MCMVdie1 and MCMVrev
using microarray technology. The following objectives were set:
• To determine the effect of the absence of IE1 in viral replication in
BMMθs
• To determine to what extent host gene expression were affected by the
absence this viral protein
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• To make an initial observation of the biological processes and path-
ways most affected after infection with MCMVdie1 by performing
analysis based on Pathway biology.
2. What effect does MCMVdie1 infection have on cytokine production in-
duced by BMMθs?
Considering the key role that BMMθs play in the control of MCMV infec-
tion, the next step in this investigation was to study in more detail the cy-
tokine production in the context of MCMVdie1 infection. The following
objectives were set up:
• To study the effect of MCMVdie1 infection in the cytokine production
in BMMθ
• To study the transcript level of those cytokines of interest
3. What are the molecular mechanisms for MCMVdie1-induced cytokine
modulation?
As it has been introduced, TNF is a key player in the control of MCMV
infection. Several viruses have been shown to target different steps of the
TNF biology however only few have been reported to target TNF produc-
tion. Results also revealed a significant regulation of TNF response by
MCMV infection. Therefore the next objective was to study in more de-
tail the molecular mechanisms of TNF response in the context of MCMV
infection in the presence and absence of ie1. To fulfill this aim two different
approaches were taken:
• A literature review was performed in order to understand the mecha-
nisms of TNF production and create a model of the different transcrip-
tion factors that might be involved in the induction of tnf expression
after MCMV infection.
• Based on the review, a extensive study on the activation of signalling
molecules was performed in infected-BMMθ. This study was done
in collaboration with Upstate (Millipore, UK). Furthermore, in order
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to validate this study, conventional Western Blot approach was also
taken.
4. Is TNF response to MCMVdie1 infection also seen in vivo?
Experimental findings in tissue culture led to the final stage of this investi-
gation, where it was of interest to determine whether MCMVdie1-induced
TNF production was also seen in vivo. The essential role of IE1 for an effi-
cient replication of the virus in BALB/c and SCID mice has been reported
[Ghazal et al., 2005]. Therefore the following objectives were set:
• Study the role of the IE1 protein in the viral replication in MCMV-
resistant C57Bl/6 mice and confirm the attenuated phenotype in MCMV-
susceptible BALB/c.
• To establish whether MCMVdie1 infection induces a significant TNF
production in both BALB/c and C57Bl/6 mice.
5. Is TNF responsible for the growth defect of the ie1-deletion mutant MCMV?
The final question of this investigation was to study whether the replication
defect seen for the mutant virus was due to the regulation of TNF response.
In the first place the effect of TNF was studied in the viral replication in
BMMθs and later was expanded to an in vivo system where genetically de-
pleted TNF C57Bl/6 mice were used.
CHAPTER 2
Materials and Methods
2.1 General Chemicals and Solutions
For general solution recipes refer to Appendix I
2.2 General Methods in Tissue Culture
2.2.1 Culturing NIH 3T3
The murine fibroblast cell line NIH-3T3 cells (ATCC CRL1658) was obtained
from American Type Culture Collection (Manassas, VA.). Cells were grown in
Dulbecco’s modified essential medium (DMEM) supplemented with 10% calf
serum (CS), 2 mM glutamine (Invitrogen, UK) and 100 U of penicillin/streptomycin
(Invitrogen, UK) per ml. Cells were incubated at 37◦C and 5% CO2 in tissue
culture flasks (Corning, UK), until they reached 70-80% confluency. Cells were
expanded as described in Section 2.2.3.
2.2.2 Culturing Primary Murine Embryonic Fibroblasts (MEFs)
MEFs were prepared from embryos of pregnant BALB/c mice on day 16 of gesta-
tion. Cells were grown in DMEM supplemented with 10% fetal calf serum (FCS),
2 mM glutamine (Invitrogen, UK) and 100 U of penicillin/streptomycin (Invit-
rogen, UK) per ml. Cells were incubated at 37◦C and 5% CO2 in tissue culture
flasks (Corning, UK), until reached confluency, but never left to 100% confluency




2.2.3 Handling cells for passaging
Cells were expanded when they reached 70-80% confluency. Medium was dis-
carded and cells were washed with PBS (Sigma, UK). PBS was discarded and
cells were detached from the flask by using Trypsin. The flask was gently rocked
for a couple of min and most of the Trypsin solution was discarded. Cells were
transferred to a 15 ml Falcon tube and spun at 1100 rpm for 5 min at room tem-
perature in 4 ml of DMEM supplemented with the specific serum. The cell pellet
was resuspended in culture media and transferred to a new tissue culture flask.
Table 2.1: Handling cells for passaging
Tissue Culture Flask PBS (ml) Trypsin (ml)
25 cm2 5 3
75 cm2 10 4
175 cm2 20 5
2.2.4 Freezing cells for long term storage
Cells were trypsinised as described previously in Section 2.2.3. Cells were trans-
ferred to a 15 ml Falcon tube and centrifuged at 1100 rpm for 5 min at room
temperature. The cell pellet was resuspended in 3 ml of freezing medium. 1 ml
aliquots were transferred to 1.8 ml cryovials (Corning, UK). The cryovials were
labelled and stored in liquid nitrogen until use.
2.2.5 Thawing cells from liquid nitrogen storage
Cryovials containing frozen cells were removed from liquid nitrogen and thawed
slowly at 37◦C. Cells were then tranferred to a 15 ml Falcon tube and 5 ml of
culture medium was added to wash out the DMSO contained in the freezing
medium. Cells were centrifuged at 1100 rpm for 5 min at room temperature.
Supernantant was discarded and cell pellet was resuspended in 1 ml of culturing
medium and transferred to a 25 cm2 tissue culture flask and grown as previously
described (Sections 2.2.1 and 2.2.2)
2.2.6 Bone Marrow Derived Macrophages (BMMθs)
1. Preparation and culture of BMMθs
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BMMθs were prepared from 10-12 week old male BALB/c mice. Animals
were killed by cervical dislocation. Fur was cleaned with ethanol, an in-
cision was made from the abdomen and the femurs exposed by remov-
ing muscles surrounding the bone. The hip and knee joints were cut and
any remaining tissue was removed using desinfectant wipes. The femur
was held with sterile forceps and the marrow cavitiy was flushed with
DMEM:F12 supplemented with 10% FCS and 10% L929 conditioned medium.
Cells were recovered in a 50 ml Falcon tube, centrifuged at 1100 rpm at
room temperature for 5 min and resuspended in DMEM:F12 medium. Cell
number was determined by microscopy using a haemocytometer (described
in Section 2.3). Cells were plated into either 24- or 6-well plates and cul-
tured for 7 days in DMEM:F12 containing 10% FCS and 10% L929 condi-
tioned medium to stimulate the differentiation of macrophages. Medium
was replaced every 2 days.
2. Characterization of BMMθs
(i) Cytospin followed by Diff-quik staining.
Morphology and maturation of BMMθs was examined on Cytospins
stained with Diff-quik, a commercial stain commonly used to differ-
entiate a variety of smears. 100-200 µl from a BMMθs suspension (ap-
proximately 1 x 106 cells/ml) was added to the well of a ’cytospin
holder’ and the cells were cytocentrifuged at 300 g for 3 min in a Shan-
don Cytospin II (Shandon, UK). The cells were then fixed with 100%
methanol for 2 min, followed by staining in the Diff-quik Red solution
for 1 min and Diff-quik Blue solution (both from Gamidor Ltd, UK)
for 1 min. All steps were performed at room temperature. The slides
were rinsed with distilled water, left to air-dry overnight and finally
coverslipped and mounted (Figure 2.1).
(ii) Flow Cytometry.
Maturation of BMMθs was also tested by flow-cytometric analysis of
surface markers. Thus, an analysis was performed for expression of
murine macrophage cell surface proteins F4/80 and CD11b. Double
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Figure 2.1: Phenotype of BMMθs after 7 days of culture
Maturation of day 7 BMMθs was determined by cytopsin followed by Diff Quik staining.
A. x100 magnification of mature BMMθs, without any contaminating cells and B. x1000
magnification indicating the features of BMMθs.
labelling allows the detection of mature BMMθs compared to mono-
cytes, which only express CD11b. At day 7, BMMθs were detached
from the culture plates using a cell scraper, transferred to polystyrene
FACS tubes (BD Falcon, UK) and centrifuged at 300 g for 5 min at 4◦C.
The supernatant was discarded and the cells were washed by adding
2 ml of cold PBS, followed by centrifugation at 300 g for 5 min at
4◦C. Cells were resuspended (2x105 cells/ml per FACS tube) in 100 µl
blocking solution (PBS containing 10% mouse serum) and incubated
for 30 min on ice. Allophycocyanin (APC) conjugated monoclonal
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rat-anti-mouse F4/80 (IgG2aκ, Caltag Laboratories, UK) and fluores-
cein isothiocyanate (FITC) conjugated rat-anti-mouse CD11b (IgG2bκ,
eBiosciences, UK), both diluted 1/100 in blocking solution, or their re-
spective isotype controls were then added. Cells were mixed gently
and incubated on ice for 30 min in the dark. Before undergoing flow
cytometric analysis, the cells were washed with cold PBS and resus-
pended in 200-300 µl of PBS. Analyses were performed using a FAC-
Scan instrument (Becton Dickinson, UK) and the results were analysed
with Cell Quest software (Becton Dickinson, UK) or FlowJo software
(Treestar, USA). A typical flow cytometric analysis of day 7 BMMθs
after staining for F4/80 and CD11b is shown in Figure 2.2.
Figure 2.2: Phenotype of BMMθs after 7 days of culture by Flow Cytometry Anal-
ysis
Maturation of day 7 BMMθs assessed by staining for the specific expression of murine Mθs cell
surface proteins F4/80 and CD11b. The level of expression was analysed by flow cytometry. A.
FACS dot blot showing the gating in forward scatter (FSC) and side scatter (SSC). B. A pure Mθs
population (93.1%) expressing both F4/80 and CD11b is seen in the upper right quadrant of the
FACS dot blot. Histograms for C. F4/80 and D. CD11b staining.
43
2.2.7 TNF treatment of BMMθs
Recombinant mouse tumor necrosis factor α (Biosource International, USA) was
prepared in DMEM:F12 supplemented with 10% FCS and 10% L929 conditioned
medium as 1U/mL or 10U/mL (10 µg/mL corresponds to 105 U/mL). Cytokine
was added to the cells 24h prior infection. After infection, cytokine was added
to the medium.
2.2.8 Cell viability assay
To determine the number of viable cells after TNF treatment CellTiter-Blue Cell
Viability Assay (Promega, UK) was performed following manufacturer’s instruc-
tions. Briefly, BMMθs were plated out in a 96-well plate at a seeding density of
4 x 104 cells/well. Cells were either treated for 24h with 1U/mL or 10U/mL of
TNF or mocked treated by adding medium. All treatments were done in tripli-
cates. After the specified time 5µL of the reagent were added to each well leaving
the plate for 4h incubation at 37◦C. Viabiliy of cells was measured according to a
fluorescent signal, correponsing to the metabolic activity of viable cells. Fluores-
cence was measured in a POLARstar OPTIMA Multifunction Microplate Reader
(BMG LabTech, UK).
2.2.9 Testing cell culture for presence of Mycoplasma
Tests for the presence of the mycoplasma were carried out every 4 months by
Minerva Biolabs GmbH (Berlin, Germany), all found negative.
2.2.10 Testing cell culture for Lymphotoxin contamination
Tests for LPS contamination were carried out regularly by SNBTS (Edinburgh,
UK), all found negative.
2.3 Cell counting
Cell counts were determined by using a haemocytometer. Cells were harvested
and resuspended in 2 ml of the appropiate medium. The haemocytometer slide
and coverslip were washed with 70% ethanol prior to use. Carefully both cham-
bers of the haemocytometer were filled with an aliquot of the cell suspension by
capillary action using a pipette. Using the microscope viable cells were counted
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only in the centre square of the 9 squares on the main grid. Counting was re-
peated for the grid on the other side of the haemocytometer. To calculate the
number of viable cells per ml in the original cell suspension the following equa-
tion was used:
Cell/ml = Average count x 104 x Dilution Factor
2.4 General Methods in Virology
2.4.1 Preparation of viral stocks
All viruses used during this thesis were propagated in NIH 3T3 cells. Cells were
cultured as described in Section 2.2.1. and infected at a MOI 0.001 with the de-
sired virus. The viral inoculum was prepared in DMEM supplemented with 3%
FCS, 2mM Glutamine and 100 U of penicilin/streptomycin per ml. 10 days after
infection, viral stock was harvested. Cells were detached from the flask and spun
at room temperature at 1100 rpm for 5 min. Supernantant was then aliquoted and
kept at -70◦C until use.
2.4.2 Titration of viral stock: plaque assay
Viral titers were quantitated by standard plaque assay. Briefly, MEFs were grown
(Section 2.2.2) and plated out in a 24- well plate at a seeding density of 105
cells/well and left at 37◦C and 5% CO2 for 24 hours. Plates were gently agitated
vertically and horizontally to evenly distribute the cells. On the day of the assay,
a serial dilution of virus was made in DMEM supplemented with 3% FCS in a 96-
well plate. MEFs were then infected with 250 µl of the specific viral dilution, and
left for 1 hour adsorption gently shaking the plate every 10 min. After 1 hour the
viral inoculum was carefully aspirated and monolayer were washed with PBS.
Meanwhile DMEM supplemented with 3% FCS was mixed with melted 2.5%
agarose (1:10) and 1.5 ml were added to each well. Plates were placed at 37◦C
and 5% CO2. Lysis plaques were counted in each well after 3-4 days of culture
and viral titer was determined as plaque forming units per ml (PFU/ml).
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2.4.3 Viral infection of BMMθs
BMMθs were prepared (Section 2.2.6) and plated out at a seeding density of 5x105
cell/well for a 24-well plate or 8x105 cell/well for a 6- well plate, unless specified.
After 7 days culture cells were infected with virus at a MOI of 1. As described
for NIH 3T3 and MEFs, the viral inoculum was prepared in DMEM:F12 supple-
mented with 3% FCS and left for 1 hour adsorption with gently shaking of the
plate every 10 min. BMMθs were washed in PBS and fresh media was added.
Plates were placed at 37◦C and 5% CO2.
2.5 General Methods for RNA
2.5.1 Trizol/RNA extraction
RNA extraction was done using Invitrogen reagents and protocols. Briefly, 200
µl of chloroform were added per 1 ml of Trizol. The mixture was shaken vigor-
ously by hand and incubated at room temperature for 15-30 min. After incuba-
tion, samples were centrifuged at 12,000 xg for 15 min at 4◦C. The upper phase
was carefully removed and transferred to a fresh microcentrifuge tube. 500 µl
of isopropanol alcohol were added per 1 ml of Trizol and incubated for 10 min
at room temperature. After incubation samples were centrifuged once again at
12,000 xg for 10 min at 4◦C. Supernatant was then removed and the pellet was
washed with 75% ethanol, vortexed and centrifuged at 7,500 xg for 5 min at 4◦C.
The pellet was air dried and dissolved in RNAse free water. Extracted RNA was
kept at -80◦C.
2.5.2 Quantification of RNA concentration.
RNA concentration was determined by using a NanoDrop ND-1000 spectopho-
tometer (NanoDrop Technologies, USA).
2.5.3 qRT-PCR
For each sample, 2x Taqman R⃝ PCR mix (Applied Biosystems, USA) was mixed
with 40 u of Superscript III (Invitrogen, USA). 4 µL total RNA was then added
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and each sample split into two reactions. A Taqman R⃝ primer/probe set (Ap-
plied Biosystems, USA) for tnf was then added to one reaction at the recom-
mended concentration while a Taqman R⃝ primer/probe set for gapdh was added
to the other reaction. Samples were then run on a MX1000P quantitative PCR
thermal cycler (Stratagene, USA). Samples were first heated to 50◦C for 30 min
then heated to 95◦C for 10 min. Samples were then subject to 40 cycles under
Taqman R⃝ standard conditions. Data was analysed by using Stratagene MXPro
software.
2.5.4 Microarray
RNA samples from MCMVdie1 or MCMVrev infeced-BMMθs were processed
using the Affymetrix Genechip Mouse 430A 2.0 protocol and the One Cycle
cDNA synthesis method with a starting amount of 2.5 µg of RNA. This was fol-
lowed by a cDNA clean-up step and an in vitro transcription step to synthesise
biotin-labelled cRNA. Biotin labelled cRNA was then processed through a clean-
up step prior to quantification (260/280nm) using a Nanodrop spectrophotome-
ter.
Samples were then run on an Agilent 2100 Bioanalyser to check the quality of
the cRNA produced. All samples produced the expected profile at this stage and
were therefore put forward for the fragmentation procedure. Following frag-
mentation, samples were again run on the Agilent Bioanalyser to check for the
correct fragmentation of the cRNA. Only high quality samples (MCMVdie1 n=4,
MCMVrev n=3) were put forward for the array hybridisations.
All samples passed the basic Affymetrix QC report file tests based mostly on
the spiked in Poly-A controls.
2.5.5 Data analysis
Data from the microarray were analyzed by using the Ingenuity Pathway Anal-
ysis (IPA) application (Ingenuity Systems R⃝ www.ingenuity.com).
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2.6 Protein Methods
2.6.1 Whole cell extract preparation.
Whole lysate was extracted from BMMθs using Beadlyte R⃝ Cell Signaling Ly-
sis Buffer (Millipore, UK), following manufacter’s instructions. BMMθs were
cultured for 7 days (Section 2.2.6) in 6- well plates at a seeding density of 106
cells/well. After treatment or infection cells were washed with ice-cold TBS
and 10 ml of 1X lysis buffer prepared. At this stage 1 tablet of Complete Mini-
proteinase inhibitor (Roche, UK) and 100 µl of Phosphatase Inhibitor cocktail I
and II (both from Sigma, UK) were also added to the lysis buffer. 100 µl of lysis
buffer was added to the cells. Cells were then scraped from the plate using a
plastic cell scraper and transferred to a 1.5 ml Eppendorf tube. The suspension
was then gently rocked for 15 min at 4◦C to lyse the cells. The lysate was clarified
by centrifugation at 14,000 g for 15 min at 4◦C. Supernatant was transferred to a
new 1.5 ml Eppendorf and the lysate was kept at -70◦C until use.
2.6.2 Measure of protein concentration
Total protein concentration was determined using the Micro BCA protein assay
(Pierce, UK), following manufacturer’s instructions. A set of protein standards
was prepared by diluting an Bovine Serum Albumin standard (BSA) ampule
(2000µg/ml) as follows:
Table 2.2: Preparation of Micro BCA protein assay standard
Vial Final Concentration Volume (Diluent + Stock)
A 2000 µg/ml 300µl of stock
B 1,500 µg/ml 375µl of stock
C 1,000 µg/ml 325µl of stock
D 750 µg/ml 175µl of vial B + 125 µl of diluent
E 500 µg/ml 325 µl of vial C + 325µl of diluent
F 250 µg/ml 325 µl of vial E + 325µl of diluent
G 125 µg/ml 325 µl of vial F + 325µl of diluent
H 25 µg/ml 100 µl of vial G
I 0 µg/ml 400µl of diluent
48
Along with the standards, 20 µl of the sample was loaded onto a 96- well
plate. The samples were analysed in duplicates. Working reagents were pre-
pared in a 50:1 (Reagent A:B) ratio adding 200 µl of the mixture per well. The
plate was incubated for 30 min at 37◦C and protein concentration was deter-
mined from the measurement of the absorbance at 562 nm on a POLARstar OP-
TIMA Multifunction Microplate Reader (BMG LabTech, UK).
2.6.3 PathwayProfilerTM
PathwayprofilerTMis used to detect changes in the phosphorylated status of a
number of proteins in cell lysates by using the LuminexTMx-MAPTMsystem. This
assay has been developed as an alternative to Western Blotting and immunopre-
cipitation procedures. Cell lysates from infected- and non-infected-BMMθs was
extracted at the specified times and protein concentration was determined as de-
scribed in Sections 2.6.1 and 2.6.2, respectively. Lysates were then analysed in the
PathwayprofilerTMby the Upstate team based in Dundee, UK. Analysis of the as-
say was carried out by comparing the median fluorescent value (MFI) provided
by Upstate (Dundee, UK).
2.6.4 SDS-PAGE and Western Blotting
Equal amounts of proteins were mixed with 2X Laemmli Sample Buffer, con-
taining 10% of DTT and loaded onto 10% SDS-PAGE gels, along with 6 µl of
molecular weight markers (Prestained Protein Marker Broad Range, New Eng-
land Bioloabs, UK). The gel was run for 45 min approximately at 200 V constant
on a BioRad PowerPac 200 Power Supply. Filter papers (BioRad) were soaked in
transfer buffer along with fiber pads. Polyvinylidene difluoride (PVDF) mem-
branes were cut to the dimension of the gel (maximum size 7.5 cm x 10 cm) and
soaked in methanol for 10 seconds, washed in distilled water for 5 seconds and
soaked in transfer buffer for a couple of minutes. Once the electrophoresis was
finished the gel cassette was dissasembled and foot and wells were cut. With
the help of a filter paper, the gel was separated from the glass and placed on
the transfer sandwich, on the top of the PVDF membrane. The gel sandwich
was placed in the TransBlot module along with the cooling unit filled with cold
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water. The tank was then filled with transfer buffer and run for 1 hour at 100
V/constant. When transfer was finished, the cassette was carefully dissasem-
bled and the PVDF membranes were blocked with 20 ml of blocking buffer at
room temperature with gentle shaking on a Belly Dancer (Stovall Life Sciences,
USA). The membrane was then washed 3 times for 15 min with washing buffer.
The primary antibody was diluted into the primary antibody dilution buffer. The
membrane was incubated with the primary antibody overnight at 4◦C with gen-
tle rocking. After primary antibody incubation membranes were again washed
in washing buffer and then incubated with the secondary antibody, diluted in
blocking solution for 1 hour at room temperature. Membrane was washed again
and overlaid onto mix of detection reagents (ECL Plus Western Blotting Detec-
tion Reagents, Amersham Biosciences, UK) for 5 min. The membrane was then
exposed to the VersaDoc imaging system 4000. Densitometric analysis of the
blots was performed by Quantity One software 4.5.0.
Table 2.3: Primary Antibodies
Antibody Species Dilution Supplier
Phospho-Erk1/2 Mouse 1:1000 Sigma
Erk1/2 Rabbit 1:1000 Cell Signalling
Phospho-p38 Mouse 1:1000 Cell Signalling
p38 Rabbit 1:1000 Cell Signalling
Phospho-SAPK/JNK Rabbit 1:1000 Cell Signalling
SAPK/JNK Rabbit 1:1000 Cell Signalling
β-Actin Rabbit 1:1000 Cell Signalling
CROMA101 Mouse 1:1000 *
CROMA103 Mouse 1:1000 *
* CROMA101 and CROMA103 antibodies were kindly donated by Prof. Stipan Jonjinc (Riejka
University, Croatia)
Table 2.4: Secondary Antibodies
Conjugate Antibody Species Dilution Supplier
HRP-linked mouse IgG Horse 1:2000 Cell Signalling




Cytokine levels in cell culture supernantants were detected by Cytometric Bead
Array mouse inflammation kit (BD Biosciences, UK), and flow cytometry anal-
ysis. This kit allows quantification of Interleukin-6 (IL-6), Interleukin-10 (IL-
10), Monocyte Chemoattractant Protein-1 (MCP-1), Interferon-γ (IFNγ), Tumor
Necrosis Factor (TNF), and Interleukin-12p70 (IL-12p70) protein levels in a sin-
gle sample. Cytokines can be detected in a range of 20-5000 pg/ml. The pro-
cedure was performed following manufacter’s instruction. Briefly, protein stan-
dards were first prepared by serial dilution. 50µl of Capture Beads, standards
and samples were mixed into assay tubes along with the detection reagents. Af-
ter 2 h incubation at room temperature and avoiding direct light samples were
washed in the washing solution and centrifuged at 200 g for 5 min. Analysis was
performed using BD CBA Software.
2.7.2 ELISA
Murine TNF levels were also determined from cell culture supernatants using
a mouse TNF-α/TNFSF1A DuoSet ELISA Development kit (R&D Systems Eu-
rope LTd.) designed to detect TNF in the range of 32.5-2000 pg/ml. ELISA was
performed following manufacturer’s instruction. Briefly, an ELISA 96-well plate
was coated with the capture antibody and left overnight at room temperatuere.
The antibody was then washed and the plate was blocked for 1 h at room tem-
perature. A series of standards was prepared and after blocking 100 µl of each
standard along with 100 µl of sample was added to the plate. Standards and
samples were left for 1 h incubation at room temperature, after which the plate
was washed 3 times followed by 1 h incubation at room temperature with the de-
tection antibody. The washing step was repeated and Streptavidin- horseradish
peroxidase (HRP)-conjugated solution was added at the recommended working
concentration. The plate was incubated in the dark at room temperature for 20
min, washed and 100 µl of substrate solution was added. The plate was then
incubated in the dark for 20 min at room temperature. To stop the reaction, stop
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solution was added (50 µl). TNF concentration was determined by reading the
absorbance at 450 nm in a POLARstar OPTIMA Multifunction Microplate Reader
(BMG LabTech, UK).
2.8 General Methods for in vivo experiments
2.8.1 Mice and Infection
BALB/c (Charles Rivers, France), C57Bl/6 (B&K, UK) and TNF-/- C57Bl/6 (B&K,
UK) mice were housed in the animal facilities at the University of Barcelona or
the University of Edinburgh under specific-pathogen-free conditions. All exper-
iments were carried out under appropiate personal and project licenses in ac-
cordance with the Home Office and the University of Barcelona and University
of Edinburgh regulations. Mice were inoculated with the specified PFU by the
intraperitoneal route (i.p). During the course of the different experiments, mice
were monitored daily. At designated times mice were killed by cervical disloca-
tion.
2.8.2 Sample processing
Dissection instruments were sterilized before use and between mice. Fur was
cleaned with ethanol and an incision was made in the abdomen. Spleen, liver,
kidneys, lungs and hearts were removed and placed in 500 µl of PBS. Organs
were then weighed and processed as a 10% (wt/vol) tissue homogenate. Ho-
mogenates were sonicated (Fisher Scientific) for 10 seconds on ice . A small vol-
ume of the homogenate was not sonicated in order to measure cytokine levels.
Both samples were washed by centrifugation and kept at -70◦C until use. Viral
titers were determined by standard plaque assays (Section 2.4.2) and cytokine
levels by ELISA (Section 2.7.2).
CHAPTER 3
MCMVdie1 replication in BMMθ
3.1 Introduction
The β-herpesvirus human cytomegalovirus (HCMV) can establish both acute
and latent infection, remaining in the host for life. As a human pathogen, it is
highly relevant with more than 60% of the population worldwide infected. Clin-
ically HCMV infection varies according to the status of the patient’s immune sys-
tem; infection of immunocompetent individuals is usually asymptomatic whereas
a variety of severe pathologies are presented in immunocompromised patients
such as those with AIDS or organ transplant recipients. Also, CMV infection in
newborn children can result in birth defects such as nervous system maldevel-
opment, deafness and mortality [Jarvis and Nelson, 2002, Stagno et al., 1986].
The murine cytomegalovirus (MCMV) model provides a useful tool for study-
ing the human virus and its pathogenesis thanks to the ease of handling the virus
in vivo and its genotypic and biological similarities to HCMV. Similar to HCMV,
the murine virus has a dsDNA genome that is sequentially expressed in three
phases, immediate early (IE), early (E) and late (L) genes [Keil et al., 1984]. The
IE phase is independent on newly synthesized proteins, while the expression of
early genes requires control by IE proteins. The last phase of the transcription
cascade which starts after viral replication encodes late proteins responsible for
the structure of the viral particle. The MCMV IE1 protein has been described as a
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trans-activator for cellular and viral gene expression [Gribaudo et al., 1996, Grib-
audo et al., 2000, Koszinowski et al., 1986]. However, the role of IE1 in the reg-
ulation of gene expression and immune response has not been described. So far
the requirement of IE1 for efficient replication of the virus in the natural host has
been reported [Ghazal et al., 2005].
Macrophages (Mθs) play an important role in CMV infection as a major site
for viral replication and establishment of latency, as well as providing a vehicle
for viral dissemination throughout the host [Hanson et al., 1999, Stoddart et al.,
1994]. In addition, Mθs constitute one of the principal effectors of innate immu-
nity. Upon activation, Mθs produce a number of cytokines such as TNF, IL1, IL6,
IFNαβ, and IL12, which have been reported to be key mediators of the response
against MCMV [Orange and Biron, 1996, Orange et al., 1995, Randolph-Habecker
et al., 2002]. This cytokine response will recruit other immune cells, such as NK,
very well known to mount an antiviral activity by inducing IFNγ [Orange et al.,
1995]. These two faces that Mθs seem to have in MCMV infection has been con-
sidered as ’paradoxical’ [Hanson et al., 1999], since the same cellular population
is equally important for viral replication and for viral clearance. However and
regardless of this duality, it is clear that Mθs are crucial for MCMV infection.
3.2 Aim of the chapter
MCMV ie1-deletion mutant (MCMVdie1) replication in vitro in fibroblasts and
peritoneal Mθs is similar to the parental and revertant virus [Ghazal et al., 2005],
demonstrating that IE1 is dispensable for MCMV replication in these cells. How-
ever, the replication of MCMVdie1 in BMMθs has not been described. Consid-
ering the importance of Mθs in the immune response against viral infection, the
aim of this chapter was to study MCMVdie1’s growth kinetics in this cellular
population, as well as gain an insight in what the effect of the absence of IE1
would be on BMMθ gene expression upon infection.
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3.3 Results
3.3.1 Replication in bone marrow derived macrophages
BMMθs from 10-12 week old male BALB/c mice were cultured for 7 days as
described in Section 2.2.6. After one week and prior to infection, maturation of
the Mθs was characterized by flow cytometry (Section 2.2.6). Cells were then
infected at a multiplicity of infection (MOI) of 1 and 0.2. Previous experience in
the laboratory showed that infection of BMMθs with MOIs higher than 1 resulted
in high cell death. Therefore at MOI of 1 was used in all experiments of this thesis
unless specified. Intracellular and extracellular infectious infectious virus were
determined by standard plaque assays as described in Section 2.4.2. Figure 3.1
shows MCMV, MCMVdie1 and MCMVrev growth kinetics after infection at a
MOI of 1 and MOI of 0.2 of two independent experiments.
From the graph it can be seen that infection at a MOI of 1 did not result in no-
table differences in the replication of MCMVdie1 when compared to the parental
and revertant virus. However, a slight decrease, not statistically significant, in
MCMVdie1 yields was seen at late times of infection. Similar results were found
when infections were done at a lower MOI. All together, these results indicate
Figure 3.1: Growth curves in infected-bone marrow derived macrophages
Cells were infected with the different viruses at a (A) MOI 1 or (B) MOI 0.2. At indicated
times intracellular and extracellular virus were harvested and viral titers were determined by
standard plaque assay in MEFs. Each data point represents the average and SD of results of
different samples from 2 independent experiments (n=6).
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that MCMVdie1 establishes an infection in BMMθs and although the mutant
virus replication tended towards lower yields at later times of infection these dif-
ferences were not significant (t-test, p=0.15 and p=0.52 when comparing MCMV
and MCMVrev against MCMVdie1, respectively).
3.3.2 Microarray and data anlysis
Study of viral growth kinetics in BMMθs showed that MCMVdie1 replication
tends to be slightly lower than parental or revertant MCMV. Work done by Ghazal
and coworkers revealed that the IE1 protein is essential for viral growth in the
natural host [Ghazal et al., 2005]. The same study revealed that the absence of IE1
also resulted in an attenuation of MCMVdie1 replication in SCID mice, lacking T
and B cells and relying on the innate immune response to control the infection.
The fact that the trend towards lower viral yields is not seen in fibroblasts but in
BMMθs raised the possibility of that the absence of IE1 might have an effect on
cellular mechanisms involved in viral control, as seen in vivo. Therefore, to gain
an insight in the effect of MCMVdie1 infection of BMMθs a comparative study
on MCMVdie1- and MCMVrev-induced host gene expression was performed
using microarray technology. It is known that MCMV induces changes in host
gene expression when compared to mock-infected samples, therefore this pilot
study was only focused on MCMVdie1 and MCMVrev infection at early times
post infection, in order to test the effect of the absence of ie1. Considering the
limitations of the study, as well as the small numer of samples, the observations
from this experiment were not considered as conclusive. Instead they have been
used as a guide of what might be happening after infection, as well as to provide
an example of how microarray data could be analysed.
BMMθs from male BALB/c mice were infected with either MCMVdie1 (n=4)
or MCMVrev (n=3) at a MOI of 1 for 10 h. After the indicated time, total RNA was
isolated as described in Chapter 2. As indicated in Section 8.1.2, RNA quality was
confirmed on RNA 6000 Nanochips in the Agilent 2100 Bioanalyzer. Only high
quality RNA preparations, indicated by the RNA integrity number (RIN>7.5),
were considered for microarray screening in the the Affymetrix Mouse 430v2
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array. This work was done in collaboration with S. Burgess and P. Lacaze (Edin-
burgh University).
A total number of 22690 probesets from the Affymetrix Mouse 430v2 array
were imported into Partek R⃝ Genomic SuiteTMand normalized using the RMA
and quantile methods. An expression level filter was applied to the data for
probesets with absolute expression values of above 100 in two or more of the
seven arrays. 1455 filtered probesets were obtained and analyzed for differen-
tial expression between the MCMVdie1- and MCMVrev-infected samples using
ANOVA. 532 probesets were found to be differentially expressed to a statisti-
cally significant level using a p value (<0.05) and fold change (>1.2) cut off. In
general, significant p values are more important than the magnitude of the ef-
fect. However, in practice, a combination of statistically significant p value and
fold change are commonly used. Although this cut off is not very stringent it
was used in order to obtain a reasonable number of genes to work with in the
analysis. In any case, the results obtained from microarray always require in-
dependent validation. The differentially expressed probesets were then used to
identify genes whose expression was likely to be altered after MCMVdie1 infec-
tion. The complete list of these genes can be found in Appendix B.
From the data analysis, it was seen that, although the vast majority of the
genes were not affected in the absence of ie1, approximately 550 genes showed
differential expression. Strikingly, according to gene ontology analysis performed
with DAVID Bioinformatics Resources (http://david.abcc.ncifcrf.gov/home.jsp),
nearly 33% were relevant for the immune response triggered upon infection (see
Figure 3.2). In order to gain a better understanding of the biological processes
affected by these genes, a more extensive study was performed by pathway anal-
ysis.
3.3.3 Pathway Analysis
One of the obstacles of the microarray technology is the difficulty of analysing
the amount of data generated. However, there are several tools which help to un-
derstand microarray data. In this thesis, Ingenuity Pathway Analysis (IPA) (In-
genuity Systems R⃝, www.ingenuity.com) tool was used in order to identify the
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Figure 3.2: General description of microarray data analysis
BMMθs were infected with the MCMVdie1 and MCMVrev at a MOI 1 (n=4 and n=3,
respectively) for 10 hours. RNA was extracted and microarray was performed. Approximately
550 genes were differentially expressed, ∼65% of which were upregulated and 35% were
downregulated. An important percentage of those genes were involved in the immune response.
pathways and biological processes which were most affected after MCMVdie1
infection. Therefore, genes accession numbers from the 532 genes with differen-
tial expression along with the fold change were imported to IPA. This applica-
tion has also an extense manual-curated database, known as Ingenuity Pathways
Knowledge Base, derived from an important number of journals and text books,
which enables the identification of those genes of interest. The analysis of the
gene list was based on (1) the most relevant genetic networks identified and, (2)
the canonical pathways affected after infection.
Networks of gene interaction after viral infection
Those identified genes were overlaid onto a global molecular network developed
from information contained in the Ingenuity Pathways Knowledge Base and in-
terconnected algorithmically by using the Network Generation Algorithm [Cal-
vano et al., 2005]. Networks are also scored based on the number of molecules
included. Thus, the higher the score of a network the lower probability of find-
ing molecules by chance. This score is calculated with the right-tailed Fisher’s
Exact test. Furthermore, IPA also carries out a functional analysis of a network,
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identifying the biological functions and/or diseases that were most significant
to the genes in the network. Fisher’s exact test was also used to calculate a p-
value determining the probability that each biological function and/or disease
assigned to that network is due to chance alone.
The top 5 genetic networks identified by the Ingenuity Pathways Knowledge
Base are summarized in Table 3.1. The first 3 networks will be described in more
detail in this section, since they showed the highest scores and they have been
associated with functions relevant for viral infections, including cell death. It
has to be noticed that several genes appeared in more than one network which
indicates that they are associated with several biological processes.
CELL DEATH. As can be seen in Figure 3.3, this first genetic network repre-
sents genes affected after MCMVdie1 infection and mainly involved in the reg-
ulation of gene transcription and induction of apoptosis. Regarding the regula-
tion of DNA transcription different genes were found, including histone cluster
1 (HIST1H1C) and nucleosome assemble protein 1 (NAP1L1). The expression of
these genes was affected after MCMVdie1 infection, as well as MED21, which is
involved in the regulation of the RNA polymerase II, HSPA9, Daxx, known tran-
scriptional repressor, and p53. This last one seems so have a central role in this
network, since the vast majority of the genes interact with p53. Other genes in-
volved in the aminoacid metabolism are also represented in this network such as
histidine decarboxylase (HDC). All together, it can be seen that the expression of
genes involved in transcription are affected after MCMVdie1 infection. Indeed,
as has been already introduced IE1 protein acts as a trans-activation of cell gene
expression, so it is not surprising that these genes appear altered in the absence
of IE1.
Kinases like Death-associated protein kinase 1 (DAPK1) and Homeodomain
interacting protein kinase 3 (HIPK3) were also affected after MCMVdie1 infec-
tion. DAPK1 has also been reported to mediate IFNγ-induced apoptosis [In-
bal et al., 2000], whereas HIPK3 has been shown to phosphorylate the adaptor
protein FADD [Rochat-Steiner et al., 2000], modulating an alternative apopto-
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.3: Genetic Network associated with Cell Death.
point to a regulation of the activation of apoptosis after MCMV infection, how-
ever qRT-PCR validation would be required to further investigate this potential
mechanism.
LIPID METABOLISM. Little is known about the role of lipids in infection of
MCMV, however there are some reports showing that Hepatitis C virus (HCV)
interacts with lipid aggregates known as ’lipid rafts’ in order to start the viral
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replication cycle [Aizaki et al., 2004]. Human CMV replication in endothelial
cells has also been shown to require the activity of Hydroxymethyl-Glutaryl
Coenzyme A (HGM-CoA) reductase, known to be part of the metabolic path-
way that produces cholesterol. When this enzyme was blocked by cholesterol
lowering drugs it was seen that the expression of viral immediate early and late
antigens was inhibited [Potena et al., 2004]. Interestingly, microarray analysis
pointed to an alteration of the expression of several genes involved in the cellu-
lar lipid metabolism after MCMVdie1 infection. These genes have been mapped
as shown in Figure 3.4. Within the genes differentially expressed it could be
found lipoprotein lipase (LPL), esterases (LIPA), binding proteins (FABP3) and
lipid transporters (ABCA1).
Intermediate compounds originated from the lipid metabolism are also known
to have an integral role in signalling pathways, such as Ras family of small GT-
Pases. Indeed, members of this family, including Rho and Ras, are localized in
the plasma membrane thanks to posttranslational lipid modification of the pro-
teins. Alteration of this lipid portion of the protein would result in a change in
cellular localization as well as biological activity [Wennerberg et al., 2005]. In
addition, these molecules are involved in the activation of the immune response
by leading to the activation of gene expression [Monick et al., 2003]. Moreover,
evidences on the anti-inflammatory role of LPL has been reported [Ziouzenkova
et al., 2003].
There are also experimental results showing a link between lipids and regu-
lation of apoptosis. It has been reported that LPL can induce apoptosis in human
cells by promoting caspase activation [Napoli et al., 2000]. Indeed, this genetic
network revealed an interaction between LDL and caspase-2. GOLGA3, also
known as Golgin 160, is a caspase-2 substrate which transduces pro-apoptotic
signals [Mancini et al., 2000].
Overall, this genetic network raises the possibility that MCMV targets lipid
metabolism by regulating the expression of several enzymes. The alteration of
this metabolism might also affect other cellular responses, including the immune
response. Therefore, it would be of interest to investigate further the interaction
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between MCMV and the lipid metabolism, and how that would affect either viral
infection and cellular responses to infection.
Figure 3.4: Genetic Network associated with Lipid metabolism.
VIRAL FUNCTION. This genetic network includes those genes which are in-
volved in biological process happening after viral infection, in particular with
viral replication and apoptosis. TNF appears to have a central role in this spe-
cific network (see Figure 3.5), as well as members of the canonical and alter-
native NFκB pathway, involved in the innate immune response and develop-
ment of lymphoid organs. Both human and murine CMV induce activation of
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NFκB. MCMV IE1 has been shown to induce the expression of NFκB subunits
p65 and p50/p105 [Gribaudo et al., 1996] and human IE1 induces expression of
relb [Wang and Sonenshein, 2005]. Another study has shown that human IE1
leads the activation of the MIE region by trans-activating NFκB sites in human
fibroblasts [Sambucetti et al., 1989]. However, work done by different groups
have also demonstrated that this factor is dispensable for HCMV and MCMV
replication [Benedict et al., 2004, Gustems et al., 2006]. In addition, inhibition of
NFκB activation in human cell cultures reduced the antiviral effect induced by
TNF and IFNγ [Eickhoff and Cotten, 2005], and very likely many other responses
mediated by this factor. However, microarray data could indicate a differential
expression of both relb and p100 in the absence of IE1. Results indicated that
TNFAIP3 interaction protein 1 (TNIP1), also known as NAF-1 or ABIN-1, is also
altered after MCMVdie1 infection. NAF-1 is induced by TNF in human cells
[Gallagher et al., 2003] and it negatively regulates NFκB-dependent gene expres-
sion, by interfering with IKK complex [Mauro et al., 2006]. Other groups have
revealed that this protein can also act as a attenuator of the Erk1/2 signalling
pathway [Zhang et al., 2002]. Therefore, it might be that NAF-1 could be acting
as a negative regulator of TNF-induced signalling, and the absence of IE1 affects
NAF-1 expression via TNF.
Several TNF family members are also part of this network, such as TNFSF10
(also known as TRAIL) and TNFAIP2, both of which induce apoptosis [Aggar-
wal, 2003]. The expression of the mitochondrial adenylate kinase 2 (AK2) also
appeared altered. This kinase initiates the activation of the FADD/caspase-10
pathway [Lee et al., 2007] and, consequently, the activation of caspase- 9 and -3.
These data may suggest that the absence of IE1 affects the expression of AK2,
raising a possible strategy to block the AK2/FADD/caspase-10 induced apopto-
sis.
Strikingly, in the genetic networks described above, expression of several
other genes has been shown to be affected in the absence of ie1, and these also
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play a role in the regulation of apoptosis, such as DAPK1 and HIPK3. There-
fore, this analysis might indicate that apoptosis is a key cellular response for the
control of MCMV infection which might involve the IE1 protein.
In this regard it is noteworthy that the presence of the homeodomain inter-
acting protein kinase 1 (HIPK1). TNF has been shown to induce translocation of
HIPK1 [Li et al., 2005]. When it is in the nucleus, HIPK1 interacts with Daxx and
regulates transcription. HIPK1 relocalized Daxx from ND10 to chromatin, where
Daxx acts as a repressor. However, HIPK1-induced phosphorylation of Daxx
also regulates Daxx repressor capacity [Ecsedy et al., 2003]. As has been intro-
duced, Daxx is part of the ND10 aggregates, along with PML and Sp100. The pre-
cise function of these bodies in MCMV infection has not been totally elucidated,
however it is known that both human and murine CMV disrupt these protein
complexes [Tang and Maul, 2003, Lee et al., 2004]. Unlike MCMV, HCMV in-
duces the degradation of Daxx [Saffert and Kalejta, 2006]. Therefore, it might be
possible that MCMV has evolved other mechanisms to counteract Daxx-induced
repression by interfering with its localization and activity, rather than induc-
ing its degradation. Although ie1-deletion mutant did not disrupt ND10 bodies
early after infection it did not affect viral replication, since MCMVdie1 repli-
cates as wild type in tissue culture [Ghazal et al., 2005]. However, this function
is not shared by other viruses such as HCMV and HSV because they show de-
fective replication in the absence of their respective IE1 proteins [Greaves and
Mocarski, 1998, Everett et al., 2004]. Nevertheless, this possible function of IE1
where it might regulate Daxx function by interfering with its phosphorylation
status might be the alternative to the degradation seen for human CMV. It has
been suggested the role of these molecules in antiviral defense, since they are
induced by IFN [Gongora et al., 2001, Grotzinger et al., 1996]. IFN-induced Daxx
is also known to act as a transcriptional repressor. Microarray analysis pointed
to the differential expression of Daxx and HIPK1. However, why these proteins
might be targeted by MCMV requires further investigation.
The interaction between TNF and cholesterol 25-hydroxylase (CH25H) is also
of great interest. Microarray data might indicate that TNF expression is altered
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in the absence of IE1. The previous section pointed to the alteration of several
genes involved in the regulation of the lipid metabolism. This enzyme is known
to transform cholesterol into 25-hydroxycholesterol, which has been reported to
negatively regulate the LPS-induced TNF production in Mθs [Englund et al.,
2001]. Moreover, it has been shown that cholesterol plays a role in the regula-
tion of TNF production. The mitogen activated protein kinase Erk1/2 plays a
role in the induction of tnf gene expression in Mθs [Shi et al., 2002]. As a pro-
tein kinase, Erk1/2 activity is regulated by a specific kinase and phosphatase.
It has been described that cholesterol is essential for the negative regulation of
the phosphatase complex [Wang et al., 2005], which ultimately might affect the
activation of gene expression, including tnf. Microarray data might indicate that
TNF expression is regulated after MCMVdie1 infection. One possible explana-
tion might be that the apparent regulation of tnf expression might be partially
cholesterol-dependent. However, further validation has to be done in order to
investigate these speculations.
Canonical pathways affected by MCMVdie1 infection
In the previous section it has been described how the genes differentially ex-
pressed after MCMVdie1 infection interact with each other in different genetic
networks, giving an initial idea of the biological processes which might be tar-
geted. The Ingenuity Pathway Analysis also includes the study of the different
canonical pathways which have been altered after MCMVdie1 infection. As for
the genetic networks, these pathways have also been curated and drawn from
information found in the literature. The significance of the association between
the data set and the canonical pathway was measured by Fischer’s exact test,
giving a p-value which determines the probability that the association between
the genes in the dataset and the canonical pathway is explained by chance alone.
Below, a number of pathways are described not only for their relevance on the
control of infection, but also for the significance with which they were scored in
the analysis.
IL10 AND IL6 SIGNALLING PATHWAYS. The production of IL10 after MCMV
infection of primary Mθs has been reported. This anti-inflammatory cytokine
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Figure 3.5: Genetic Network associated with Viral function.
appeared to be involved in the MCMV-induced inhibition of the MHC class II
molecules in infected cells [Redpath et al., 1999]. Moreover, it has been shown
that IL10 is responsible for the control of MCMV in the salivary glands, sug-
gesting a mechanism involving the balance between IL10 and IFNγ production
[Humphreys et al., 2007]. However, very recently it has also been demonstrated
that IL10 has a pivotal role during MCMV infection, since MCMV-infected mice
with severe disease were found in the absence of IL10 because of the abundant
and persistent production of other cytokines including TNF, IFNγ and IL6 [Oak-
ley et al., 2008]. Pathway analysis from the microarray data might indicate that
the absence of IE1 has a strong effect on IL10 expression early after infection
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of BMMθs, as well as other molecules involved in the IL10 signalling pathway
(Figure 3.6).
Another signalling pathway altered in the absence of IE1 was IL6 (Figure 3.7).
After MCMV infection IL6 levels can be detected in vitro and in vivo. Moreover,
Ruzek and coworkers also reported the association between IL6 and the produc-
tion of glucocorticoids in the natural host [Ruzek et al., 1997], which has been
shown to inhibit immune response [Kunicka et al., 1993]. IL6 can also induce
other immune cells by inducing MCP1 [Rott et al., 2003] as well as the activa-
tion and expansion of B cells [Barton, 1997]. There is evidence demonstrating
that human CMV induces il6 expression by its IE1 [Geist and Dai, 1996], but this
analysis pointed to a possible regulation of IL6 by MCMV. Figure 3.7 shows that
by interfering with the expression of il6 the signalling cascade induced by this
cytokine might also be altered, as well as the induced biological activities.
IFN SIGNALLING PATHWAYS. The role that IFN plays in the control of MCMV
infection has been extensively studied, as has been already introduced in this
thesis. Pathway analysis identified this as one of the most affected by MCMVdie1
infection. Microarray data showed that IFN-induced genes ifitm1, irf1 and mx1,
were up-regulated by the IE1 protein (see Figure 3.8). Besides, interferon induced
transmembrane protein 2 and 6 (ifitm2, ifitm6) expression also was altered by
MCMVdie1 infection (see complete gene list from Appendix B). Moreover, these
results are consistent with the work recently published by Busche and coworkers,
where they show that the induction of IFN response elements were decreased in
the absence of IE1 [Busche et al., 2008].
It has been reported that human IE1 protein targets type I IFN-induced gene
expression by interfering with the complex STAT1-STAT2-IRF9, preventing the
activation of transcription [Paulus et al., 2006]. However, this microarray study
along with the recently published work might indicate that, unlike the human
virus, MCMV IE1 induces this specific response rather than blocking it.
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Figure 3.6: IL10 signalling pathway
Analysis of the IL10 signalling pathway by IPA showed genes differentially expressed from
the microarray data. Green and red color denotes genes which expression is down- and
up-regulated, respectively.
3.4 Conclusions
MCMV IE1 has been shown to be dispensable for viral replication in different
types of cells in vitro, however, the role of this viral protein in viral replication
in primary Mθs has not been studied. Mθs are key players in both immune re-
sponse against viruses and other pathogens and MCMV infection. Therefore,
it was of interest to study viral infection in this particular cellular population.
BMMθs were infected at different MOIs with MCMVdie1, parental MCMV and
a revertant. Viral growth kinetics revealed that, there was a marginal decrease
in MCMV replication was seen in the absence of ie1, although not statistically
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Figure 3.7: IL6 signalling pathway
Analysis of the IL6 signalling pathway by IPA showed genes differentially expressed from
the microarray data. Green and red color denotes genes which expression is down- and
up-regulated, respectively.
significant. The reason of trend towards lower replication is not known, how-
ever there are several factors which could explain this difference. For instance,
the virus could have adapted to replicate in fibroblasts and does not take into
consideration factors to which the virus could be exposed in BMMθs. It is also
known that Mθs are semipermisive cells which could also affect viral replica-
tion. Considering that the phenotype of MCMVdie1 seen in vivo it might be that
BMMθs simulate the closest environment to in vivo conditions, including factors
involved in the immune response which are not present in fibroblasts, and all
together could explain the trend towards lower viral yields.
When gene expression was studied after infection of BMMθs it was seen that,
although the vast majority of genes had a similar expression after Mθs infection
with MCMVdie1 and MCMVrev, approximately 550 genes were differentially
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Figure 3.8: IFN signalling pathway
Analysis of the IFN signalling pathway by IPA showed genes differentially expressed from
the microarray data. Green and red color denotes genes which expression is down- and
up-regulated, respectively.
expressed in the absence of IE1. Of these, ∼33% are genes involved in the regula-
tion of the immune response, including cytokines. In order to gain an insight of
the biological processes in which those genes are involved, the Ingenuity Path-
way Analysis application was used. It has to be noticed that this tool is used
with the goal of obtaining a broad idea of the effect of the viral infection on cell
host expression and validation of the data is always required in order to make
firm conclusions. The use of the ie1-deletion mutant has shown that IE1 might to
be involved not only in the expression of genes required for viral replication, but
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also in the regulation of the immune response triggered by BMMθs upon infec-
tion. This study has helped to point to potential targets for viral regulation, and
further validation and work has to be done to completely elucidate the role that
IE1 might have in the regulation of immune pathways in the cell host.
IL10, IL6, TNF, IFN and NFκB signalling pathways are affected after viral
replication, and the absence of IE1 resulted in the differential expression of sev-
eral members of these pathways. Because all these signalling cascades interact
with each other, viral interference with a single gene might have an effect on
many others. For instance, by regulating the expression of IκBα, not only the ac-
tivation of the NFκB might be affected, but also the biological activity induced by
other cytokines which depend on the activation of this transcription factor. This
includes IL1, TNF and other members of the TNF superfamiliy, such as TWEAK
and TRAIL. IL1 has been shown to play a role in the control of CMV infection, by
blocking viral spread in different cell types [Randolph-Habecker et al., 2002]. By
targeting this cytokine, or IL1-induced responses, MCMV might control its own
dissemination.
TNF superfamily members TWEAK and TRAIL also appeared to be differen-
tially expressed after MCMVdie1 infection. Both proteins have been shown to
activate caspase 8-induced apoptosis [Aggarwal, 2003]. Modulation of the ex-
pression of these ligands suggests that MCMV might also regulate the induction
of apoptosis. Very recently, it has been reported that MCMV also targets other
members of the TNF signalling pathway in order to counteract the immune re-
sponse induced after receptor engagement [Mack et al., 2008]. Human CMV has
been reported to encode a viral protein that blocks caspase 8 activation [Skalet-
skaya et al., 2001]. In addition, the human virus has also been shown to induce
the activation of the caspase-inhibitor c-FLIP by its immediate early 2 protein
(correspondent to the IE3 MCMV) [Chiou et al., 2006]. The activation of c-FLIP is
NFκB-dependent. Microarray data pointed to the regulation of the IκBα gene ex-
pression in the absence of IE1, suggesting that MCMV might also block caspase
8/10-induced apoptosis. Moreover, it was seen that the AK2/FADD/caspase-10
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signalling pathway was also affected by MCMVdie1 infection, as well as DAPK1
and HIPK3. Considering the importance of apoptosis in the immune response
against viral infection, it is of interest to study further the interaction between
IE1 and the regulation of apoptosis.
Microarray analysis might also indicate that IE1 may be required for the ac-
tivation of IFN-induced genes, including irf1, ifitm1 and mx1. In fact, this re-
sult would be consistent with another report demonstrating that IE1 is required
for induction of IFN response elements [Busche et al., 2008]. However, another
study has shown that MCMV blocks IFNβ expression, although the molecular
mechanism is not known [Le et al., 2008]. Human CMV has been shown to
prevent binding of STAT1-STAT2-IRF9 to specific DNA sites in order to block
IFNαβ-induced gene expression.
The Ingenuity Pathway Analysis tool is able to represent the interaction of
different genes, giving a number of genetic networks which might reveal new
interactions. Table 3.1 summarizes the top 5 genetic networks found in this
analysis, along with the different genes involved. As can be seen, cell death,
lipid metabolism and biological processes involved with viral infections are in-
cluded. From these genetic networks it was seen that IE1 protein might also be
involved in regulation of lipid metabolism. The enzyme CH25H appeared to be
differentially expressed. This enzyme has a role in regulation of the cholesterol
metabolism. Moreover, it has been shown that cholesterol plays an important
role in activation of Erk1/2 phosphatase, by supporting the OSBP and specific
enzymes in an active complex.
Overall, microarray study and pathway analysis are useful tools to obtain in-
formation about the functional relationship between BMMθs and MCMV in the
abscense of IE1. Despite the need for further validation of the microarray data
this is the first study done trying to understand the impact of this viral protein
in the host cell. The results presented in this chapter gives an overview on how
MCMVdie1 might affect host cell gene expression. IE1 has been suggested to
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be a trans-activator of viral and host gene expression to favor viral replication,
however Pathway Analysis has pointed to a possible regulation of expression
of genes involved in the immune response in the absence of ie1. Moreover, mi-
croarray analysis could be very useful to identify potential targets for viral infec-
tions. For instance, in the context of MCMVdie1 infection: (1) lipid metabolism
which has not been described until now to be crucial for MCMV infection, but
might be important in the regulation of the immune response and (2) apoptosis
which is known to be part of the cellular response against viral infection and is
also exploited for some viruses to their own convenience. This study might in-
dicate a role for IE1 in the regulation of such a response. Cytokine production
also appeared to be regulated in the absence of IE1, as seen for TNF, IL10 and
IL6. Considering the relevance of these biological processes and molecules in the
control of cell survival and immune response further work has to be done in or-
der to validate the microarray data as well as make firm conclusions about these
possible immune evasion strategies.
CHAPTER 4
Modulation of TNF response by MCMV
4.1 Introduction
In the previous chapter the growth kinetics of the MCMVdie1 were described,
showing a trend towards a lower replication in BMMθ. Although this result was
not statistically significant, the difference in viral replication, which is not seen
in other cell types such as fibroblasts, might be due to the production of factors
involved in the control of viral replication such as cytokines. Moreover, cytokines
have been shown to play a crucial role in the control of MCMV infection in vivo
and in vitro, so it is not be surprising that MCMV has evolved mechanisms to
suppress or evade cytokine-induced responses in order to persist within the host.
IL10 has been reported to have a role in MCMV infection in primary Mθs.
Redpath and coworkers demonstrated that MCMV-induced down-regulation of
MHC class II in infected cells was driven by the induction of IL10 in these cells
[Redpath et al., 1999]. Very recently IL10 has been described as an important
regulator of the immune response against infection, since it can control both
pathogen invasion and pathology [Couper et al., 2008]. This would be consis-
tent with a recent study showing that depletion of IL10 resulted in dramatic
symptoms of MCMV infection in the natural host, related to uncontrolled pro-
duction of other pro-inflammatory cytokines such as IFNγ, IL6 and TNF [Oakley
et al., 2008]. Unlike MCMV, the human virus encodes a viral homolog of IL10,
cmvIL10, which is capable of engaging the IL10 receptor as well as activating
signalling molecules such as STAT3 [Spencer, 2007].
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IL6 has also been shown to be induced upon MCMV infection [Ruzek et al.,
1997]. Moreover, the human virus has been reported to induce a transcriptional
regulation of IL6 mRNA in Mθs by a mechanism involving the IE1 protein [Geist
and Dai, 1996].
Several viruses have been shown to induce TNF production [D’Addario et al.,
2000, Ameglio et al., 1994, Paludan and Mogensen, 2001], however very few ex-
amples can be found in the literature regarding viral regulation of TNF produc-
tion. One of these examples is the African swine fever virus (ASFV). It has been
reported that ASFV infection of Mθs results in inhibition of TNF expression by
interfering with the activity of CBP/p300 [Granja et al., 2006]. Epstein Barr virus
(EBV) has also been shown to inhibit TNF production in cell culture [Gosselin
et al., 1992], however the molecular mechanism of this regulation is not clearly
understood. Besides, another study has shown that EBV gp350 induces TNF
production [D’Addario et al., 2000], contrary to the previous report. To date both
human and murine CMV have been reported to block TNF-induced gene expres-
sion by interfering with TNF receptors expression [Popkin and Virgin, 2003, Bail-
lie et al., 2003, Montag et al., 2006], TNF-induced caspase-dependent apoptosis
[Skaletskaya et al., 2001] and very recently caspase-independent apoptosis by di-
rect binding and degradation of RIP1 by the viral protein M45 [Mack et al., 2008].
Other viruses, such as Dengue Virus and Hepatitis C virus,have been also shown
to overcome the TNF-induced response [Saito et al., 2006, Choi et al., 2006, Wati
et al., 2007].
4.2 Aim of the chapter
Mθs are essential for MCMV infection as well as the cytokine response triggered
upon infection. However, little is known about the role of IE1 protein in the infec-
tion of primary Mθs. There is evidence showing that IE1 activates transcription
of cellular genes in order to create the optimal environment for viral replication,
but there is not much information about the role that IE1 could be playing in
regulation of the immune response induced upon viral infection. Therefore, in
order to characterize the role of IE1 protein in regulation of the immune response
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against MCMV, the aim of this chapter was to study the effect of this viral protein
in BMMθs-induced cytokine production during early hours of infection.
4.3 Results
4.3.1 Cytokine production after infection
To investigate the role of IE1 protein in modulation of the immune response in
infected-BMMθs, cytokine secretion at early times after infection was studied.
Thus BMMθs were prepared as described before and after 7 days of culture were
either mock infected or infected with MCMVdie1 or MCMV at a MOI 1 (n=3).
Supernatants were harvested at 10 and 24 hpi and flow cytometry-based Cyto-
metric Bead Array (CBA) was performed for IL6, IL10, IFNγ, TNF and IL12p70.
Figure 4.1 shows that MCMV infection resulted in the induction of IL6 (75
pg/mL) at 10 hpi when compared to the mock-infected cells, which levels were
under limit of detection (p<0.05). At 24 hpi IL6 levels were reduced, just above
the limit of detection (55 pg/mL). MCMV is known to induce production of IL10
in macrophages [Redpath et al., 1999]. In this experimental system, MCMV also
induced IL10 production after 10 hours (118 pg/mL, p=0.03, when compared to
mock infection), with a moderate decrease by 24 hpi (58 pg/mL). IFNγ levels
were under limit of detection, as expected, but also the levels of IL12p70 at both
time points. The most significant response detected after MCMV infection was
TNF production, which reached 206 pg/mL (p=0.006) and 160 pg/mL at 10 and
24 hpi, respectively, although TNF levels found in the supernatants of mock-
infected cells were above the base line at 24 hpi.
When cytokine production was studied after MCMVdie1 infection it was seen
that, except for IFNγ and IL12p70, all cytokines were also found in the cellular
supernatant early after infection. Moreover, the TNF response was markedly
higher, when compared to the levels seen for wild type infection.
Considering the role that TNF plays in the control of viral infections, and the
significant production of the cytokine after infection with MCMVdie1, it was of
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Figure 4.1: Cytokine production after 10 and 24 hours post infection
Cytokine production was determined from supernatant of infected-BMMθs after A. 10 and B.
24 hours post infection (n=3). Mean values and SD are shown. Dash lines represent limit of
detection. Significance of the cytokine production is given by Student’s T-test p values (* p<0.05,
** p<0.01).
interest to confirm the TNF production in the absence of IE1. Therefore, a sec-
ond experiment was performed where BMMθs were infected with either MCMV
or MCMVdie1, or mock-infected and cytokine levels were measured by ELISA.
As a positive control for macrophage activation, cells were also treated with LPS
78
and TNF levels were measured after 6 hours post stimulation. Figure 4.2 clearly
shows that MCMV infection induced TNF production. After 10 hpi MCMV in-
duced 50 pg/mL of TNF. When compared to the mutant virus however, the ab-
sence of IE1 protein resulted in a significant production of the cytokine, 3-fold
higher amount of TNF. At 24 hpi both MCMV and MCMVdie1-induced TNF
production slightly decreased, but there was still a significant difference between
viral infections. It is of note that there was a difference in the cytokine concen-
tration between the flow cytometry based-CBA and ELISA. The higher sensi-
tivity of the first assay is well known [Jimenez et al., 2005], in comparison to
conventional ELISA, which would explain the difference in protein concentra-
tion. However and despite the sensitivity difference of the technique used, these
independent experiments showed a significant production of TNF in the absence
of IE1. Therefore, these data suggest that MCMV modulates the production of
TNF in BMMθs at early times post infection, in a mechanism that involved the
presence of the IE1 protein.
Figure 4.2: Confirmation of TNF production in BMMθs by ELISA.
Mθs were either infected with MCMV or MCMVdie1 or mock-infected (n=3). Cytokine
production was determined from the supernatant of infected-BMMθs after A. 10 and B. 24 hours
post infection. Mean values and SE are shown. Significance of the cytokine production is given
by Student’s T-test p values (* p<0.05, ** p<0.01).
4.3.2 Role of MCMVdie1 in tnf expression in BMMθs.
To further investigate regulation of TNF production after infection by MCMV,
the activation of tnf gene expression in BMMθs was studied. Cells were infected
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Figure 4.3: Relative expression of tnf after infection
Relative fold expression of tnf gene in infected-BMMθs. Total RNA was extracted at 10 hours
post infection from BMMθs. Quantitative RT-PCR was performed for relative expression levels
of tnf in these cells. Shown are relative levels of gene expression which have been normalized
against gapdh gene and calibrated against MCMV induced-gene expression. SE bars also shown.
Significance of mRNA levels is given by Student’s T-test p values.
with MCMVdie1, MCMVrev or parental MCMV or mock infected (n=3) and total
RNA was extracted after 10 hpi. This time point was chosen since TNF produc-
tion was found to be higher (Figure 4.2). Quantitative (q)RT-PCR was performed
to detect tnf mRNA levels. Data was normalized against expression of gapdh
and calibrated against MCMV infection. Figure 4.3 shows relative levels of tnf
transcripts. When compared to the mock-infected samples, MCMV infection in-
duced expression of tnf (p<0.05). However, TNF mRNA levels in MCMVdie1-
infected BMMθs were 2.5- fold higher than those seen for the parental and rever-
tant MCMVs (p<0.01). MCMVrev induction of tnf expression was similar to that
induced by wild type virus. It has been reported that MCMV infection inhibits
expression of TNF receptors in macrophages [Popkin and Virgin, 2003], altering
the signalling cascade of cellular activation. However, this is the first time that tnf
gene expression has been shown to be regulated by MCMV. Therefore, the data
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suggest that MCMV modulates both tnf transcript levels and protein production
in BMMθs.
4.4 Conclusion
Mθs are a key cellular population for MCMV infection. MCMV disseminates
throughout the host by using blood monocytes derived from bone marrow pro-
genitors as vehicles [Hanson et al., 1999]. Differentiation from monocytes to Mθs
has been shown to favor the cellular environment for viral replication. Mθs also
play a role during latency, since it has been found that these cells are a major
site of persistence of MCMV DNA in latent state. Moreover, the bone marrow
has been defined as a ’source’ of latent MCMV [Pollock et al., 1997, Mitchell
et al., 1996]. Mθs are as important for MCMV infection as for the immune re-
sponse against MCMV. Mθs are part of the first line of defense, becoming active
and secreting cytokines, such as TNF, IL12, IL1 and IL6 and chemokines to alert
and recruit other cells to the site of infection. Together, cells in collaboration
with cytokines control pathogen invasion and kill infected cells to avoid further
spread of the virus. However, and despite all the efforts made by the immune
cell ’army’ to control MCMV infection, infectious virus can still be found in sali-
vary glands after resolution of acute infection. That indicates that MCMV has
evolved mechanisms to sabotage Mθs function. It is reported here the modula-
tion of TNF production by MCMV in the absence of IE1. TNF has a central role in
control of MCMV infection. In synergy with IFNγ MCMV replication is reduced
in MEFs [Lucin et al., 1994], confirming the antiviral activity of this cytokine.
TNF-induced immune effects in the cells are mediated through a signalling cas-
cade which involves both TNF receptors. For that reason, it is not surprising that
one of the CMV’s immune evasion strategies is to block the activation of such
a response. Indeed, it has been shown that both human and murine CMV tar-
gets expression of TNF receptor 1 (TNFR1) on the surface of Mθs [Baillie et al.,
2003, Popkin and Virgin, 2003], however the exact viral protein responsible for
this regulation is not known.
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Experiments described in this chapter show the modulation of BMMθs-induced
TNF production by MCMV in the absence of the ie1 gene. It is shown that
MCMV suppresses the tnf gene expression and protein production. By using an
ie1-deletion mutant MCMV it was seen that the induction of the cytokine early
after infection was significantly higher when compared to the cytokine produc-
tion induced by the wild type MCMV. Moreover, when tnf mRNA levels were
quantified it was seen that MCMVdie1-induced activation of tnf expression was
2.5-fold higher. Work done by Geist and coworkers showed that HCMV IE1 pro-
tein induced expression of the tnf gene in cultured cells [Geist et al., 1994, Geist
et al., 1997]. However, in contrast to the work described in this chapter which
was done in the context of viral infection, these studies were performed by using
transient transfection assays.
It could be argued that the dramatic TNF production is not due to a viral-
induced regulation but the result of a defect of the mutant virus instead. How-
ever, this investigation has been focused on early times post infection, prior to
viral replication. In addition, previous observations show that MCMVdie1 is
able to replicate as wild type in other cell types such as fibroblasts. Since the
trend towards lower yields was only found in BMMO it was hypothesized that
IE1 is involved in the regulation of the immune response, since this cellular pop-
ulation is known to have a role in the control of MCMV infection. Data presented
in this chapter show independent experiments where the modulation of TNF is
shown in the absence of IE1, suggesting that MCMV is regulating this cytokine
response. The mechanism by which this modulation takes place is not known
but it is clear that involves the presence of IE1. In any case, a comparative study
of the genome copies found in infected cells could be very informative to confirm
that cultures were equally infected. Therefore, the observations described here
were made under the assumption of that equal number of cells being infected
(see Figure 5.3 for controls). Hence, it can be concluded that MCMV regulates
the production of TNF in BMMθs at early times post infection, in a mechanism
that involved the presence of the IE1 protein.
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IL6 protein production presented a similar profile to TNF, although not as sig-
nificant as TNF. A possible explanation for this induction of IL6 after MCMVdie1
infection could be that IL6 is produced as secondary response to the dramatic
levels of TNF found in the cellular supernatant, since IL6 production is induced
by TNF.
Overall, data presented in the above sections indicates that MCMV modu-
lates TNF at both RNA transcripts and protein levels. The mechanisms of such
modulation are not known however data also indicates that IE1 plays a role. This
raises a potential strategy of evasion of the immune response by MCMV, particu-
larly the escape from the known TNF-induced response. These data, along with
previous work regarding the inhibition of TNF-induced signalling pathway by
blocking expression of TNF receptors, reinforce the key role that TNF plays in
control of MCMV infection.
CHAPTER 5
Molecular study of MCMV-induced TNF pro-
duction
5.1 Introduction
Nearly every step of TNF biosynthesis and the TNF-induced signalling pathway
has been shown to be targeted by different pathogens. For instance, members of
the Poxvirus family have been reported to directly interact with TNF by a viral
TNF receptor homolog [McFadden et al., 1997], avoiding TNF binding to the
receptor and induction of the immune response. Blocking of caspase activation
is another common mechanism used by pathogens. That is the case for Hepatitis
C virus (HCV) which suppresses TNF-induced caspase 8-dependent apoptosis
by sustaining expression of the caspase-8 inhibitor c-FLIP [Saito et al., 2006].
HCV also inhibits TNF-induced NFκB activation by interfering with TRAF2
and the inhibitory complex IKKα by the viral proteins NS5A and NS5B, respec-
tively [Choi et al., 2006]. It is more common for viruses to target either TNF
superfamliy ligands or TNF-induced signalling rather than production of the
protein. However, different bacteria and parasites such as Listeria monocyto-
genes, Staphylococcus aureus, Plasmodium falciparum, Toxoplasma gondii among oth-
ers, have been reported to interfere with the expression of the tnf gene, mainly
by targeting NFκB and members of the MAPK [Rahman and McFadden, 2006],
known to be crucial for tnf expression and which will be described in more detail
in different sections of this Chapter.
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HCMV has also been reported to block TNF-induced NFκB-dependent re-
sponses by targeting the TNFR1 [Baillie et al., 2003]. A similar mechanism has
been described by MCMV which inhibits TNF-induced ICAM-1 expression by
altering the levels of both TNFR1 and TNFR2 [Popkin and Virgin, 2003].
5.2 Aim of the Chapter.
Work presented in previous Chapters has shown that the absence of ie1 resulted
in a significant production of TNF at both transcript and protein levels in infected-
BMMθs. The aim of this Chapter was to explore the molecular mechanism of this
potential modulation of TNF production in primary Mθs.
5.3 Bibliographic characterization of tnf promoter activation.
In order to study at the molecular level the MCMVdie1-induced production of
TNF it was of interest to firstly understand the induction of this response. From
the literature it can be seen that tnf activation occurs by different mechanisms de-
pending on the stimuli, as well as the species under study, that is between human
and murine gene expression. Therefore, a literature review was performed in or-
der to characterize the molecular mechanisms by which murine tnf promoter is
activated, and to identify common transcription factors which might also be in-
volved in the activation of the gene, as well as the signalling pathways leading
to the activation of these molecules.
The first part of this study involved an extensive literature review in order to
characterize which factors are crucial for tnf activation. This study was done in
colaboration with Y. Naiyachit, as part of an MSc project done during the time
of this thesis. As it has been previously introduced, TNF is mainly produced
by macrophages, however other cells like T cells, B cells and NK cells also pro-
duce TNF. The cytokine response normally occurs after cellular activation by a
wide variety of stimuli, such as bacterial peptidoglycan, lypopolysacharide, viral
and bacterial infection, among others. Interestingly, all these stimuli induce the
activation of tnf expression by the recruitment and activation of different tran-
scription factors. Moreover, this response has also been reported to be cell type-
and stimuli-dependent [Falvo et al., 2000].
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LPS-induced TNF production has been extensively studied in both human
and murine monocytic cell line. For instance, comparative studies have shown
similarities in both promoters, but there are also several differences regarding
the contribution of transcription factor NFκB in the induction of tnf promoter
[Kuprash et al., 1999]. In contrast to this study, others have shown that NFκB
is not required for a full induction of the promoter, and the recruitment of tran-
scription factors such as Sp1, Egr-1, Ets and ATF2/Jun is sufficient for an optimal
activation of tnf expression in LPS-activated Mθs [Tsai et al., 2000]. However, a
recent study has shown that blocking NFκB activation resulted in a reduction in
the activation of tnf by LPS, suggesting that although NFκB might not be essen-
tial for the initial activation of the gene expression it is required for the stability
of the mRNA [Tsytsykova et al., 2007]. The coactivator proteins CREB binding
protein (CBP) and p300 seem to function to maintain the correct alignment of the
factors for the optimal induction of the promoter [Barthel et al., 2003].
The molecular mechanisms of TNF production by Mycobacteria has also been
studied in macrophages, showing a number of similaties with LPS [Barthel et al.,
2003] regarding the induction of the enhanceosome formation. This study also
compared the assembly of the enhanceosome in virus-infected cells or in re-
sponse to ionophore. The results are shown in Figure 5.1, where it can be seen
that, even though cell type and and stimili play a role in the formation of the ini-
tiation complex, there are a number of factors which are equally essential in all
three scenarios. They are ATF2/Jun, Sp1, Ets, Egr-1 and coactivators CBP/p300.
Taking all the information together, figure 5.2 shows the transcription factors
which have been shown to be involved in the activation of the murine tnf pro-
moter. The identification of these transcription factors along with the upstream
signals driving their activation might give the basis of the molecular mechanisms
underlying MCMV IE1-induced suppression of tnf expression in Mθs.
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5.4 Investigation of Mitogen Activated Protein Kinases.
Once the transcription factors involved in tnf promoter activation were deter-
mined, the second step in this investigation was to identify which signalling
pathways would drive the recruitment and activation of these factors, which also
might be targeted by MCMV IE1. It has been shown that the engagement of dif-
ferent TLRs results in activation of pro-inflammatory cytokines, including TNF.
In fact, M. tuberculosis and LPS activate TLR2- and TLR4- signalling pathways,
respectively. It is also known that viral infection is normally sensed by TLR3 or
TLR9, or both, inducing the signalling cascade. These receptors induce the acti-
vation of NFκB and mitogen activated protein kinases (MAPK), which cultimate
in the activation of an pro-inflammatory response.
MAPK is a family of signalling proteins expressed in all eukaryotic cells and
involved in many different cellular responses and functions, from cellular growth
and differentiation to cytokine responses. Three important groups of MAP ki-
nases have been characterized in mammalian cells; the extracellular signal reg-
ulated protein kinase 1 and 2 (Erk1/2), p38 MAPK, and c-Jun amino-terminal
kinase/stress-activated protein kinase (JNK/SAPK). All of these have been shown
to be activated in different macrophage cell lines [Rao, 2001]. Their effects on
the induction of TNF gene expression and protein release have been extensively
documented, as well as their involvement in the activation of cytokine responses
against different pathogens [Pazdrak et al., 2002, Nakamichi et al., 2004, Lee et al.,
2005, Zhang et al., 2005, Zhu et al., 2005], and immune evasion strategies [Prive
and Descoteaux, 2000]. Moreover, it has been shown that activation of at least
Erk1/2 and p38 is required for successful induction of the TNF gene [Rutault
et al., 2001]. This suggests a cooperative effect between the different MAP kinase
signalling pathways, which would regulate different stages of TNF production
[Zhu et al., 2000].
The activation of Erk1/2 has also been reported in LPS-stimulated bone mar-
row derived macrophages [Valledor et al., 2000], as well as its role in TNF pro-
duction. However, the precise role that these molecules, and the subsequent
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cascades triggered upon kinase activation, play in the processes responsible for
TNF production remains unclear. Both Elk-1 and Egr-1 are involved in Erk1/2
signalling pathway in different Mθs cell lines. It is known that there are binding
sites for both transcription factors in the tnf promoter (see Figure 5.2), and that
Elk-1 can activate Egr-1 expression [Shi et al., 2002, Xu et al., 2001]. MAPK also
phosphorylate CREB, shown to be involved in activation of the transcription of
tnf gene [Roach et al., 2005]. Very recently it has been reported that MNK ki-
nases, downstream Erk1/2 and p38, also play an essential role in regulation of
tnf expression, as well as balance the activation of a pro-inflammatory response
against anti-inflammatoy response [Rowlett et al., 2008].
TLR3 and TLR9 [Tabeta et al., 2004], and very recently TLR7 [Zucchini et al.,
2008], have been shown to play a role in innate immunity against MCMV in-
fection. These TLRs are also known to activate MAPK, however this has not
been described in the context of MCMV infection. Moreover, data presented in
Chapter 3 might indicate that MCMV regulates lipid metabolism of the infected
cell, including cholesterol. A recent study has shown that cholesterol is also im-
portant for the regulation of Erk1/2 kinase activity, by being an integral part of
the Erk1/2 specific phosphatase complex [Wang et al., 2003, Wang et al., 2005].
Nevertheless, since members of the MAPK family and NFκB are common targets
for different pathogens in the inhibition of TNF, it was of interest to investigate
whether MCMVdie1 infection resulted in a differential activation of any of these
molecules which could give an insight into the molecular mechanisms of TNF
production.
Hence, BMMθs from 10-12 week old male mice were cultured as described be-
fore and made quiescent by serum starvation for 24 hours prior infection. Infec-
tion was carried out at a MOI 1 with MCMVdie1, wild type MCMV or MCMVrev
for 10 hours. The length of infection used was determined according to the peak
of TNF shown in the results described in Chapter 4. This study was done in
collaboration with Upstate (Millipore, UK), using the PathwayProfilerTMservice.
This multiple bead-based array was used as an alternative to Western Blot for
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Table 5.1: Panel of target
































Analytes that are targeted by the assay. Table shows the list of targets along with the specific
antibody, the total protein analysis and validation by Western Blot.
the study of the activation of members of the MAPK family, along with other
signalling molecules.
In order to validate this technology, Western Blot was also used on the pro-
teins indicated on the last columm of Table 5.1. Therefore, two of the biolog-
ical replicates were analysed using PathwayProfilerTM, and the third replicate
was used for validation in Western Blot. At the same time, a second experiment
was performed and activation of signalling molecules was analyzed by Western
Blot. After infection, the whole cellular lysate was extracted as described in Sec-
tion 2.6.1 and analysed by the PathwayProfilerTMassay and by Western blot for
the activated forms of the MAPK family members and several other signalling
molecules. In order to establish the intensity of activation, data was normalized
against β-Actin protein, followed by normalization against the mock infected
signal, and total amount of protein when applicable, showing fold activation
values. Values above 1 indicates that viral infection induces stronger activation
of the kinase than non-infected samples.
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As a control of infection, Western Blot was performed against IE1 and early 1
(E1) viral proteins. As it can be seen from the first panel in Figure 5.3 IE1 protein
was absent in both non-infected and MCMVdie1-infected samples. Comparable
levels of E1 protein were seen in all infected samples, but not in mock-infected.
The slight background found in the mock-infected line could be the result of
several washes and stripping of the blot. In any case, the analysis was done on
the basis of equal amounts of protein, as seen in the rest of the blots. Panel B
shows the positive control for BMMθs activation. Cells were stimulated with
LPS for 6 h and Western Blot was performed against IκBα. Degradation of the
protein after LPS stimulation demonstrated normal activation of the cells.
5.4.1 MAPK family
Figure 5.4 shows the activation of members of the MAPK family (A-C). The top
panels shows the PathwayProfilerTManalysis and with the Western Blot valida-
tion along with the densitometric analysis of each blot below. Panel A.1 de-
picts Erk1/2 activation and from the graph it can be seen that after infection
with MCMV kinase phosphorylation was similar to the mock-infected BMMθs.
However, when infection was carried out with the revertant virus a 3-fold ac-
tivation was detected. The phosphorylation of Erk1/2 after MCMVdie1 was 4-
fold higher than with mock-infection (p<0.05). Figures 5.4 A.2 and A.3 show
Western Blot and correspodent densitometric analysis, respectively. In contrast
to what was seen in A.1, MCMV infection resulted in a significant activation
of Erk1 (p=0.03) after 10 hours of infection, whereas Erk2 activation was only
modest when compared to mock-infected samples (p=0.5). A similar response
was seen after infection with revertant virus, however both proteins were signif-
icantly activated (p<0.05), with 4.8 and 3.6-fold higher phoshorylation of Erk1
and 2, respectively. Similar to what was seen from the Luminex analysis, Erk1/2
activation after MCMVdie1 was 5.5 and 4.2-fold higher than mock-infected sam-
ples (p=0.01).
90
Other members of the MAPK family, p38 and JNK, were also analyzed. Lu-
minex based PathwayProfilerTManalysis shows in panel B1 that p38 was acti-
vated after infection, however median fluorescent intensity (MFI) values from
MCMVrev-infected cells were below base line. MCMVdie1-induced p38 phos-
phorylation seemed to be slightly higher than MCMV-induced activation, how-
ever Western Blot analysis did not reveal any difference between viruses. Anal-
ysis of JNK was not included since MFI values were under limit of detection.
However, Western Blot analysis showed (panel C.2) that MCMVdie1 infection
resulted in activation of the kinase, but no differences were found when activa-
tion was compared to MCMV and MCMVrev infection.
In summary, this analysis showed that PathwayProfilerTMwas not consistent
with the results obtained by Western Blot, indicating that it is not a reliable tech-
nology for the molecules tested. On the other hand, based on Western Bot results,
no differences were found in the activation of Erk1/2, p38 or JNK between the
different viral infections. Therefore, the significant production of TNF seen after
MCMVdie1 infection does not seem to be due to a stronger activation of these
pathways.
5.4.2 IκBα, CREB and STAT6 activation
Next, the activation of other molecules which have been shown to play a role
in the activation of tnf gene expression was studied. It is well documented that
the transcription factor NFκB participates in the activation of tnf gene expression
in macrophages, although there is some controversy regarding the contribution
of this factor in the initial steps of the promoter activation. The role of NFκB
has also been studied in MCMV replication. Although there are several bind-
ing sites of this transcription factor in both human and murine CMV enhancer
region [Stinski and Isomura, 2008], NFκB is not required for either HCMV or
MCMV replication in vitro [Benedict et al., 2004, Gustems et al., 2006]. Moreover,
mutation of the NFκB sites did not have any effect on the expression of the ie1
gene in both viruses. Human IE1 has been shown to induce the expression of
members of the NFκB, such as RelB [Wang et al., 2005] or the NFκB p105/p50
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promoter [Gribaudo et al., 1996]. The dispensable role of NFκB in HCMV repli-
cation has also been demonstrated by Eickhoff and coworkers. However, the
same study also showed that blockade at NFκB activation decreases both TNF
and IFNγ-induced inhibition of HCMV replication [Eickhoff and Cotten, 2005].
In contrast, Sambucetti and coworkers showed that the IE1 protein was leading
the activation of the MIE region by trans-activating NFκB sites [Sambucetti et al.,
1989]. Taken all together, it can be seen from the literature that the role that NFκB
plays in CMV infection is not completely understood, but it is clear that this fac-
tor acts as a mediator in the immune response. In fact, several NFκB sites have
been localized in the tnf promoter (Figure 5.2), therefore activation of NFκB was
also included to test the activation of TNF after MCMV infection.
In resting cells, NFκB is sequestered in the cytoplasm by association with
IκBα. Cell activation leads to the phosphorylation and ubiquitination of the
NFκB inhibitor IκBα. Once free from IκBα, the active form of NFκB translocates
to the nucleus and activates gene expression. The activation of NFκB was studied
in two different ways. Figure 5.5 D.1 shows the phosphorylation of IκBα, which
precedes its degradation. Below is Western Blot for IκBα the degradation of the
protein and therefore the activation of NFκB. Densitometric analysis of the blot
are also shown in Figure 5.5 D.3. Analysis from the PathwayProfilerTMshows that
IκBα phosphorylation was induced after MCMVdie1 infection, however both
MCMV-induced inhibitor phosphorylation was not as strong as in the mutant
virus. MCMVrev infection did not seem to activate phosphorylation. Western
Blot and densitometric analysis show the degradation of IκBα. Results did not
reveal any significant degradation between viral infections, and IκBα levels in
MCMVrev-infected samples were similar to mock-infected samples. From this
data it cannot be concluded that MCMV infection induced activation of NFκB
at the time point under study, and that IE1 did not seem to play a role in this
activation.
Along with IκBα, the activation of the transcription factor CREB was also
studied. As it has been introduced before, CREB is phosphorylated by members
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of the MAPK family, and takes part in the enhanceosome complex during tnf
induction after cellular activation with different stimuli. Once phosphorylated,
the active form of CREB binds to the cyclic AMP response elements (CRE) lo-
calized in the tnf promoter as part of the transcriptional machinery responsible
for activation of gene expression. The phosphorylation analysis can be seen in
Figure 5.5 E.1-E.3. Luminex-based PathwayProfilerTMrevealed that after 10hpi,
MCMV infection induced a modest phosphorylation of CREB, however both
MCMVdie1 and MCMVrev-induced phosphorylation was significantly higher
than the mock-infected sample (p<0.001 in both cases). As seen for Erk1/2
activation in the previous section, there were differences between MCMV and
MCMVrev, and CREB activation was higher after MCMVrev infection. However,
MCMVdie1 infection results in a stronger phosphorylation of CREB when com-
pared to both parental and revertant virus (p<0.001 in both cases). In contrast
to the PathwayProfilerTM, Western Blot showed strong phosphorylation of CREB
after viral infection and no difference was found in the phosphorylation in the
absence of IE1.
Finally, the activation of STAT6 was studied. STAT6 is reported to be in-
volved in the negative regulation of cytokines [Ohmori and Hamilton, 2000].
Analysis can be seen in Figure 5.5 F.1-F.3. PathwayProfilerTManalysis showed
that STAT6 activation was similar to the levels of mock-infected samples. West-
ern blot showed similar results, and no differences were found between either
mock-infection or between viruses.
Taking all the data together, the Luminex-based PathwayProfilerTMwas not
found to be a reliable technique for the purpose of this study since there was no
consistency with the data obtained by Western Blot. Nevertheless, initial obser-
vations might indicate that MCMVdie1 infection does not apparenlty result in a
stronger activation of members of the MAPK family Erk1/2, p38 and JNK, when
compared to MCMV and MCMVrev. Very similar results were found in the acti-
vation of NFκB where, by looking at the phosphorylation and degradation of its
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inhibitor IκB, Western blot analysis did not reveal differences between MCMV
and the mutant virus.
The rest of the proteins included in this study (see Table 5.1) were not val-
idated by Western Blot because an important variability were found between
samples. Nevertheless, results from PathwayProfilerTManalysis can be found in
Appendix C.
5.5 Conclusion
It was of interest to explore the potential regulation of tnf activation after MCMV
infection. Hence, a study on the activation of the tnf promoter was performed,
followed by the identification of different signalling molecules which might be
involved. An extensive literature review identified a number of transcription
factors which are commonly recruited to the tnf promoter after cellular activa-
tion with different stimuli such as LPS and Mycobacterium tuberculosis. These
transcription factors included ATF2/Jun, CREB, Ets, Elk, Egr-1 and Sp1, as well
as different κB sites in distal sequences of the promoter. It is known that af-
ter BMMθs infection, a number of signalling molecules are activated to start a
cascade of events which drive the activation of gene expression. Within this cas-
cade, and in the context of the activation of tnf expression, the MAPK family
has been shown to play a role. It has been reported that several stimuli lead to
phosphorylation of Erk1/2, p38 and JNK, after which they translocate to the nu-
cleus and activate different transcription factors and gene expression. The use
of specific inhibitors for Erk1/2 and p38 has shown that LPS-induced tnf gene
expression can be completely abrogated [Rutault et al., 2001]. Together with the
MAPK family, NFκB is also important for the activation of a number of immune
genes, including tnf. There are several IκB sites within the tnf promoter, mak-
ing NFκB another candidate for MCMV. This study was done as part of a col-
laboration with Upstate (Millipore, UK) in order to validate the Luminex-based
PathwayProfilerTM. This protein array is presented as an alternative to Western
Blot, since it allows testing of a number of different molecules simultaneusly.
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The validation by Western Blot was not consistent with the analysis and there-
fore no conclusions were drawn from this study. Initial observations indicate
that MCMVdie1-induced TNF production does not involve the differential acti-
vation of Erk1/2, p38, JNK and NFκB. However, further work has to be done to
elucidate the mechanisms of the TNF response.
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Figure 5.1: Proposed model for TNF promoter activation after different stimuli
in T cells and monocytes.
Schematic diagrams representing models for transcription factor recruitment and enhanceosome
formation on the tnf promoter in T cells (top and middle panel) and monocytes (bottom panel)
after different stimuli. Illustration taken from [Barthel et al., 2003] with the permission of the
American Society of Microbiology.
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Figure 5.2: Murine TNF promoter topography (adapted from Lee and Schorey
2005).
Figure 5.3: Western Blot for IE1 and E1 proteins and LPS positive control
BMMθs were infected at a MOI of 1 with MCMV, MCMVdie1 or MCMVrev or mock infected as
a negative control (n=2). Western blot was perfomed as a control of infection using anti-IE1 and
anti-E1 specific monoclonal antibodies. A. Viral proteins IE1 and E1 after M. mock infection or
infection with 1. MCMV, 2. MCMVdie1, 3. MCMVrev. B. Cells were also M. mock-stimulated or
treated for 6 h with LPS as a positive control. Western blot shows LPS-induced degradation of
IκBα.
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Figure 5.4: Activation of MAPK after infection of BMMθs
BMMθs were infected at a MOI of 1 with MCMV, MCMVdie1 or MCMVrev or mock infected
as a negative control. Samples were analyzed as n=4 using the PathwayProfilerTMservice by
Upstate (Millipore, UK) or Western Blot (n=3). 1. Fold activation of the kinases are shown. MFI
data have been normalized against total amount of protein and mock-infected samples. Blank
values were also extrated from the final values. Bars show media values and SD. 2. Western blot
for the activated forms of the kinases and total amount of protein (M mock-infected, 1 MCMV, 2
MCMVdie1, 3 MCMVrev). 3. Densitometric analysis of the blot. Fold activation of the kinases
are shown. Data have been normalized against β-Actin, mock-infected and total amount of
protein. Bars show media values and SD.
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Figure 5.5: Activation of IκBα, CREB and STAT6 after infection of BMMθs
BMMθs were infected at a MOI of 1 with MCMV, MCMVdie1 or MCMVrev or mock
infected as a negative control (n=3). Samples were analyzed in duplicate as n=2 using the
PathwayProfilerTMservice by Upstate (Millipore, UK) or Western Blot (n=2). 1. Fold activation
of the kinases are shown. MFI data have been normalized against total amount of protein
and mock-infected samples. Blank values were also extrated from the final values. Bars show
media values and SD. 2. Western blot for the activated forms of the kinases and total amount of
protein (M mock-infected, 1 MCMV, 2 MCMVdie1, 3 MCMVrev). 3. Densitometric analysis of
the blot. Fold activation of the kinases are shown. Data have been normalized against β-Actin,
mock-infected and total amount of protein. Bars show media values and SD.
CHAPTER 6
Investigation of MCMVdie1 regulation of TNF
levels in vivo
6.1 Introduction
In vitro systems allow scientists to easily examine the behavior of individual cel-
lular populations. However, this misses one of the most important factors for
the optimal activation of the cellular immune response upon infection, and that
is cell-to-cell interaction, within the context of intact multicellular tissues. To
date, this can only be modeled in intact organisms so that it is essential to have
animal models to study.
Studying MCMV infection in vivo is a well established model. Moreover, be-
cause of the strict species specificity of MCMV infection the mouse model is a
useful tool to study viral-induced pathogenesis in the natural host. The outcome
of any infection is both host and virus-dependent and there are a number of
factors which could affect the outcome of experimental infection, including the
origin of the viral preparation. Whether MCMV has been prepared in vivo from
salivary glands (SVG) or tissue culture is an important factor since SVG-derived
MCMV has been shown to be more virulent than MCMV generated in tissue cul-
ture. This observation has already been documented [Krmpotic et al., 2003] and
it might be due to factors in the salivary glands but the reasons remain unknown.
In addition, the passage of MCMV in culture results in a loss of viral infectivity,
maybe as a result of an adaptive response of the viral strain to tissue culture. The
route of inoculation has also to be taken into consideration. Although saliva is
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considered to be the most natural route of infection, intraperitoneal injection is
one of the common routes used in in vivo studies, after which spleen and liver
become infected. But other routes such as intravenous, intraglandular or nasal
aspiration are also used. The immune status of the mouse at the time of infec-
tion is crucial for in vivo studies, since infection of immunocompromised mice
results in high mortality, pneumonitis and myocarditis [Krmpotic et al., 2003].
Infection of neonatal mice differs from immunocompetent adult mice in the tis-
sue tropism seen. Neonatal infection is characterized by an early infection of the
Central Nervous System (CNS) which results in high mortality whereas adult
mice have asymptomatic infection which is normally controlled within days.
The genetic background of the mouse to be infected is also important. Infection
of various mouse strains has been reported but the MCMV-susceptible BALB/c
and MCMV-resistant C57Bl/6 are the most commonly used. This difference in
susceptibility relies on the level of NK cell activation, which is under control of
the Cmv1 locus [Scalzo et al., 1990] within the NK gene complex [Scalzo et al.,
1992]. Cmv1 encodes for the activated NK cell receptor Ly49H. NK cells from
BALB/c mice lack this locus and as a consequence they do not induce the cor-
rect signals for NK cell activation after MCMV infection. However, 50% of the
NK cells of the C57Bl/6 mice bear the Cmv1 locus and express Ly49H. MCMV-
infected cells express the viral protein M157 which is a strong ligand for Ly49H.
The interaction between Ly49H/M157 induces effective activation of NK cells.
This results in secretion of IFNγ, which is a very potent cytokine involved in the
control of viral infection.
Infection with MCMV results in a rapid cytokine and chemokine response to
recruit and activate immune cells to the site of infection and control viral repli-
cation and dissemination to other organs. Within this pool of cytokines, special
mention has to be made of type I and II IFN, IL12, LTβ and TNF. The interplay
between these cytokines and immune cell population determines the outcome of
the infection. However, the fact that MCMV successfully establishes latency in its
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host means that MCMV has evolved several mechanisms to evade the immune
response against the infection.
As early as 2 days post infection, production of IFNαβ is detectable in spleen
and liver of infected mice. This first wave of IFNαβ production comes from plas-
macytoid (pDC) and non-plasmacytoid dentritic cells (DC) [Orange and Biron,
1996, Hokeness-Antonelli et al., 2007, Zucchini et al., 2007]. pDCs have been con-
sidered to be a major source for this cytokine. However, the exclusivity of pDC
in the production of IFNαβ has been ousted by a very recent report showing
that stromal cells in the spleen of infected mice are also key in the production
of IFNαβ [Schneider et al., 2008]. Interestingly, both pDC and splenic stromal
cells induce IFNαβ response using different signalling pathways. Thus, spleen
stromal cells are activated through the crosstalk with B cells which produce lym-
photoxin β (LTβ). After production, LTβ binds to LTβ receptor (LTβR) on the
surface of the stromal cell, and LTβ-LTβR signalling pathway leads to the pro-
duction of IFNαβ. It has been also shown that pathways leading to IFNαβ pro-
duction depends on the tissue, for instance TLR9 and MyD88 are activated in
the spleen however IFNαβ production is TLR9-independent in the liver [Delale
et al., 2005, Hokeness-Antonelli et al., 2007]. The production of IFNαβ is also un-
der control; as documented by [Tailor et al., 2007] where IRF8 is involved in the
second wave of cytokine production, ensuring the optimal antiviral response.
Independently of the source and molecular mechanism by which IFNαβ is
produced, its role in the control of MCMV infection in the natural host has been
extensively studied. Activation of NK and CD8+ T cells depends in part to
IFNαβ. Upon activation, these cells produce IFNγ. However, the uncontrolled
production of this cytokine could cause damage on the host and therefore, IFNαβ
production requires to be under control [Hahm et al., 2005]. One example of this
cytokine control has been recently documented by [Robbins et al., 2007] where it
is shown that overactivation of CD8+ T cells could be avoided by the control of
pDC-induced IFNαβ.
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IFNγ is produced by activated-NK and CD8+ T cells. It has been well docu-
mented the effect of this cytokine in MCMV infection both in vivo [Pomeroy et al.,
1998] and in vitro [Lucin et al., 1994]. IFNγ is responsible for the establishment of
the antiviral state by inducing the transcription of a huge number of genes. The
IFNγ receptor is ubiquitously expressed, which helps to activate bystander cells
and prepare them to control viral infection. Although how IFNγ blocks viral
replication remains unknown. Nevertheless, MCMV has developed strategies to
circumvent the antiviral activity induced by IFNγ. One examples is the degrada-
tion of STAT2 by the viral protein pM27 [Zimmermann et al., 2005]. By blocking
STAT2 activation both type I and II IFN responses are affected, suggesting that
both pathways cross-talk during the antiviral activity. Another strategy to escape
from IFNγ-induced effects has been shown by [Heise et al., 1998]. In this study
it is shown how MCMV has evolved to inhibit the expression of MHC class II on
the cell surface induced by IFNγ. With this strategy MCMV also circumvents the
activation of CD4+ T cells.
IL12 is also produced very early after infection and is required for the optimal
activation of NK cells and subsequent production of IFNγ in spleen and liver af-
ter acute infection. The strength of IL12 signalling is related with the activation
of NK cells [Orange et al., 1995]. In addition, IL12 production is also under con-
trol since it has been reported that IFNαβ inhibits IL12 production, which in turn
affects the consequent NK-induced IFNγ. It has been shown that MCMV infec-
tion of DC results in significant reduction in IL12 production after 4 days post
infection [Andrews et al., 2001], resulting in a decrease in activation signals to
NK and T cells. However, the mechanisms by which this reduction is regulated
have not been elucidated.
Along with type I and II IFN and IL12, TNF is also produced. Macrophages
and activated NK and CD8+ T cells are the main producers of this cytokine. TNF
is involved with cellular differentiation, proliferation and apoptosis. Although
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the presence of TNF is sufficient to reduce viral replication in infected cells, it
has been shown that IFNγ in combination with TNF has a more effective antivi-
ral effect [Lucin et al., 1994]. Also TNF has a paracrine action, which will induce
the activation of bystander cells which will respond to viral infection. Consider-
ing the important role that TNF plays in the control of viral infection, there have
been several studies trying to elucidate its role in natural settings. However,
there is a lot of controversy in the results. Shanley et. al. showed that after both
lethal and sublethal infection of BALB/c mice TNF levels were undetectable in
serum. However, levels of this cytokine in serum were found in MCMV-infected
BALB/c [Trgovcich et al., 2000] and C57BL/6 [Lenzo et al., 2001] and in all or-
gans examined. It also appears that TNF was produced in a viral dose-dependent
manner. Trgovcich et. al. showed as well that the tnf gene was expressed during
sublethal infection in spleen, liver and lung. Tang-Feldman reported on the lev-
els of expression of different cytokines after MCMV infection in BALB/c mice,
showing an induction in TNF expression at day 5 p.i in spleen, liver, lungs and
salivary glands [Tang-Feldman et al., 2006]. Thus, the production of TNF early
after infection suggest a role in the control of in vivo infection of different strains
of mice in serum, spleen, liver and heart.
6.2 Aim of the chapter
Because in vitro conditions may not correspond to those of the natural host, it
is essential to study viral infection in vivo, where an important number of in-
teractions and crosstalk between cells take place, which may influence the out-
come of the infection. Work presented in Chapter 4 of this thesis suggests that
MCMV regulates the production of BMMθ-induced TNF production. Therefore,
the next question to be addressed was whether the modulation of TNF produc-
tion by MCMVdie1 also occurs in vivo. Two different mouse strains were used.
An attenuated phenotype for the ie1-deletion mutant MCMV was previously de-
scribed in immunocompetent MCMV-susceptible BALB/c mice [Ghazal et al.,
2005]. The work presented in the following sections confirms these results and
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describes viral growth in the MCMV-resistant C57Bl/6 mice. The production of
TNF is described for the first time in MCMVdie1-infected mice in vivo.
6.3 Results
6.3.1 MCMVdie1 induces higher levels of TNF in competent BALB/c mice.
In order to characterize the induction of TNF in MCMVdie1 infected mice, the
following experiment was designed. Groups of 8-weeks old, male BALB/c mice
were inoculated i.p. with 1.6 x 106 PFU of tissue culture-derived MCMVdie1 or
the revertant virus or mocked infected. At 4 and 7 days post infection, 4 mice
from the different infected-groups and 2 from the mock-infected group were
killed and selected organs were harvested to determine viral titers and TNF in-
duction. Wild type MCMV was not included in this experiment since there were
no significant differences between the replication of MCMV and MCMVrev in
infected BALB/c mice, as had been described in previous publications [Ghazal
et al., 2005]
Confirmation of the attenuated growth phenotype of MCMVdie1 in vivo.
Spleen, liver, kidney, lung and heart were removed from mice at specified time
points. As described in Section 2.8.2 from Material and Methods, samples were
weighed and homogenized as in 10% w/v. Tissue homogenate was then soni-
cated and after clearing by centrifugation, viral titers were determined by stan-
dard plaque assay (Section 2.4.2). Figure 6.1 depicts viral titers per gram of tissue
in selected organs. From the graph it can be seen that, as expected, MCMVdie1
shows an attenuation in its growth phenotype, when compared to MCMVrev
replication. At day 4 pi MCMVrev viral load was high in spleen and liver, as
normally occurs after an acute infection [Krmpotic et al., 2003], and 6-, and 12-
fold higher than MCMVdie1 replication, respectively (t-test, p<0.05). A very dra-
matic difference in viral titers was also seen in kidneys where MCMVdie1 titers
were more than 100-fold less (t-test, p=0.0094). MCMVdie1 replication in heart
and lung was 21- and 35-fold lower when compared to MCMVrev, respectively
(t-test, p<0.05).
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Figure 6.1: Growth of MCMVdie1 and MCMVrev in different organs from in-
fected BALB/c mice at day 4 and 7 post infection.
Groups of BALB/c mice (n=4 mice per group, except MCMVdie1-infected mice at 7 days was
n=5) were inoculated with 1.6 x 106 PFU of tissue-derived MCMVdie1 or MCMVrev. On day 4
and 7 post infection mice were sacrificed and the indicated organs were harvested, weighted,
and sonicated as a 10% (wt/vol) tissue homogenate in DMEM. Viral titers were determined by
standard plaque assay on MEFs. Red lines show median values and blue lines show limit of
detection. All titers were significantly different between MCMVdie1 and MCMVrev (t-test,
p<0.05).
At day 7 pi MCMVdie1 could not be detected in spleen, liver or heart. In or-
der to calculate median values of viral titers in these particular organs the limit
of detection was set for 2 x 102 PFU/g, which corresponds to one single PFU.
However, MCMVrev burden in these organs remained elevated (600-, 250- and
45-fold higher in spleen, liver and heart, respectively). MCMVdie1 titers in kid-
neys were 2-fold lower than at day 4 p.i. No changes in titers were found in lungs
of MCMVdie1-infected mice, whereas after 7 days of infection with MCMVrev
there was a 2.5-fold higher titers in this organ, suggesting that MCMVrev had
spread to the lungs in the period of a week of infection.
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Figure 6.2: TNF production in selected organs from BALB/c mice at day 4 and 7
post infection.
TNF levels were detected in tissue homogenate by ELISA at indicated times. Compared to
mock-infected mice, both MCMVdie1 and MCMVrev induced significant levels of TNF. No
differences were found in TNF levels induced by MCMVrev and MCMVdie1.
TNF production in infected-BALB/c mice.
In order to asses induction of TNF after MCMV infection, cytokine concentration
was measured in selected organs by ELISA as described in Material and Methods
(Section 2.7.2). It has been already shown that MCMV infection of immunocom-
petent mice induced TNF production at early times after infection [Trgovcich
et al., 2000, Lenzo et al., 2003, Tang-Feldman et al., 2006]. When compared to the
mock-infected mice, MCMVrev induced significant levels of TNF in all organs
after 4 days p.i. (Figure 6.2). Spleen and liver of infected-mice showed 10-fold
higher levels of TNF when compared to uninfected-mice and a difference of 5-
fold was found in kidneys. Although the levels of TNF found in heart and lung
were not statistically significant, it appears that viral infection also results in in-
duction of this cytokine in these organs. However, what was more surprising
about these results was that after infection with MCMVdie1 no significant differ-
ences were seen in the levels of TNF produced when compared to those seen for
the revertant virus (t-test, p>0.05) on day 4.
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After day 7 p.i (Figure 6.2) TNF was also detectable after both ie1-deletion
mutant and revertant MCMV infection. Data showed (Figure 6.2, right pannel)
that after a week of infection, MCMVrev-induced TNF levels remained elevated
in spleen and kidneys, whereas a slight drop in hepatic levels was seen when
compared to levels detected after 4 days of infection. A significant 3.5-fold in-
crease was detected in the heart at this time point. There was no difference in
TNF levels in the lungs. When TNF induction was compared between viral in-
fections there were no differences in splenic, hepatic or lung levels. However,
MCMVdie1-induced levels in kidneys and heart were significantly lower com-
pared to MCMVrev-induced TNF. These differences might be due to lower repli-
cation rate of the mutant virus in these organs. In order to establish a relation be-
tween viral replication and cytokine response a correlation study was performed,
which is been described in the following section.
Correlation between PFU and TNF levels in infected-BABL/c mice
It has been reported that levels of cytokine expression correlates with viral repli-
cation in different organs [Tang-Feldman et al., 2006]. An earlier study showed
contrary results regarding the expression of TNF after infection [Trgovcich et al.,
2000]. However, these differences might be explained due to the higher sensi-
tivity of the qRT-PCR used in the latter report. Nevertheless, in order to better
understand the results of the experiment described above, a correlation study
was carried out to test whether TNF levels corresponded to viral loads in the dif-
ferent organs. Figure 6.3 shows a significant positive correlation between TNF
levels and viral load in kidneys and heart after 4 days p.i. (Pearson correlation
coefficient, R2=0.89 and R2=0.85 in kidney and heart, respectively).
Since these two organs showed a significant correlation between viral titers
and TNF levels, it was assumed that the relation also existed in the rest of the
organs. The relation between PFU and TNF can be seen in Figure 6.4. The graph
shows that at day 4 p.i., MCMVdie1 induced similar levels of TNF in spleen and
liver than those detected for MCMVrev. Higher levels of TNF were found in
kidneys, heart and lungs, even though viral yields were more than 10-fold less
in these organs. At 7 days pi (Figure 6.4) the difference between MCMVdie1 and
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Figure 6.3: Correlation in heart and kidney after 4 days post infection.
Pearson’s correlation coefficient showed a significant relation between TNF levels and viral load
in kidneys and heart from MCMVrev-infected BABL/c mice after 4 days p.i.
Figure 6.4: Correlation between TNF levels and PFU per gram of tissue
Correlation between TNF levels and PFU in different organs at day 4 and 7 p.i.
MCMVrev induction of TNF was even more dramatic since the mutant viral load
was 25-1000-fold lower than the revertant virus.
Because of the different titers found in selected organs after MCMVdie1 and
MCMVrev infection, BALB/c mice were also infected with a dose of MCMV
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which resultant titers were similar to those seen for MCMVdie1. Thus, mice were
infected with 3 x 105 PFU of MCMV, and titers and TNF production were also de-
termined and compared to both mock-infected mice and MCMVdie1. Figure 6.5
shows viral titers (right panel) and TNF production (left panel) in selected or-
gans after 4 and 7 dpi. Viral titers show that MCMV and MCMVdie1 replication
was comparable in all organs examined, except in the kidney, where replication
of MCMV in the kidneys after 4 dpi was significantly higher than titers found
after MCMVdie1 infection (p=0.02), but in the rest of the organs at both times
post infection, it was shown comparable PFU per gram of tissue.
When TNF levels were determined by ELISA it was seen that MCMV infec-
tion induced the cytokine production after 4 dpi. Only in the heart TNF levels
were similar to those seen after mock-infection. Interestingly, when compared
to MCMVdie1 infection, the mutant virus-induced TNF production was signif-
icantly higher in all organs, except in the heart. After 7 days, TNF levels in-
duced by MCMV dropped to similar levels as mock-infected mice. However,
MCMVdie1-induced TNF production was significantly higher in all the organs
examined. It could be argued that the levels of TNF found after MCMVdie1
infection were due to the initial dose of virus, but it has to be noted that the
interpretation of the data has been based on the output levels of infection.
6.3.2 MCMVdie1 attenuation is not strain-dependent.
A second study was designed in a different mouse strain. In this way, the strain-
dependency on the cytokine response would also be ruled out. Thus, the murine
strain C57Bl/6 was used for the second part of these in vivo studies. Groups of 4,
8-week old, male C57Bl/6 mice were infected by the intraperitoneal route with
2x106 PFU. A higher dose of virus was used in this experiment since C57Bl/6
strain is considered as a MCMV-resistant strain, based on the optimal activation
of NK cell by the MCMV protein M157-Ly49H interaction [Scalzo et al., 1992]. In
this way, the viral dose would be high enough to induce a clinical infection in
C57Bl/6 and MCMVdie1 titers could be detectable.
From Figure 6.6 it can be seen that no statistical difference was found between
MCMV and MCMVrev replication (t-test, p>0.05 in lungs and p>0.5 in the rest
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of the organs), whereas MCMVdie1 titers were lower in all organs examined. In
more detail, a 20- and 12-fold reduction was seen in spleen and liver, respectively
when compared to the parental and revertant viral load (t-test, p<0.03). Repli-
cation in the heart was 11-fold lower (t-test, p=0.005) and 6-fold in lungs (t-test,
p=0.016). The attenuation was even more dramatic in kidneys with a difference
in viral load of 150-fold (t-test, p=0.0015). Therefore, it can be concluded that
MCMVdie1 attenuation in vivo and operates in both susceptible and resistant
strains.
TNF production in infected-C57Bl/6 mice
Again ELISA was performed to measure TNF levels in selected organs after
4 days of infection. In agreement with previous studies [Orange and Biron,
1996, Lenzo et al., 2003], MCMV infected-C57Bl/6 mice induced TNF produc-
tion. As seen in BALB/c (Figure 6.2), there were no significant differences in
the levels of TNF produced after MCMV, MCMVdie1 or MCMVrev infection of
C57Bl/6 mice. The highest cytokine production was found in spleen, where 2.5-
fold more levels were detected when compared to the uninfected-mice (t-test,
p=0.03), which showed a basal TNF production. Just a modest induction of TNF
was found in the liver, and 1.5-fold higher level in kidneys (t-test, p=0.013) and
lung (t-test, p<0.01) when compared to control samples. Although higher levels
were also seen in heart of infected mice, it was not statistically significant (Figure
6.7).
Correlation between PFU and TNF levels in infected-C57Bl/6 mice.
Following the same procedure as in BALB/c and assuming the correlation be-
tween TNF and PFU, Figure 6.8 represents the relation between these two factors.
From the graph it can be seen that the levels of TNF induced by MCMVdie1 are
significantly higher, considering equal input of PFU in all groups. MCMV and
MCMVrev however, showed a normal profile where TNF levels are high when
viral titers are also high.
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6.4 Conclusion
After MCMV infection, a number of cells are activated to control viral replica-
tion and spread throughout the host. This immune response involves production
of cytokines or even direct lysis of infected cells. tnf gene expression has been
demonstrated to be activated upon infection in different organs [Tang-Feldman
et al., 2006] as well as protein production, which is detected early after infec-
tion in the spleen, liver [Orange and Biron, 1996] and heart [Lenzo et al., 2003]
of infected mice. MCMV has evolved with its natural host in a way to escape
immunosurveillance and endure in a latent state.
Data presented in Chapter 4 suggest a potential modulation of TNF pro-
duction in infected-BMMθs, involving IE1. The experiments described in the
present chapter were undertaken in order to assess whether MCMV infection
had the same effect on cytokine production in the natural host. Thus, two differ-
ent mouse strains were used and infection was carried out with parental MCMV
and ie1-deletion mutant MCMV. A revertant virus was also included in the ex-
periment (MCMVrev).
In summary, the results presented in this study showed that MCMV IE1 pro-
tein is necessary for the growth of the virus in the natural host, since the ie1-
MCMV mutant failed to replicate as the parental and revertant virus. More-
over, the attenuation seen for MCMVdie1 is not strain-dependent, since in both
BALB/c (which has been confirmed with these experiments) and C57Bl/6 mice
MCMVdie1 showed the attenuated phenotype. When TNF levels were studied
it was found that cytokine levels in all organs examined were similar after infec-
tion with either the mutant or parental and revertant virus. Overall, these results
showed that MCMVdie1 induced TNF production in the natural host but does
not demonstrate that IE1 is responsible for TNF regulation. In fact, it could be
argued that the levels of TNF after MCMVdie1 infection might not be due to a
modulatory mechanism but due to a defect on MCMVdie1 instead, resulting in
lower yields and, therefore, the correlation led to high levels of TNF. Perhaps
an investigation in the number of infected cells would be helpful to determine
whether MCMVdie1-infected cells is similar to those infected by the parental and
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revertant virus. Finally, it would also be helpful to determine the source of TNF
to know whether bystander cells are also responsible for such cytokine response.
Therefore, the role of IE1 in the regulation of TNF remains open for further in-
vestigation.
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Figure 6.5: Titers and TNF production by MCMV.
Groups of BALB/c mice (n=4 mice per group, except MCMVdie1-infected mice at 7 days was
n=5) were inoculated with 3 x 105 PFU of tissue-derived MCMV and compared to MCMVdie1.
On day 4 and 7 post infection mice were killed and indicated organs were harvested, weighted,
and sonicated as a 10% (wt/vol) tissue homogenate in DMEM. Viral titers were determined by
standard plaque assay on MEFs (left panels). Red lines show median values and blue lines
show limit of detection. Right panels show TNF levels detected from tissue homogenate by
ELISA at indicated times. Significance in TNF levels is shown as p<0.05 (*) and p<0.01 (**).
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Figure 6.6: Growth of MCMV, MCMVdie1 and MCMVrev in different organs of
infected-C57Bl/6 mice at day 4 post infection.
Groups of C57Bl/6 mice (4 mice per group) were inoculated with 2 x 106 PFU of tissue-derived
parental MCMV, MCMVdie1 or MCMVrev. On day 4 post infection mice were sacrificed and the
indicated organs were harvested, weighted, and sonicated as a 10% (wt/vol) tissue homogenate
in DMEM. Viral titers were determined by standard plaque assay on MEFs cells. Red lines show
median values and blue lines show limit of detection. There was no significant differences in the
growth of MCMV and MCMVrev (t-test, p>0.05), but MCMVdie1 replication was significantly
lower when compared to the parental and revertant MCMV (t-test, p<0.05).
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Figure 6.7: TNF levels in C57Bl/6 mice at day 4 post infection.
Levels of TNF were determined by ELISA after 4 days post infection. All three infections
induced TNF productions in organs examined. No significant differences were found in the
cytokine levels induced by MCMVdie1 and parental or revertant virus.
Figure 6.8: TNF levels versus PFU in C57Bl/6 mice at day 4 post infection
Levels of TNF against PFU in different organs of infected C57Bl/6 mice. At indicated times
organs were harvested, weighted and homogenate as a 10% (wt/v). TNF levels were
determined by ELISA from the homogenate.
CHAPTER 7
Role of TNF in MCMV infection in vivo
7.1 Introduction
So far it has been shown that IE1 MCMV protein is necessary for optimal vi-
ral replication in vivo, since in both immunocompetent BALB/c and C57Bl/6,
MCMVdie1 presented an attenuated phenotype, incapable of reaching viral loads
as MCMV or the revertant virus did. When TNF levels were studied after infec-
tion, it was seen, despite of the growth defect seen with the mutant virus, it was
able to induce similar levels of TNF to those seen for the parental and revertant
virus. These results gave a hint towards a potential modulatory strategy where
MCMV by its IE1 protein reduces TNF levels not only in vitro, as seen from Chap-
ter 4, but also in vivo.
The use of neutralizing antibodies, as well as genetically modified mice, has
helped to evaluate in more depth the role that cytokines and immune cells play
in the immune response against viral infections. Thus, blocking IL12 activity
showed how important this cytokine is for an optimal activation of NK cells and
the subsequent production of IFNγ after MCMV infection [Orange et al., 1995].
Moreover, the effect of depleting IL12 is specific for MCMV, since the blockade
of IL12 activity does not have any effect on NK-induced IFNγ production af-
ter LCMV infection [Cousens et al., 1997]. MCMV infection of mice depleted of
NK cells by neutralizing antibodies resulted in an increased MCMV burden in
spleen, liver [Orange and Biron, 1996] and lungs [Krmpotic et al., 2002]. These
results established the relevance of this cellular subset for the early control of
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viral infection. Furthermore, it appeared that NK-induced antiviral activity to
MCMV infection is organ-specific, since neutralizing IFNγ in MCMV-infected
mice showed higher viral replication in the liver, but not in the spleen. The re-
sults shown in this study led to the conclusion that control of MCMV infection
was NK-induced IFNγ-dependent in the liver whereas in the spleen the antivi-
ral mechanism was IFN-independent but perforin-dependent [Tay and Welsh,
1997].
In agreement with the findings from Tay et. al., and regarding the role of
IFNγ, neutralizing IFNγ by specific antibodies [Orange et al., 1995] or genetic
depletion [Pomeroy et al., 1998] resulted in high susceptibility to MCMV infec-
tion and increased viral replication. In addition, CD4+ T cell-induced IFNγ has
been demonstrated to be critical for MCMV clearance from the salivary glands
[Lucin et al., 1992], whereas CD8+ T cells are necessary for the control of infec-
tion in the rest of the organs [Pavic et al., 1993]. Interestingly, there is evidence
showing that in the absence of the CD8+ T cells subset, CD4+ T cells alone are ca-
pable of controlling viral infection in tissues other than the salivary glands [Jonjic
et al., 1990]. This fact showed how flexible the immune system is in adapting the
response in specific situations. Besides the protective effects that IFNγ has in con-
trol of the MCMV acute infection, IFNγ is significantly produced after a second
infection [Shanley et al., 2001], suggesting a role in the control of viral replication
in a second exposure to the pathogen, and also in control of reactivation of virus
from latency.
Blocking IFNαβ by administration of specific antibodies considerably increased
MCMV titers in the liver of infected-mice [Orange and Biron, 1996]. The deple-
tion of IFNαβ has been shown to have other effects in the control of MCMV
replication. For instance, enhanced IL12 production and NK-induced IFNγ pro-
duction [Cousens et al., 1997], demonstrating that type I IFN also regulates the
production of these cytokines, maintaining the balance in the cytokines response.
CD8+ T cell expansion and activation are also impaired. Overall, by blocking the
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activity of a single cytokine such as IFNαβ the activation of the innate response
to control MCMV infection is affected. This demonstrates the key role that IFNαβ
plays in orchestrating the antiviral activity at early times upon infection. Nev-
ertheless, Krug et. al showed that in vivo depletion of cells responsible for inter-
feron production by neutralizing antibodies did not result in higher MCMV titers
in spleen. Moreover, it appeared that infected mice were able to counterbalance
the reduction of IFNαβ by increasing the production of other cytokines, such as
IL12 and IFNγ [Krug et al., 2004]. This example of compensatory mechanism is
very important when interpreting in vivo data.
Lymphotoxin has also been shown to be critical for controlling viral repli-
cation. In previous sections of this thesis it has been quoted that LTβ is pro-
duced after infection and that LTβ-LTβR signalling is crucial for the production
of IFNαβ by splenic stromal cells. Thus, it is not surprising that blocking LTβ-
induced signalling results in high viral burden. The crosstalk between LTβ-LTβR
signalling and IFNβ was demonstrated when the antiviral activity was restored
by administrating IFNβ [Banks et al., 2005]. Moreover, it has been reported that
LTβ signalling activates the production of IFNβ, but requires the presence of
MCMV [Benedict et al., 2001]. Hence, type I IFN is not only crucial for activation
of NK and CD8+ T cells, and subsequent cellular responses, but also affects LTβ-
induced antiviral activity which ultimately results in inhibition of viral replica-
tion.
7.2 Aim of the chapter
The aim of this Chapter is to further analyse the role of TNF in the antiviral re-
sponse against MCMV infection in vivo. From the data presented in previous
Chapters it was suggested that MCMV IE1 protein modulates the TNF response
induced after infection, since the ie1-deletion mutant MCMV led to a significant
cytokine production, in both primary Mθ and in the natural host. These results
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led to study in more detail the role of TNF in the control of viral infection. There-
fore, work presented in this Chapter was designed to answer the following ques-
tions: (1) what would be the effect of TNF on MCMVdie1 replication in BMMθs,
considering the significant cytokine production registered after infection and (2)
is TNF responsible for the attenuated phenotype of MCMVdie1 in vivo. Taking
into account the levels of TNF produced in the different organs analyzed it was
expected that the growth defect seen for MCMVdie1 would be restored to nor-
mal levels in the absence of TNF response.
7.3 Results
















Figure 7.1: CellTiter-BlueR Cell Viability Assay
Viable cells were determined by fluorescent-based cell viability assay after treatment for
24 hours of BMMθs with different concentrations of TNF (1U and 10U/mL) along with a
non-treated control. Fluorescent units are shown along with standard deviation bars. No
differences were seen between treatments and non-treated cells.
7.3.1 Effect of TNF on viral replication.
Previous sections in this thesis have demonstrated that MCMVdie1 infection re-
sults in a significant production of TNF in BMMθs. It has been reported that TNF
pre-treatment of MEFs results in a reduction of MCMV replication [Lucin et al.,
1994]. So it was hypothesized that TNF-treated BMMθs control MCMVdie1 repli-
cation by cooperative antiviral effect exerted by both exogenous and endogenous
TNF. In order to ascertain if this hypothesis was true, BMMθs were cultured and
incubated with 1U/mL or 10U/mL of TNF 24 h, after which cells were infected
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Figure 7.2: TNF effect on viral replication in BMMθs
Cells were treated with either 1 or 10U of TNF for 24h prior to infection. After 24h cells
were infected with the different viruses at MOI 1. Intracellular and extracellular titers were
determined by standard plaque assay. A. MCMV, B. MCMVdie1 and C. MCMVrev. Each data
point represents the average and standard deviation of results of three different samples. Dash
line represents limit of detection.
at a MOI 1 with MCMV, MCMVdie1 and correspondent revertant (n=3) and vi-
ral replication was compared to non- TNF treated and infected BMMθs. Prior
to infection, cell viability was tested to rule out that the dose of TNF was toxic
or induced apoptosis of the cells. Figure 7.1 shows that a 24 h treatment of the
cells with either 1U or 10U of TNF did not have any effect on the viability of the
cells. Cells were then pre-treated and infected and the antiviral effect of TNF was
determined by standard plaque assay.
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As described in MEFs, TNF has a weak but clear antiviral effect on MCMV
(Figure 7.2.A) since a reduction of 23% and 37% of MCMV titers was seen after
treatment with 1U and 10U of TNF, respectively. Replication of MCMVrev was
also impaired by TNF in a very similar way as observed for the wild type MCMV,
with a reduction of viral replication of 30% after 1U TNF treatment and 38% af-
ter 10U TNF (Figure 7.2.B). A reduction of 45% in MCMVdie1 titers was found in
1 U/mL pre-treated BMMθs. Moreover, the complete inhibition of MCMVdie1
replication after 10U TNF treatment was seen ( Figure 7.2.C). These results are
consistent with previous findings demonstrating the antiviral effect exerted by
TNF [Lucin et al., 1994]. The antiviral effect exerted by TNF alone in MEFs was
weaker than the effect reported here. This difference might be explain by the
fact that fibroblast do not produce TNF, and cytokine levels induced after in-
fection would synergyze with exogenous TNF resulting in a higher reduction
of viral titers. Considering the high levels of TNF induced by MCMVdie1 it is
not surprising that the higher reduction were seen in the mutant titers. It has to
be noted that the levels of TNF used for BMMθs treatment did not exceed from
virus-induced TNF levels.
It could be argued that suppression in MCMVdie1 replication might be due
to a defect in the virus, however MCMVdie1 does not have a phenotype in tissue
culture as shown by [Ghazal et al., 2005]. Results presented on Chapter 3 showed
that in BMMθs MCMVdie1 tended towards lower yields, although no statistical
difference was found. This observation might be explained by the fact that the
cytokine repertoire induced by fibroblasts do not include TNF which could be
the reason of such a high sensitivity of MCMVdie1. In addition, sensitivity of
MCMVdie1 to TNF could also be explained by the result of the engagement with
other cytokines that, when combined, successfully control viral replication. For
instance, IL6 is produced after infection (see Chapter 3) and the antiviral effect of
this cytokine on MCMV replication has been documented, therefore it is possible
that together, along with chemokines, suppress viral growth.
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7.3.2 Role of TNF in viral replication in vivo.
Work presented in Chapter 6 pointed to a potential role of IE1 in the modula-
tion of TNF production in the natural host. This result along with the attenuated
phenotype that the ie1-deletion mutant MCMV showed in vivo, and the high sen-
sitivity that MCMVdie1 presented to TNF treatment, led to pose the question of
whether TNF was responsible for such attenuation in vivo. To test this hypothe-
sis, genetically modified C57Bl/6 mice lacking tnf gene (TNF−/− C57Bl/6) were
infected with MCMVdie1 and MCMVrev in order to establish the role of TNF in
the immune response against MCMV infection in vivo. Wild type MCMV was not
included in these experiments since there were no significant differences in the
replication between MCMV and MCMVrev in infected C57Bl/6 mice. Therefore,
groups of 8 week old, male wild type C57Bl/6 and TNF−/− C57Bl/6 mice were
infected by the i.p. route with 2 x 106 PFU. After 4 days of infection mice were
killed and spleen, liver, kidneys, heart and lung were harvested and processed
as described before (section 2.8.2). The significance of the data presented in this
chapter was determined by Student’s T-test, after the normality of the population
was established, according to Lilliefors’ hypothesis test.
When MCMVrev replication was studied in TNF−/− C57Bl/6 mice, and in
agreement with previous data [Pavic et al., 1993], no significant differences were
seen in viral burden in the spleen when compared to infected-wild type C57Bl/6
mice. Viral replication in the kidneys of TNF-depleted and MCMVrev-infected
mice was not higher either in comparison to wild type mice. In the liver a slight
increase in viral replication was found, and in heart and lung the highest viral
load was observed, being statistically significant only in the heart (t-test, p<0.05).
Similar results have been already seen in the lungs [Pavic et al., 1993] and liver of
TNF-depleted and MCMV-infected mice [Orange and Biron, 1996]. However no
significant differences were observed in MCMVrev replication in these organs.
Surprisingly, when replication of the ie1-deletion mutant was studied in TNF−/−
mice it was seen that viral growth was not restored. Contrary to what was ex-
pected, there was just a slight improvement in the growth of MCMVdie1 in the
absence of TNF, similar to that seen for the revertant virus. Only in the heart of
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Figure 7.3: Growth of MCMVrev and MCMVdie1 in different organs in wild type
and TNF−/− C57Bl/6 mice after 4 days of infection.
Groups of 13 TNF−/− C57Bl/6 mice were inoculated i.p. with 2 x 106 PFU of tissue
culture-derived MCMVrev or MCMVdie1. On day 4 post infection mice were killed and
selected organs were removed, weighted and sonicated as a 10%w/v. Viral titers were
determined by standard plaque assays in MEFs. Viral growth in TNF−/− C57Bl/6 is compared
to titers found in wild type C57Bl/6 mice. Only viral replication in the heart was significantly
different for both MCMVdie1 and MCMVrev (t-test, ∗∗ p<0.05). Red lines show median values
and blue lines limit of detection.
infected mice the replication of MCMVdie1 was significantly higher when com-
pared to titers of virus in immunocompetent infected-mice (Figure 7.3). As in
MCMVrev-infected TNF−/− mice, viral titers in liver, kidneys and lungs were
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modestly higher than those seen in infected-wild type C57Bl/6, but not statis-
tically significant. Finally, the absence of TNF did not have any effect in viral
replication in the spleen.
From the data presented in this chapter it can be concluded that TNF is not
responsible for the attenuation of MCMVdie1 in vivo, since no significant changes
were seen in the replication of MCMVdie1 in the absence of TNF.
7.4 Conclusions
Infection with MCMV results in the activation of a network of cells and cytokines
which control viral replication. Within this pool of cytokines, TNF is produced
in spleen, liver, kidneys, lung and heart after viral challenge of both immuno-
compentent BALB/c and C57Bl/6 mice, as demonstrated in Chapter 6 of this
thesis. In vitro work has suggests that MCMV modulates the production of TNF
by its IE1 protein. MCMVdie1 replication in BMMθs cells resulted in a slight
decrease on viral yields at late time of the course of infection. When TNF effect
was studied on viral replication it was seen that, as seen previously in other cell
type, TNF exerted an antiviral activity and viral replication was reduced after
TNF treatments in a dose dependent manner. However, TNF-induced antiviral
effect was more dramatic in MCMVdie1-infected cells, resulting in the complete
inhibition of viral replication after 10U/mL TNF treatment. It can be concluded
that TNF antiviral effect in BMMθs is more effective than in MEFs probably be-
cause of the lack of synergy between exogenous and endogenous TNF, and that
MCMVdie1 presents high sensitivity to TNF since it was not able to overcome
the TNF-induced antiviral effect in vitro. It has to be taken in consideration the
activation of other pathways and cytokines leading to the control of the viral
infection.
Moreover, using ie1-deletion mutant MCMV it was seen that the absence of
this immediate early protein resulted in a growth defect in vivo. When TNF pro-
duction was studied after infection with MCMVdie1 it was seen that MCMV
might also modulates TNF induction in the natural host, since cytokine levels
induced by MCMVdie1 were similar to those seen for the parental and revertant
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virus. Considering the growth defect presented by MCMVdie1 and the signifi-
cant cytokine production, it was hypothesized that the attenuated phenotype of
MCMVdie1 was due, at least partially, to the strong TNF response induced in the
absence of IE1 protein. The results presented in this Chapter also showed that,
even though MCMV modulates the production of the proinflammatory cytokine
TNF in vitro (Chapter 4) and in vivo (Chapter 6), TNF is not responsible for the at-
tenuated phenotype that the ie1-deletion mutant MCMV presents in the natural
host. However, the slight increase in viral yields found in most organs analyzed
do not exclude TNF as a player in the control of MCMV infection. Moreover, it
cannot be ruled out that the presence of another cytokine such as IFNγ, which
has been shown to be essential for the complete control of MCMV infection in
vitro, blocks viral replication but requires the presence of TNF for the complete
viral clearance in vivo.
The initial hypothesis was based on the attenuated phenotype that MCMVdie1
presents in immunocompetent BALB/c mice, as well as in SCID mice, lacking T
and B cells [Ghazal et al., 2005]. These results led to question whether the at-
tenuation was due to a high susceptibility to the innate immune response. Since
data might indicate that MCMV suppresses TNF production throught an un-
kown mechanism which involves IE1 in vitro and in vivo, it was hypothezised
that TNF was responsible for the attenuation of the ie1-deletion mutant MCMV in
vivo. However, the results showed in the above sections of this Chapter showed
that TNF is not responsible for the attenuated phenotype of the mutant virus.
It has been reported that neutralization of TNF in vivo does not result in a
significant increase in viral titers [Shanley et al., 1994]. The lack of improvement
in viral replication might be explained by the fact that MCMV is not producing
the optimal amount of TNF, since it is expressing IE1, which is suppressing the
cytokine production. However, and assuming that this hypothesis was true, the
depletion of TNF would have an effect in the mutant virus replication. Contrary
to what was expected, the results presented in this Chapter showed that TNF
alone is not required for the control of viral infection in vivo.
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On the other hand, the fact that all mice survived MCMV infection, led to
the question whether the genetic depletion of the tnf gene could have induced
the development of compensatory mechanisms to counterbalance the lack of
TNF. For instance, overactivation of immune cells or overproduction of other
cytokines such as type I or II IFN has been previously described [Krug et al.,
2004]. Such compensation would help, at least, to control the infection and fore-
stall the death of the host. Thus, the fact that an organism is able to counteract the
lack of a specific cytokine or cellular subset does not mean that it is not impor-
tant for the control of infection. Perhaps, by forcing the overproduction of other
cytokines or overwhelming different cells with activation signals the success in
viral clearance is transient and may not be successful in a second exposure.
CHAPTER 8
Final Conclusions
8.1 Summary of results and discussion
The IE1 protein of murine CMV has been shown to be involved in the activa-
tion of the viral gene transcription in collaboration with the IE3 protein, and in
driving the switch from the immediate early to the early phase of the MCMV
transcription cascade [Angulo et al., 2000]. In addition, IE1 induces the activa-
tion of several cellular genes in order to create the optimal environment for viral
replication [Koszinowski et al., 1986, Gribaudo et al., 1996, Schickedanz et al.,
1988, Gribaudo et al., 2000, Lembo et al., 2000]. It has also been reported the dis-
pensable role of IE1 in viral replication in tissue culture [Ghazal et al., 2005] since
an ie1-deletion mutant MCMV (MCMVdie1), lacking the entire exon 4 of the ie1
gene, replicated as wild type in several cell lines. In contrast, IE1 is required
for optimal replication in the natural host [Ghazal et al., 2005]. The fact that
the ie1 mutant virus also presented a growth phenotype in SCID mice, which
exclusively relies on the innate immune response to control the infection raise
the possibility of an immunomodulatory role for IE1 protein. Hence, the initial
hypothesis of this investigation was that the IE1 protein is involved in the regu-
lation of the immune response triggered upon infection.
8.1.1 Effect of IE1 protein in viral replication in BMMθs.
It is now well established that after MCMV infection, innate immunity plays a
critical role in the initial control of the virus. This first defense is characterized by
the activation of macrophages, NK and dendritic cells. Upon activation a cascade
of cytokines and chemokines production is initiated in order to alert bystander
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cells of the invasion and recruit immune cells to the site of infection. This initial
response is triggered to inhibit viral replication and dissemination throughout
the host. However, as other viruses, MCMV has also developed strategies to
escape from immunosurveillance. The success of such an evolution can be seen
from the fact that MCMV can be found in organs such as the salivary glands after
resolving the acute infection.
Within the cells activated early after infection, macrophages have been de-
scribed as having ’two-faces’ in the context of MCMV infection. On one hand,
Mθs are essential for viral replication, dissemination and pathogenesis, and on
the other hand they are crucial for the control of viral infection. Therefore, it
was of interest to study the role of the IE1 protein in the control of the im-
mune response in this cellular population. In addition, it was possible to fur-
ther understand the interplay between MCMV and Mθs. Therefore, the first
step in this investigation was to characterize the role of the IE1 protein in vi-
ral replication in BMMθs. Contrary to other viruses, it has been shown that IE1
is not essential for viral replication in fibroblasts, endothelial cells and peritoneal
macrophages. However, replication in BMMθs has not been described. Results
from independent experiments revealed that the ie1-deletion mutant MCMV also
showed comparable replication in BMMθs (see Figure 3.1), however, a trend to-
wards lower viral yields is observed at late times of the infection at both MOIs
studied. These differences were not found to be statistically significant, reflect-
ing high level of variability between samples and the overall sensitivity of the
plaque assay. In addition, the fact that this cellular population is considered as
semi permissive for viral infection might also explain that titers were not sta-
tistically significant, which might indicate a similar replication of the mutant in
this cellular population. It could also be argued that the trend towards a lower
replication of MCMVdie1 could be due to a critical defect on the viral replication.
Time constraints prevented to explore this possibility and therefore this investi-
gation was carried out under the assumption of the MCMVdie1 is not defective.
Nevertheless, it would be very informative to investigate the PFU/viral genome
copies ratio, since it would elucidate whether or not the absence of IE1 results
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in a defective virus. In addition, in order to rule out any second site mutations
and ensure that the effect seen was solely due to IE1 protein a revertant virus
(MCMVrev) was also included in this investigation. As expected there was no
differences between replication of wild type and revertant virus. The trend to-
ward lower titers of MCMVdie1 is not completely understood. The effect of the
absence of the IE1 protein on viral gene expression has not been elucidated yet.
However, since MCMVdie1 does not present a phenotype in culture cells this re-
sponse might be due to factors produced by macrophages which might have an
effect on viral replication, such as cytokines.
8.1.2 Role of IE1 protein in the regulation of host cell gene expression after early hours
post infection.
As part of this project, an initial study was carried out in order to obtain infor-
mation about how IE1 might affect host cell gene expression. Due to the expen-
sive cost of microarrays, experiments were only performed for MCMVdie1 and
MCMVrev-infected BMMθs. While unequivocally conclusions cannot be drawn
from this experiment, the data has been used for informative purposes only, as
well as an example of how microarray data could be analysed. Considering the
role of the IE1 in the expression of cellular genes an investigation of the host gene
expression by the presence of IE1 was conducted, with particular interest in im-
mune genes. Hence, a comparative study between MCMVdie1 and MCMVrev-
induced gene expression was performed (see Section 8.1.2). Microarray tech-
nology was used in this investigation since it gives an important amount of in-
formation regarding the genes which expression is affected after viral infection.
From the microarray it was seen that, after 10 hpi, approximately 550 genes were
differentially expressed. Surprisingly nearly 30% of these genes were involved
in the immune response, including surface markers, receptors, cytokines and
transcription factors. To further understand how these genes interact and relate
to each other and what biological processes might be associated with the Inge-
nuity Pathway Analysis (IPA) application was used. The extensive database of
IPA enabled the generation of genetic networks showing the interaction between
those selected genes. Along with the interaction networks, IPA also identified
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the canonical pathways which were the most affected. Surprisingly, both net-
works and pathways also recognized processes such as apoptosis and cytokine
signalling pathways as relevantly affected by the viral protein. Therefore, this
initial study raises the possibility of a role of IE1 protein in the regulation of the
host cell gene expression. Moreover, IE1 might also be specifically targeting the
immune response triggered upon infection.
The use of IPA as a tool for analysing microarray data has been shown to
be useful regarding the identification of potential new candidates for regulation.
In this investigation, it was interesting the fact that the lipid metabolism was
one of the biological processes to appear as targeted after infection. There is no
much information in the literature regarding the interaction between viral infec-
tion and lipids. On the other hand, there are experimental data showing a link
between lipids and inflammatory response. One of this examples could also be
highlighted from the data. The enzyme CH25H appeared to be differentially ex-
pressed. This enzyme has a role in the regulation of the cholesterol metabolism.
Interestingly, it has been reported that cholesterol plays an important role in the
activation of the Erk1/2 phosphatase [Wang et al., 2003], by supporting the OSBP
and the specific enzymes in an active complex [Wang et al., 2005]. Furthermore,
this kinase has been involved in the regulation of the expression of proinflam-
matory cytokines, such as TNF, which also plays a role in the control of MCMV
replication. Therefore, pathway analysis could be useful to raise new hypothesis
such as IE1-induced modulation of the immune response throught the regulation
of the lipid metabolism.
All together, microarray and pathway analysis are useful tools to give an in-
sight into potential regulatory functions.
8.1.3 IE1 and modulation of TNF production in infected-BMMθs at the transcript
and protein level.
To further characterize the role of IE1 protein in infected-BMMθs, the cytokine
production was studied after early hours of infection. These experiments were
focused on the cytokine response based on the important role that they play in
the immune response against MCMV infection. Therefore, it was of interest to
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study the effect of IE1 protein in this response. Independent experiments were
carried out (see Section 4.3.1) and, markedly, when cytokine levels were mea-
sured from the supernatants of infected-BMMθs it was seen that MCMVdie1 in-
duced a very significant production of TNF but not other cyokine except IL6,
when compared to MCMV and MCMVrev. The IL6 response may be explained
by the fact that IL6 production has been shown to be activated by TNF and there-
fore, the concentration of cytokine after MCMVdie1 infection is just the result of
the significant TNF production.
Next, it was of interest to study whether the cytokine response was also reg-
ulated at the transcript level (see Section 4.3.2). Thus, tnf gene expression was
studied by determining the relative levels of tnf mRNA. Quantitative RT-PCR
revealed a similar regulation after infection with the mutant virus. MCMVdie1-
induced tnf expression was 2.5-fold higher than MCMV and the revertant virus.
Therefore, results pointed to a regulation of TNF involving the IE1 protein in
BMMθs.
One of the responses in which macrophages have a role is cytokine and chemokine
production. MCMV has also developed strategies to counteract cytokine pro-
duction and/or cytokine-induced responses. Within the pool of MCMV’s strate-
gies to modulate cytokine responses, TNF has been targeted in virtually every
step of its biology, although the regulation of TNF production is the less studied.
Different groups have shown that both human and murine CMV regulate TNF-
induced immune response by blocking the expression of TNF receptors [Pop-
kin and Virgin, 2003, Baillie et al., 2003, Montag et al., 2006]. Interfering with
TNF receptors is also shared with other viruses, such as Poxviruses which were
the first example of a virus encoding a TNF receptor homolog [McFadden et al.,
1997]. Along with the receptor, other molecules involved in the activation of
TNF-induced responses have been shown to be on the list of targets. For in-
stance, the viral protein M45 has been reported to block RIP1, in order to inhibit
the proinflammatory response induced by TNF [Mack et al., 2008]. However,
results from this investigation could indicate that MCMV modulates the produc-
tion of TNF by mechanisms which involve IE1 protein. The direct or indirect
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effect of this viral protein or whether other viral proteins are involved is yet to
be discovered.
It has been shown, by using transient expression assays, that HCMV IE1 ac-
tivates tnf expression [Geist et al., 1994] by modulation of transcription factors
involved in the regulation of TNF [Geist et al., 1997]. However, these studies
were based on expression plasmid experiments and outside the context of an
infection. Experiments described in this investigation were based on complete
viral genomes and respective deletion mutant revertants. Therefore, it is of in-
terest to study how TNF production is affected under similar experimental con-
ditions, considering the significance of HCMV as a human pathogen and TNF as
cytokine.
8.1.4 Signalling studies to unmask a potential mechanism for TNF modulation
The next step in this investigation was to explore a potential transcriptional regu-
lation of TNF production. An extensive literature review was done regarding the
regulatory mechanisms of TNF production in different cells and in the context of
several pathogens. From the literature, it was seen that several transcription fac-
tors were commonly involved in the activation of tnf by different stimuli, such
as viral and bacterial infection. Within the transcription factors identified it was
seen that some of them like Elk, CREB, are activated by members of the MAPK
family through a signalling cascade. Therefore, this study also included the char-
acterization of the activation of signalling molecules after viral infection in order
to study the effect of ie1 defective virus in the activation of these molecules, as
well as the downstream effect in the induction of the TNF promoter. This study
was carried out by two approaches. The first approach was a Luminex-based
highthroughput technology analyzing a number of signalling molecules simul-
taneously. This experiment was done as part of a collaboration with Upstate
(Millipore, UK). The second approach and in order to validate the first technol-
ogy, conventional Western Blot was also performed against activated forms of
the molecules of interest. Unfortunately, Luminex-based analysis was not con-
sistent and therefore was not reliable for this study. On the other hand, it was
also difficult to draw conclusions from the Western blot analysis since there was
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a large variability between the samples. Nevertheless, initial observations might
indicate that member of the MAPK family such as Erk1/2, p38 and JNK are not
differentially activated in the absence of IE1 and therefore the regulation of TNF
does not depend on the activation of these pathways. Clearly, further work has
to be done in order to clarify the molecular mechanism by which IE1 targets TNF
production.
8.1.5 TNF production after infection of the natural host.
It is possible that the observed in vitro phenotype of MCMVdie1 and TNF pro-
duction may be restricted to tissue culture conditions. Hence, the next step of this
investigation was to assess whether the absence of IE1 also resulted in the modu-
lation of TNF production in the natural host. Several studies have already shown
the activation of TNF production after MCMV infection in vivo. For instance, tnf
gene expression in different organs has been demonstrated [Tang-Feldman et al.,
2006] as well as protein production, which is detected early after infection in the
spleen, liver [Orange and Biron, 1996] and heart [Lenzo et al., 2003] of infected
mice.
The role of the IE1 protein in the production of TNF was studied by using
two different mouse strains and cytokine production was measured after 4 and
7 (only in BALB/c) dpi. First viral growth was studied in order to (1) confirm at-
tenuation of MCMVdie1 in BALB/c mice and (2) study viral growth in C57Bl/6
(see Section 6.3.2). Results confirmed that MCMV IE1 protein is necessary for
viral replication in vivo. As expected, the ie1-MCMV mutant failed to grow as
the parental and revertant virus in both competent BALB/c and C57Bl/6. TNF
production was also determined in spleen, liver, kidney, heart and lung of in-
fected mice, and compared to the cytokine production in non-infected control.
Remarkably, similar levels of cytokine between viral infections were found in
all organs examined. Since TNF production upon MCMV infection is positively
correlated with the output of infectious virus (PFU/g tissue), these results indi-
cate that IE1 also regulates the production of TNF in vivo. MCMVdie1-induced
TNF production reached similar levels to those seen after MCMV and MCMVrev
infection, regardless of the low viral titers detected. Taking into consideration
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the difference in viral titers and in order to rule out that the results were af-
fected by the non-equivalency of viral synthesis, a second study was carried out
where BALB/c mice were infected with a different dose of parental MCMV and
MCMVdie1 to obtain similar PFU and measure cytokine production under this
condition (see Figure 6.5). ELISA showed that TNF induction after MCMVdie1
infection was significantly higher than the levels observed after MCMV infection.
It could be argued that the levels of cytokine found in the different tissues is the
result of the higher dose of MCMVdie1 used for the infection. However TNF lev-
els were based on the output levels of infection it is also important to account for
the input. Perhaps an investigation on the actual number of cells infected and
the identification of the cells responsible for the cytokine response would help
to resolve this issue. Therefore further studies couild be need to determine the
contribution of input virus in the TNF response.
8.1.6 TNF is not responsible for the attenuated phenotype of MCMVdie1 in the
natural host.
The in vivo studies raised the final question of whether the significant TNF pro-
duction seen after MCMVdie1 infection was responsible, at least in part, for the
growth phenotype that the mutant virus presents in the natural host. It has been
demonstrated the antiviral role of TNF in tissue culture [Lucin et al., 1994], in
synergy with IFNγ. However, the effect of the cytokine in MCMVdie1 replication
has not been described. Therefore, TNF effect was studied in infected-BMMθs.
As expected, infection of TNF-primed BMMθs resulted in a reduction of viral
replication in a dose dependent fashion (see Figure 7.2). Moreover, TNF-induced
antiviral effect was more dramatic in MCMVdie1-infected cells, resulting in the
complete inhibition of viral replication after 10U/mL TNF treatment. This result
might be explained by the synergy between exogenous and endogenous TNF
in MCMVdie1-infected cells, however the activation of alternative pathways as
well as the production of other factors involved in the control of the virus have
also need to be taken into considerantion. On the other hand, as it has been stated
before, it is also possible that the susceptibility of MCMVdie1 could be due to the
fact that this is not a competent virus, which could explain these results.
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To go further in this investigation, the role of TNF in the attenuation of MCMVdie1
replication in vivo was also tested (see Section 7.3.2). Thus, genetically depleted
mice lacking tnf gene were infected with either MCMV or MCMVdie1 and viral
replication was compared in different organs. If the significant TNF response
seen after MCMVdie1 infection was responsible for the growth defect of the
mutant virus, the absence of TNF production should result in an increase in
MCMVdie1 burden. However, the results showed that TNF is not responsible
for the attenuated phenotype that the ie1-deletion mutant MCMV presents in the
natural host. Only a slight increase in viral yields found in most organs analyzed
was seen but it does not exclude TNF as a player in the control of MCMV in-
fection. Moreover, it cannot be ruled out that the presence of another cytokine
such as IFNγ, which has been shown to be essential for the complete control of
MCMV infection in vitro, blocks viral replication but requires the presence of TNF
for the complete viral clearance in vivo. However, the results of this experiment
clearly showed that TNF is not responsible for the attenuation of MCMVdie1 in
the natural host.
On the other hand, the fact that all mice survived MCMV infection, lead to
the question whether the genetic depletion of the tnf gene could have induced
the development of compensatory mechanisms to counterbalance the lack of
TNF. For instance, overactivation of immune cells or overproduction of other cy-
tokines such as type I or II IFN has been previously described [Krug et al., 2004].
Such compensation would help, at least, to control the infection and forestall the
death of the host.
8.2 Concluding remarks
This thesis has investigated the role of the MCMV IE1 protein in the regulation of
the immune response triggered upon infection in BMMθs and in the natural host
(BALB/c and C57Bl/6 mice). Previous studies have demonstrated that IE1 pro-
tein is required for viral replication in vivo, but not in vitro, where a mutant virus
lacking the entire exon 4 of the ie1 gene replicated as the parental virus. Since the
ie1 mutant virus showed an attenuated phenotype in competent BALB/c mice
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and SCID mice, it was hypothezied that IE1 protein acts as a immuno modulator.
The central hypothesis of the thesis was addressed by the following questions:
1. Does IE1 protein play a role in the gene expression of BMMθs?
2. Is it involved in the modulation of the cytokine response in BMMθs?
3. What are the molecular mechanisms underlying the cytokine production
regulation?
4. Does MCMV regulate the cytokine response in the natural host as in vitro?
5. Is TNF responsible for the attenuated phenotype of MCMVdie1 in vivo?
During the course of this investigation, a number of important limitations
were found and made not possible to draw any conclusions regarding the im-
munomodulatory function of IE1. Several issues should be addressed in order
to clarify and better explain the results presented in previous chapters. Taking
all the data together, it is not clear why MCMVdie1 does not show a replication
defect in cells like fibroblasts but shows a decrease, although not statistically sig-
nificant, in BMMθs. Initially it was assumed the competence of MCMVdie1 and
therefore the hypothesis of the immunomodulatory function of IE1 was inves-
tigated. However, after reviewing the data it is clear that a comparative study
on the MCMVdie1 genome copies could have been very useful to the interpre-
tation of the results. On the other hand, the study of the activation of signalling
molecules was unsuccessful to identify a possible pathway by which this mod-
ulation might be taking place. Same limitations were identified in studies done
in the natural host where it was difficult to descifrer whether the production of
TNF in different tissues were due to a regulatory function of the virus or just as a
result of a defective virus.Finally, TNF depleted mice experiment did not reveal
any significant change on MCMVdie1 replication in vivo, which means that this
cytokine is not responsible for the attenuation of the virus in vivo in the absence
of IE1.
Overall, work presented in this thesis has not proved the initial hypothesis
of that IE1 is an immunomodulator targeting TNF in vitro and in vivo. Instead
it has highlighted a number of limitations which have to be taken into account
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for future work and that will definetly clarify most of the problems presented in
previous chapters.
8.3 Future work
This thesis has demonstrated a novel function for the IE1 protein of MCMV and
therefore has expanded the existing knowledge regarding the role of this viral
protein in the host-pathogen interaction. However, the different findings ob-
tained from this investigation also has raised new questions:
Investigation on the PFU/genome copies ratio. This study will clarify MCMVdie1
phenotype being possible to determine whether the lower replication of the virus
is due to the immune control induced in the absence of IE1 or because the muta-
tion resulted in a defective virus.
Molecular mechanism of TNF production. The results presented in this
study has given an insight of a possible regulation of TNF production. Since
it is known the role that TNF plays in the control of viral infection, and the fact
that several pathogens have been shown to developed strategies to suppress this
cytokine production, it could be very interesting to investigate the molecular
mechanisms involved in this response in the context of MCMV infection.
Role of cytokines in the control of viral infection in vivo. Following find-
ings presented in previous sections of this thesis it was seen that regardless the
significant TNF production in vivo after infection with MCMVdie1, wild type
phenotype was not recovered when TNF was genetically depleted. However,
there are a number of other cytokines involved in the control of viral infections
in vivo, such as type I and II IFN. To study how MCMV infection is affected by
these factors could be also be very informative.
Production of TNF after HCMV infection. Human CMV is an important
pathogen for immunocompromised patients. HCMV-induced pathogenesis has
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been associated in part with the immune response triggered upon infection, there-
fore it would be of a great interest to determine whether the human virus has also
evolved a mechanism for TNF production modulation. So far, it has been shown
that the IE1 protein induces the activation of the TNF promoter, but no study has
been done in the context of the life virus.
Role of MCMV in the lipid metabolism and how this regulation affect
TNF production. Very few examples can be found in the literature regarding
the role of lipids in viral infection. Microarray analysis pointed out that sev-
eral enzymes involved in the metabolism of cholesterol were altered after viral
infection. Hence, it would be interesting to further study to what extent viral
infection, and in particular the IE1 protein, affects this metabolism and how the
lipids affect viral and cellular response against infection.
APPENDIX A
General solutions and buffers
A.1 General solutions
• 10% Ammonium persulphate (APS)
1 g of APS (Sigma, UK) in 10 ml of distilled water. Solution was stored at
4C covered in foil.
• 10% sodium dodecyl sulfate (SDS) (Invitrogen, UK)
• TEMED (Biorad, UK) Stored at 4◦C.
• Glycerol (BDH Ltd., UK)
• 2x Laemmli sample loading buffer
0.125M Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.01% bromophenol blue
and 100 mM DTT (Sigma, UK) (just added prior to use).
• TBS
6.05 g Tris base (Sigma, UK), 8.76 g NaCl (Sigma, UK). Add distillied water
up to 800 mL and adjust pH to 7.5 with HCl. Make up to 1 L with distilled
water.
• 1 M Tris buffer (pH 6.8)
12.1 g of Tris base (Sigma, UK) was dissolved in 80 ml of distilled water.
pH was adjusted with HCl and volume was adjusted to 100 ml. Solutions
was kept at RT after sterilization by autoclave.
• 1 M NaCl
5.84 g NaCl (Sigma, UK) into 80 mL distilled water Dissolved and made up
to 100 mL with distilled water
• Complete mini-Protease Inhibitor Solution
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1 tablet of the inhibitor (Roche) was added to 10 ml of lysis buffer. Stored
at 4◦C.
• Phosphatase inhibitor Cocktail I
100 µL of phosphatase inhibitor cocktail (Sigma, UK) was added to lysis
buffer just prior to use.
• Phosphatase inhibitor Cocktail II
100 µL of phosphatase inhibitor cocktail (Sigma, UK) was added to lysis
buffer just prior to use.
• Beadlyte Cell Signaling Lysis Buffer (Millipore, UK)
• PBS (Sigma, UK) Dissolve 1 tablet in 200mL.
• 10% Acrylamide gel for SDS-PAGE
For 10 mL, 4 mL of distilled water, 3.3 mL of 30% Acrylamide (Sigma,UK),
2.5 mL of 1.5 M Tris (pH 8.8), 0.1 mL of 10% SDS (Invitrogen, UK), 0.1 mL
of 10% APS (Invitrogen, UK), 0.004 mL TEMED (Biorad, UK)
• Stacking gel for SDS-PAGE
For 5 mL, 3.4 mL of distilled water, 0.83 mL of 30% Acrylamide (Sigma,UK),
0.63 mL of 1 M Tris (pH 6.8), 0.05 mL of 10% SDS (Invitrogen, UK), 0.05 mL
of 10% APS (Invitrogen, UK), 0.005 mL TEMED (Biorad, UK)
A.2 Solutions for Tissue Culture
• Calf Serum (CS) (Lonza, UK)
500 mL heat inactivate CS (56◦CC for 35 min) were filtered in a StericupR
vacuum filtration unit (Millipore, UK). The filtered serum was then aliquoted
into 50 mL lots and store at - 20◦C until use.
• Fetal Calf Serum (FCS) (Lonza, UK)
500 mL heat inactivate FCS (56◦C for 35 min) were filtered in a StericupR
vacuum filtration unit (Millipore, UK). The filtered serum was then aliquoted
into 50 ml lots and store at - 20◦C until use.
• L929 conditioned medium
Grow cells in a 165 cm2 flask in DMEM:F12 growth medium. When conflu-
ent, trypsinise and re-suspend in 30 ml growth medium. Add 1 ml cells to
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49 mL growth medium and seed into several 165 cm2 flasks. Culture for 5
days, harvest medium, centrifuge at 1500 rpm for 10 min, filter, aliquot and
freeze at -20◦C.
• Freezing medium
30 mL DMEM, 1.5 mL FCS (Lonza, UK), 5 mL DMSO (Sigma, UK). Aliquoted
into 8 x 6 mL and stored at -20◦C.
• Trypsin/Versene (Lonza, UK)
200 mg/L Versene and 170000 U Trypsin/L
A.3 Solutions for SDS-polyacrylamide-gel electrophoresis
(SDS-PAGE)
• 10X SDS running buffer
303 g of Tris base (Sigma, UK), 1442 g of glycine (Sigma, UK), SDS were
dissolved in 8 L of distilled water. pH was adjusted to pH 8.3 and volume
was adjusted to 10 L. Solution was kept at room temperature and was used
as in 1X solution diluted in distilled water.
• Solutions for chemiluminescent blotting
ECL Plus Western Blotting Detection reagents (Amersham Biosciences, UK)
• Transfer buffer
25 mM Tris base, 0.2 M glycine, 20% methanol (pH 8.5). Buffer was pre-
pared fresh for every transfer.
• 10X Tris Buffered Saline (TBS)
To prepare 1 L of 10X TBS: 24.2 g Tris base, 80 g NaCl; pH to 7.5.
• Washing buffer
1X TBS, 0.1% Tween-20 (TBS/T)
• Blocking buffer
1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk
• Primary Antibody Dilution Buffer
1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk.
• Secondary Antibody Dilution Buffer
1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk.
APPENDIX B
Microarray Data
Figure B.1: Box plots before and after normalization
Box plot showing log2 intensity values from Affymetrix Mouse 430v2 array individual .CEL
files. The bottom and top of the box represents the 25th and 75th percentile, and the band in the
middle of the box represents the median. The horizontal lines, also known as the ”whiskers”,
represent observed data below the first quartile and beyond the third quartile. In other words,
the whiskers represent all observed value outside the box. The left pannel shows spread of the
data before RMA and quantile normalization and right pannel shows data after normalization.




Figure B.2: List of genes down-regulated after MCMV infection in the absence of
IE1 protein
144
Figure B.3: List of genes down-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure B.4: List of genes down-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure B.5: List of genes down-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure B.6: List of genes down-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure B.7: List of genes down-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure B.8: List of genes up-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure B.9: List of genes up-regulated after MCMV infection in the absence of
IE1 protein (continuation)
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Figure C.1: Analysis of the rest of the signalling proteins
BMMθ were infected at a MOI of 1 with MCMV, MCMVdie1 or MCMVrev or mock infected as a
negative control. Samples were analyzed as n=4 using the PathwayProfilerTMservice by Upstate
(Millipore, UK). Fold activation of the kinases are shown. MFI data have been normalized
against total amount of protein and mock-infected samples. Blank values were also extrated
from the final values. Bars show media values and SD.
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